Patent Grant
11155810
The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jan. 26, 2018, is named 43487770203SL.txt and is 6,833 bytes in size.
Samples may be processed for various purposes, such as identification of a type of sample of moiety within the sample. The sample may be a biological sample. The biological samples may be processed for various purposes, such as detection of a disease (e.g., cancer) or identification of a particular species. There are various approaches for processing samples, such as polymerase chain reaction (PCR) and sequencing.
Biological samples may be processed within various reaction environments, such as partitions. Partitions may be wells or droplets. Droplets or wells may be employed to process biological samples in a manner that enables the biological samples to be partitioned and processed separately. For example, such droplets may be fluidically isolated from other droplets, enabling accurate control of respective environments in the droplets.
Biological samples in partitions may be subjected to various processes, such as chemical processes or physical processes. Samples in partitions may be subjected to heating or cooling, or chemical reactions, such as to yield species that may be qualitatively or quantitatively processed.
Certain applications may benefit from the amplification or sequencing of species obtained from single cells obtained from a much larger population. In some cases, the single cells of interest may be quite rare.
The present disclosure provides sample preparation techniques that allow sequencing of nucleic acids from single cells of interest. In eukaryotic genomes, chromosomal DNA winds itself around histone proteins (i.e., “nucleosomes”), thereby forming a complex known as chromatin. The tight or loose packaging of chromatin contributes to the control of gene expression. Tightly packed chromatin (“closed chromatin”) is usually not permissive for gene expression while more loosely packaged, accessible regions of chromatin (“open chromatin”) is associated with the active transcription of gene products. Methods for probing genome-wide DNA accessibility have proven extremely effective in identifying regulatory elements across a variety of cell types and quantifying changes that lead to both activation or repression of gene expression.
One such method is the Assay for Transposase Accessible Chromatin with high-throughput sequencing (ATAC-seq). The ATAC-seq method probes DNA accessibility with an artificial transposon, which inserts specific sequences into accessible regions of chromatin. Because the transposase can only insert sequences into accessible regions of chromatin not bound by transcription factors and/or nucleosomes, sequencing reads can be used to infer regions of increased chromatin accessibility.
Traditional approaches to the ATAC-seq methodology requires large pools of cells, processes cells in bulk, and result in data representative of an entire cell population, but lack information about cell-to-cell variation inherently present in a cell population (see, e.g., Buenrostro, et al., Curr. Protoc. Mol. Biol., 2015 Jan. 5; 21.29.1-21.29.9). While single cell ATAC-seq (scATAC-seq) methods have been developed, they suffer from several limitations. For example, scATAC-seq methods that utilize sample pooling, cell indexing, and cell sorting (see, e.g., Cusanovich, et al., Science, 2015 May 22; 348(6237):910-14) result in high variability and a low number of reads associated with any single cell. Other scATAC-seq methods that utilize a programmable microfluidic device to isolate single cells and perform scATAC-seq in nanoliter reaction chambers (see, e.g., Buenrostro, et al., Nature, 2015 Jul. 23; 523(7561):486-90) are limited by the throughput of the assay and may not generate personal epigenomic profiles on a timescale compatible with clinical decision-making.
In an aspect, the present disclosure provides a method for nucleic acid processing, comprising: (a) generating a partition comprising: (i) a biological particle comprising chromatin comprising a template nucleic acid molecule; (ii) a plurality of nucleic acid barcode molecules comprising a common barcode sequence; (iii) a plurality of transposon end nucleic acid molecules comprising a transposon end sequence; and (iv) a plurality of transposase molecules; (b) generating a plurality of template nucleic acid fragments with the aid of a transposase-nucleic acid complex comprising a transposase molecule of the plurality of transposase molecules and a transposon end oligonucleotide molecule of the plurality of transposon end oligonucleotide molecules; and (c) generating a barcoded nucleic acid fragment using a nucleic acid barcode molecule of the plurality of nucleic acid barcode molecules and a template nucleic acid fragment of the plurality of template nucleic acid fragments.
In some embodiments, the barcoded nucleic acid fragment is generated by ligation of the nucleic acid barcode molecule with the template nucleic acid fragment, or a derivative thereof.
In some embodiments, the barcoded nucleic acid fragment is generated by amplification of the template nucleic acid fragment, or a derivative thereof, using the nucleic acid barcode molecule as a primer.
In some embodiments, the transposase-nucleic acid complex is generated in the partition using transposase molecules of the plurality of transposase molecules and transposon end nucleic acid molecules of the plurality of transposon end nucleic acid molecules.
In some embodiments, the transposase-nucleic acid complex is partitioned into the partition. In some embodiments, the plurality of nucleic acid barcode molecules are attached to a bead and wherein the partition further comprises the bead. In some embodiments, the nucleic acid barcode molecules are releasably attached to the bead. In some embodiments, the method further comprises releasing the plurality of nucleic acid barcode molecules from the bead. In some embodiments, the bead is a gel bead. In some embodiments, the gel bead is a degradable gel bead. In some embodiments, the degradable gel bead is degradable upon application of a stimulus. In some embodiments, the stimulus is a chemical stimulus. In some embodiments, the stimulus is a reducing agent. In some embodiments, the partition further comprises the chemical stimulus.
In some embodiments, prior to (b), the template nucleic acid molecule is released from the biological particle. In some embodiments, subsequent to (b), the plurality of template nucleic acid fragments is released from the biological particle.
In some embodiments, the biological particle is a cell. In some embodiments, the biological particle is a nucleus.
In some embodiments, the partition is an aqueous droplet in an emulsion. In some embodiments, the partition is a well.
In some embodiments, the method further comprises releasing or removing the barcoded nucleic acid fragment or a derivative thereof from the partition.
In some embodiments, the method further comprises sequencing the barcoded nucleic acid fragment, or a derivative thereof.
In some embodiments, the plurality of transposon end nucleic acid molecules further comprise a sequence complementary to a sequence of the plurality of nucleic acid barcode molecules. In some embodiments, the partition further comprises a plurality of second nucleic acid molecules comprising a transposon end sequence and a primer sequence, and wherein the transposase-nucleic acid complex comprises: (i) transposase molecules of the plurality of transposase molecules; (ii) a transposon end oligonucleotide molecule of the plurality of transposon end oligonucleotide molecules; and (iii) a second nucleic acid molecule of the plurality of second nucleic acid molecules. In some embodiments, the plurality of nucleic acid barcode molecules are partially double-stranded and comprise (i) a first strand comprising the common barcode sequence and a sequence complementary to a sequence of the plurality of first nucleic acid molecules; and (ii) a second strand comprising a sequence complementary to the common barcode sequence. In some embodiments, the plurality of nucleic acid barcode molecules are single-stranded and comprise the common barcode sequence and a sequence complementary to a sequence in the plurality of transposon end nucleic acid molecules.
In some embodiments, the biological particle further comprises a template ribonucleic acid (RNA) molecule, and wherein the method further comprises generating a barcoded complementary deoxyribonucleic acid (cDNA) molecule from the template RNA molecule or a derivative thereof. In some embodiments, the barcoded cDNA molecule is generated in the partition. In some embodiments, the partition comprises a second plurality of nucleic acid barcode molecules comprising the common barcode sequence and a capture sequence. In some embodiments, the capture sequence is a poly-T sequence. In some embodiments, the capture sequence is a template switching oligo sequence and wherein the barcoded cDNA molecule is generated using a template switching reaction. In some embodiments, the plurality of nucleic acid barcode molecules are attached to a first bead, the second plurality of nucleic acid barcode molecules are attached to a second bead, and wherein the partition comprises the first bead and the second bead. In some embodiments, the first bead or the second bead is a magnetic bead. In some embodiments, the first bead is a gel bead and the second bead is a magnetic bead. In some embodiments, the gel bead comprises the magnetic bead. In some embodiments, the method further comprises degrading the gel bead. In some embodiments, the first bead is a magnetic bead and the second bead is a gel bead. In some embodiments, the gel bead comprises the magnetic bead. In some embodiments, the method further comprises degrading the gel bead. In some embodiments, the plurality of nucleic acid barcode molecules and the second plurality of nucleic acid barcode molecules are attached to a bead, and wherein the partition further comprises the bead. In some embodiments, the barcoded nucleic acid fragment and the barcoded cDNA molecule is released from the partition. In some embodiments, the method further comprises sequencing the barcoded nucleic acid fragment or a derivative thereof and the barcoded cDNA molecule or a derivative thereof.
In some embodiments, the method further comprises cleaving one or more mitochondrial nucleic acid fragments, or derivatives thereof, using (i) one or more guide ribonucleic acid molecules (gRNAs) targeted to the one or more mitochondrial nucleic acid fragments; and (ii) a clustered regularly interspaced short palindromic (CRISPR) associated (Cas) nuclease. In some embodiments, the partition further comprises the one or more gRNAs and the Cas nuclease. In some embodiments, the Cas nuclease is Cas9.
In another aspect, the present disclosure provides a method of generating barcoded nucleic acid fragments, comprising: (a) providing: (i) a plurality of biological particles, an individual biological particle of the plurality of biological particles comprising chromatin comprising a template nucleic acid; (ii) a plurality of transposon end nucleic acid molecules comprising a transposon end sequence; and (iii) a plurality of transposase molecules; (b) generating a plurality of template nucleic acid fragments in a biological particle of the plurality of biological particles with the aid of a transposase-nucleic acid complex comprising a transposase molecule of the plurality of transposase molecules and a transposon end nucleic acid molecule of the plurality of transposon end nucleic acid molecules; (c) generating a partition comprising the biological particle comprising the plurality of template nucleic acid fragments and a plurality of nucleic acid barcode molecules comprising a common barcode sequence; and (d) generating a barcoded nucleic acid fragment using a nucleic acid barcode molecule of the plurality of nucleic acid barcode molecules and a template nucleic acid fragment of the plurality of template nucleic acid fragments.
In some embodiments, the barcoded nucleic acid fragment is generated by ligation of the nucleic acid barcode molecule with the template nucleic acid fragment, or a derivative thereof.
In some embodiments, the barcoded nucleic acid fragment is generated by nucleic acid amplification of the template nucleic acid fragment, or a derivative thereof, using the nucleic acid barcode molecule as a primer.
In some embodiments, the plurality of nucleic acid barcode molecules are attached to a bead and wherein the partition further comprises the bead. In some embodiments, the nucleic acid barcode molecules are releasably attached to the bead. In some embodiments, the method further comprises releasing the plurality of nucleic acid barcode molecules from the bead. In some embodiments, the bead is a gel bead. In some embodiments, the gel bead is a degradable gel bead. In some embodiments, the degradable gel bead is degradable upon application of a stimulus. In some embodiments, the stimulus is a chemical stimulus. In some embodiments, the stimulus is a reducing agent. In some embodiments, the partition further comprises the chemical stimulus.
In some embodiments, subsequent to (c), the template nucleic acid fragments are released from the biological particle.
In some embodiments, the biological particle is a cell. In some embodiments, the cell is a permeabilized cell.
In some embodiments, the biological particle is a nucleus. In some embodiments, the nucleus is a permeabilized nucleus.
In some embodiments, the partition is an aqueous droplet in an emulsion. In some embodiments, the partition is a well.
In some embodiments, the method further comprises releasing or removing the barcoded nucleic acid fragment or a derivative thereof from the partition.
In some embodiments, the method further comprises sequencing the barcoded nucleic acid fragment, or a derivative thereof.
In some embodiments, the plurality of transposon end nucleic acid molecules comprise a plurality of first nucleic acid molecules comprising a transposon end sequence and a sequence complementary to a sequence of the plurality of nucleic acid barcode molecules. In some embodiments, the plurality of transposon end nucleic acid molecules further comprise a plurality of second nucleic acid molecules comprising a transposon end sequence and a primer sequence. In some embodiments, the plurality of nucleic acid barcode molecules are partially double-stranded and comprise a first strand comprising the common barcode sequence and a sequence complementary to a sequence of the plurality of first nucleic acid molecules; and a second strand comprising a sequence complementary to the common barcode sequence. In some embodiments, the plurality of nucleic acid barcode molecules are single-stranded and comprise the common barcode sequence and a sequence complementary to a sequence of the plurality of first nucleic acid molecules.
In some embodiments, the biological particle further comprises a template RNA molecule, and wherein the method further comprises generating a barcoded cDNA molecule from the template RNA molecule or a derivative thereof. In some embodiments, the barcoded cDNA molecule is generated in the partition. In some embodiments, the partition comprises a second plurality of nucleic acid barcode molecules comprising the common barcode sequence and a capture sequence. In some embodiments, the capture sequence is a poly-T sequence. In some embodiments, the capture sequence is a template switching oligo sequence and wherein the barcoded cDNA molecule is generated using a template switching reaction. In some embodiments, the plurality of nucleic acid barcode molecules are attached to a first bead, the second plurality of nucleic acid barcode molecules are attached to a second bead, and wherein the partition comprises the first bead and the second bead. In some embodiments, the first bead or the second bead is a magnetic bead. In some embodiments, the first bead is a gel bead and the second bead is a magnetic bead. In some embodiments, the gel bead comprises the magnetic bead. In some embodiments, the method further comprises degrading the gel bead. In some embodiments, the first bead is a magnetic bead and the second bead is a gel bead. In some embodiments, the gel bead comprises the magnetic bead. In some embodiments, the method further comprises degrading the gel bead. In some embodiments, the plurality of nucleic acid barcode molecules and the second plurality of nucleic acid barcode molecules are attached to a bead, and wherein the partition further comprises the bead. In some embodiments, the barcoded nucleic acid fragment and the barcoded cDNA molecule is released from the partition. In some embodiments, the method further comprises sequencing the barcoded nucleic acid fragment or a derivative thereof and the barcoded cDNA molecule or a derivative thereof.
In some embodiments, the method further comprises (a) lysing a plurality of cells in the presence of a cell lysis agent and a blocking agent; and (b) separating a plurality of nuclei from the plurality of lysed cells to generate the plurality of biological particles, wherein the blocking agent reduces the fraction of sequencing reads corresponding to a mitochondrial genome compared to sequencing reads obtained in the absence of the blocking agent. In some embodiments, the blocking agent is bovine serum albumin (BSA).
In some embodiments, the method further comprises cleaving one or more mitochondrial nucleic acid molecules or derivatives thereof, using (i) one or more guide ribonucleic acid molecules (gRNAs) targeted to the one or more mitochondrial nucleic acid fragments and (ii) a clustered regularly interspaced short palindromic (CRISPR) associated (Cas) nuclease. In some embodiments, the Cas nuclease is Cas9. In some embodiments, the mitochondrial nucleic acid molecules are cleaved prior to (c). In some embodiments, the mitochondrial nucleic acid molecules are cleaved in the partition. In some embodiments, the partition comprises the Cas nuclease. In some embodiments, the partition further comprises the one or more gRNAs. In some embodiments, the mitochondrial nucleic acid molecules are cleaved subsequent to (d).
Additional aspects and advantages of the present disclosure will become readily apparent to those skilled in this art from the following detailed description, wherein only illustrative embodiments of the present disclosure are shown and described. As will be realized, the present disclosure is capable of other and different embodiments, and its several details are capable of modifications in various obvious respects, all without departing from the disclosure. Accordingly, the drawings and description are to be regarded as illustrative in nature, and not as restrictive.
All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and/or take precedence over any such contradictory material.
The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings (also “Figure” and “FIG.” herein), of which:
While various embodiments of the invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions may occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed.
Where values are described as ranges, it will be understood that such disclosure includes the disclosure of all possible sub-ranges within such ranges, as well as specific numerical values that fall within such ranges irrespective of whether a specific numerical value or specific sub-range is expressly stated.
The term “barcode,” as used herein, generally refers to a label, or identifier, that conveys or is capable of conveying information about an analyte. A barcode can be part of an analyte. A barcode can be independent of an analyte. A barcode can be a tag attached to an analyte (e.g., nucleic acid molecule) or a combination of the tag in addition to an endogenous characteristic of the analyte (e.g., size of the analyte or end sequence(s)). A barcode may be unique. Barcodes can have a variety of different formats. For example, barcodes can include: polynucleotide barcodes; random nucleic acid and/or amino acid sequences; and synthetic nucleic acid and/or amino acid sequences. A barcode can be attached to an analyte in a reversible or irreversible manner. A barcode can be added to, for example, a fragment of a deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sample before, during, and/or after sequencing of the sample. Barcodes can allow for identification and/or quantification of individual sequencing-reads.
The term “real time,” as used herein, can refer to a response time of less than about 1 second, a tenth of a second, a hundredth of a second, a millisecond, or less. The response time may be greater than 1 second. In some instances, real time can refer to simultaneous or substantially simultaneous processing, detection or identification.
The term “subject,” as used herein, generally refers to an animal, such as a mammal (e.g., human) or avian (e.g., bird), or other organism, such as a plant. For example, the subject can be a vertebrate, a mammal, a rodent (e.g., a mouse), a primate, a simian or a human. Animals may include, but are not limited to, farm animals, sport animals, and pets. A subject can be a healthy or asymptomatic individual, an individual that has or is suspected of having a disease (e.g., cancer) or a pre-disposition to the disease, and/or an individual that is in need of therapy or suspected of needing therapy. A subject can be a patient. A subject can be a microorganism or microbe (e.g., bacteria, fungi, archaea, viruses).
The term “genome,” as used herein, generally refers to genomic information from a subject, which may be, for example, at least a portion or an entirety of a subject's hereditary information. A genome can be encoded either in DNA or in RNA. A genome can comprise coding regions (e.g., that code for proteins) as well as non-coding regions. A genome can include the sequence of all chromosomes together in an organism. For example, the human genome ordinarily has a total of 46 chromosomes. The sequence of all of these together may constitute a human genome.
The terms “adaptor(s)”, “adapter(s)” and “tag(s)” may be used synonymously. An adaptor or tag can be coupled to a polynucleotide sequence to be “tagged” by any approach, including ligation, hybridization, or other approaches.
The term “sequencing,” as used herein, generally refers to methods and technologies for determining the sequence of nucleotide bases in one or more polynucleotides. The polynucleotides can be, for example, nucleic acid molecules such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), including variants or derivatives thereof (e.g., single stranded DNA). Sequencing can be performed by various systems currently available, such as, without limitation, a sequencing system by Illumina®, Pacific Biosciences (PacBio®), Oxford Nanopore®, or Life Technologies (Ion Torrent®). Alternatively or in addition, sequencing may be performed using nucleic acid amplification, polymerase chain reaction (PCR) (e.g., digital PCR, quantitative PCR, or real time PCR), or isothermal amplification. Such systems may provide a plurality of raw genetic data corresponding to the genetic information of a subject (e.g., human), as generated by the systems from a sample provided by the subject. In some examples, such systems provide sequencing reads (also “reads” herein). A read may include a string of nucleic acid bases corresponding to a sequence of a nucleic acid molecule that has been sequenced. In some situations, systems and methods provided herein may be used with proteomic information.
The term “bead,” as used herein, generally refers to a particle. The bead may be a solid or semi-solid particle. The bead may be a gel bead. The gel bead may include a polymer matrix (e.g., matrix formed by polymerization or cross-linking). The polymer matrix may include one or more polymers (e.g., polymers having different functional groups or repeat units). Polymers in the polymer matrix may be randomly arranged, such as in random copolymers, and/or have ordered structures, such as in block copolymers. Cross-linking can be via covalent, ionic, or inductive, interactions, or physical entanglement. The bead may be a macromolecule. The bead may be formed of nucleic acid molecules bound together. The bead may be formed via covalent or non-covalent assembly of molecules (e.g., macromolecules), such as monomers or polymers. Such polymers or monomers may be natural or synthetic. Such polymers or monomers may be or include, for example, nucleic acid molecules (e.g., DNA or RNA). The bead may be formed of a polymeric material. The bead may be magnetic or non-magnetic. The bead may be rigid. The bead may be flexible and/or compressible. The bead may be disruptable or dissolvable. The bead may be a solid particle (e.g., a metal-based particle including but not limited to iron oxide, gold or silver) covered with a coating comprising one or more polymers. Such coating may be disruptable or dissolvable.
The term “sample,” as used herein, generally refers to a biological sample of a subject. The biological sample may comprise any number of macromolecules, for example, cellular macromolecules. The sample may be a cell sample. The sample may be a cell line or cell culture sample. The sample can include one or more cells. The sample can include one or more microbes. The biological sample may be a nucleic acid sample or protein sample. The biological sample may also be a carbohydrate sample or a lipid sample. The biological sample may be derived from another sample. The sample may be a tissue sample, such as a biopsy, core biopsy, needle aspirate, or fine needle aspirate. The sample may be a fluid sample, such as a blood sample, urine sample, or saliva sample. The sample may be a skin sample. The sample may be a cheek swab. The sample may be a plasma or serum sample. The sample may be a cell-free or cell free sample. A cell-free sample may include extracellular polynucleotides. Extracellular polynucleotides may be isolated from a bodily sample that may be selected from the group consisting of blood, plasma, serum, urine, saliva, mucosal excretions, sputum, stool and tears.
The term “biological particle,” as used herein, generally refers to a discrete biological system derived from a biological sample. The biological particle may be a macromolecule. The biological particle may be a small molecule. The biological particle may be a virus. The biological particle may be a cell or derivative of a cell. The biological particle may be an organelle. The biological particle may be a rare cell from a population of cells. The biological particle may be any type of cell, including without limitation prokaryotic cells, eukaryotic cells, bacterial, fungal, plant, mammalian, or other animal cell type, mycoplasmas, normal tissue cells, tumor cells, or any other cell type, whether derived from single cell or multicellular organisms. The biological particle may be a constituent of a cell. The biological particle may be or may include DNA, RNA, organelles, proteins, or any combination thereof. The biological particle may be or include a chromosome or other portion of a genome. The biological particle may be or may include a matrix (e.g., a gel or polymer matrix) comprising a cell or one or more constituents from a cell (e.g., cell bead), such as DNA, RNA, organelles, proteins, or any combination thereof, from the cell. The biological particle may be obtained from a tissue of a subject. The biological particle may be a hardened cell. Such hardened cell may or may not include a cell wall or cell membrane. The biological particle may include one or more constituents of a cell, but may not include other constituents of the cell. An example of such constituents is a nucleus or an organelle. A cell may be a live cell. The live cell may be capable of being cultured, for example, being cultured when enclosed in a gel or polymer matrix, or cultured when comprising a gel or polymer matrix.
The term “macromolecular constituent,” as used herein, generally refers to a macromolecule contained within or from a biological particle. The macromolecular constituent may comprise a nucleic acid. In some cases, the biological particle may be a macromolecule. The macromolecular constituent may comprise DNA. The macromolecular constituent may comprise RNA. The RNA may be coding or non-coding. The RNA may be messenger RNA (mRNA), ribosomal RNA (rRNA) or transfer RNA (tRNA), for example. The RNA may be a transcript. The RNA may be small RNA that are less than 200 nucleic acid bases in length, or large RNA that are greater than 200 nucleic acid bases in length. Small RNAs may include 5.8S ribosomal RNA (rRNA), 5S rRNA, transfer RNA (tRNA), microRNA (miRNA), small interfering RNA (siRNA), small nucleolar RNA (snoRNAs), Piwi-interacting RNA (piRNA), tRNA-derived small RNA (tsRNA) and small rDNA-derived RNA (srRNA). The RNA may be double-stranded RNA or single-stranded RNA. The RNA may be circular RNA. The macromolecular constituent may comprise a protein. The macromolecular constituent may comprise a peptide. The macromolecular constituent may comprise a polypeptide.
The term “molecular tag,” as used herein, generally refers to a molecule capable of binding to a macromolecular constituent. The molecular tag may bind to the macromolecular constituent with high affinity. The molecular tag may bind to the macromolecular constituent with high specificity. The molecular tag may comprise a nucleotide sequence. The molecular tag may comprise a nucleic acid sequence. The nucleic acid sequence may be at least a portion or an entirety of the molecular tag. The molecular tag may be a nucleic acid molecule or may be part of a nucleic acid molecule. The molecular tag may be an oligonucleotide or a polypeptide. The molecular tag may comprise a DNA aptamer. The molecular tag may be or comprise a primer. The molecular tag may be, or comprise, a protein. The molecular tag may comprise a polypeptide. The molecular tag may be a barcode.
The term “partition,” as used herein, generally, refers to a space or volume that may be suitable to contain one or more species or conduct one or more reactions. A partition may be a physical compartment, such as a droplet or well. The partition may isolate space or volume from another space or volume. The droplet may be a first phase (e.g., aqueous phase) in a second phase (e.g., oil) immiscible with the first phase. The droplet may be a first phase in a second phase that does not phase separate from the first phase, such as, for example, a capsule or liposome in an aqueous phase. A partition may comprise one or more other (inner) partitions. In some cases, a partition may be a virtual compartment that can be defined and identified by an index (e.g., indexed libraries) across multiple and/or remote physical compartments. For example, a physical compartment may comprise a plurality of virtual compartments.
Single Cell Assay for Transposase Accessible Chromatin Using Sequencing (ATAC-Seq)
Disclosed herein, in some embodiments, are methods for nucleic acid processing. A method for nucleic acid processing may comprise generating a partition (e.g., a droplet or well) comprising: (i) a biological particle (e.g., a cell or nucleus) comprising chromatin comprising a template nucleic acid molecule; (ii) a plurality of nucleic acid molecules comprising a common barcode sequence; (iii) a plurality of transposon end nucleic acid molecules comprising a transposon end sequence; and (iv) a plurality of transposase molecules. A plurality of template nucleic acid fragments may then be generated with the aid of a transposase-nucleic acid complex comprising a transposase molecule of the plurality of transposase molecules and a transposon end oligonucleotide molecule of the plurality of transposon end oligonucleotide molecules. A barcoded nucleic acid fragment may then be generated using a nucleic acid barcode molecule of the plurality of nucleic acid barcode molecules and a template nucleic acid fragment of the plurality of template nucleic acid fragments.
The present disclosure also discloses a method of generating barcoded nucleic acid fragments, comprising providing: (i) a plurality of biological particles (e.g., cells or nuclei), an individual biological particle of the plurality of biological particles comprising chromatin comprising a template nucleic acid; (ii) a plurality of transposon end nucleic acid molecules comprising a transposon end sequence; and (iii) a plurality of transposase molecules. A plurality of template nucleic acid fragments may then be generated in a biological particle of the plurality of biological particles with the aid of a transposase-nucleic acid complex comprising a transposase molecule of the plurality of transposase molecules and a transposon end nucleic acid molecule of the plurality of transposon end nucleic acid molecules. A partition may then be generated, where the partition comprises the biological particle comprising the plurality of template nucleic acid fragments and a plurality of nucleic acid barcode molecules comprising a common barcode sequence. A barcoded nucleic acid fragment may then be generated using a nucleic acid barcode molecule of the plurality of nucleic acid barcode molecules and a template nucleic acid fragment of the plurality of template nucleic acid fragments.
In some embodiments, the transposase is a Tn5 transposase. In some embodiments, the transposase is a mutated, hyperactive Tn5 transposase. In some embodiments, the transposase is a Mu transposase. In some embodiments, the partitions disclosed in (a) further comprise cell lysis reagents; and/or (b) reagent and buffers necessary to carry out one or more reactions.
In some embodiments, a partition (e.g., a droplet or well) comprises a single cell and is processed according to the methods described herein. In some embodiments, a partition comprises a single cell and/or a single nucleus. The single cell and/or the single nucleus may be partitioned and processed according to the methods described herein. In some cases, the single nucleus may be a component of a cell. In some embodiments, a partition comprises chromatin from a single cell or single nucleus (e.g., a single chromosome or other portion of the genome) and is partitioned and processed according to the methods described herein. In some embodiments, the transposition reactions and methods described herein are performed in bulk and biological particles (e.g., nuclei/cells/chromatin from single cells) are then partitioned such that a plurality of partitions is singly occupied by a biological particle (e.g., a cell, cell nucleus, chromatin, or cell bead). For example, a plurality of biological particles may be partitioned into a plurality of partitions such that partitions of the plurality of partitions comprise a single biological particle.
In some embodiments, the oligonucleotides described herein comprise a transposon end sequence. In some embodiments, the transposon end sequence is a Tn5 or modified Tn5 transposon end sequence. In some embodiments, the transposon end sequence is a Mu transposon end sequence. In some embodiments, the transposon end sequence has a sequence of: AGATGTGTATAAGAGACA (SEQ ID NO: 1).
In some embodiments, the oligonucleotides described herein comprise an RI sequencing priming region. In some embodiments, the R1 sequencing primer region has a sequence of TCTACACTCTTTCCCTACACGACGCTCTTCCGATCT (SEQ ID NO: 2), or some portion thereof. In some embodiments, the R1 sequencing primer region has a sequence of TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG (SEQ ID NO: 3), or some portion thereof. In some embodiments, the oligonucleotides described herein comprise a partial R1 sequence. In some embodiments, the partial R1 sequence is ACTACACGACGCTCTTCCGATCT (SEQ ID NO: 4).
In some embodiments, the oligonucleotides described herein comprise an R2 sequencing priming region. In some embodiments, the R2 sequencing primer region has a sequence of GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT (SEQ ID NO: 5), or some portion thereof. In some embodiments, the R2 sequencing primer region has a sequence of GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG (SEQ ID NO: 6), or some portion thereof. In some embodiments, the oligonucleotides described herein comprise a T7 promoter sequence. In some embodiments, the T7 promoter sequence is TAATACGACTCACTATAG (SEQ ID NO: 7). In some embodiments, the oligonucleotides described herein comprise a region at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NO: 1-7. In some embodiments, the oligonucleotides described herein comprise a P5 sequence. In some embodiments, the oligonucleotides described herein comprise a P7 sequence. In some embodiments, the oligonucleotides described herein comprise a sample index sequence.
In some embodiments, the oligonucleotides described herein are attached to a solid support (e.g., a solid or semi-solid particle such as a bead). In some embodiments, the oligonucleotides described herein are attached to a bead. In some embodiments, the bead is a gel bead. In some embodiments, the oligonucleotides described herein are releasably attached to a bead (e.g., a gel bead). In some embodiments, the oligonucleotides described herein are single-stranded and the first strand attached to a bead. In some embodiments, the oligonucleotides described herein are double-stranded or partially double-stranded molecules and the first strand is releasably attached to a bead. In some embodiments, the oligonucleotides described herein are double-stranded or partially double-stranded molecules and the second strand is releasably attached to a bead. In some embodiments, the oligonucleotides described herein are double-stranded or partially double-stranded molecules and both the first and the second strand are releasably attached to a bead or a collection of beads.
In some embodiments, the solid support (e.g., bead, such as a gel bead) comprises a plurality of first oligonucleotides and a plurality of second oligonucleotides. In some embodiments, the first oligonucleotides, the second oligonucleotides, or the combination thereof are releasably attached to a bead. In some embodiments, the first oligonucleotides, the second oligonucleotides, or the combination thereof are double-stranded or partially double-stranded molecules and the first strand is releasably attached to a bead. In some embodiments, the first oligonucleotides, the second oligonucleotides, or the combination thereof are double-stranded or partially double-stranded molecules and the second strand is releasably attached to abead. In some embodiments, the first oligonucleotides, the second oligonucleotides, or the combination thereof are double-stranded or partially double-stranded molecules and the first strand and the second strand are releasably attached to abead. In some embodiments, the oligonucleotides, the first oligonucleotides, the second oligonucleotides, or a combination there of are bound to a magnetic particle. In some embodiments, the magnetic particle is embedded in a solid support (e.g., a bead, such as a gel bead).
In some embodiments, the first oligonucleotides are capable of coupling (e.g., by nucleic acid hybridization) to DNA molecules and the second oligonucleotides are capable of coupling (e.g., by nucleic acid hybridization) to RNA molecules (e.g., mRNA molecules). Examples of oligonucleotide architecture are provided in
In some embodiments, the first oligonucleotide comprises a P5 adaptor sequence, a barcode sequence, and an R1 sequence or partial R1 primer sequence and is partially double-stranded, and the second oligonucleotide comprises a R1 or partial R1 primer sequence, a barcode sequence, a unique molecular identifier (UNIT) sequence, and a poly(dT) sequence. In some embodiments, the first oligonucleotide comprises a P5 adaptor sequence, a barcode sequence, and an R1 or partial R1 primer sequence and is single-stranded, and the second oligonucleotide comprises a R1 or partial R1 sequence, a barcode sequence, a unique molecular identifier (UMI) sequence, and a template switching oligo sequence.
Systems and Methods for Sample Compartmentalization
In an aspect, the systems and methods described herein provide for the compartmentalization, depositing, and/or partitioning of one or more particles (e.g., biological particles, macromolecular constituents of biological particles, beads, reagents, etc.) into discrete compartments or partitions (referred to interchangeably herein as partitions), where each partition maintains separation of its own contents from the contents of other partitions. The partition can be, for example, a well or a droplet in an emulsion. A partition may comprise one or more other partitions.
A partition may include one or more particles. A partition may include one or more types of particles. For example, a partition of the present disclosure may comprise one or more biological particles and/or macromolecular constituents thereof. For example, a partition may comprise one or more cells, nuclei, chromatins, and/or cell beads. For instance, a partition may comprise one or more cell beads. A cell bead can be a biological particle and/or one or more of its macromolecular constituents encased inside of a gel or polymer matrix, such as via polymerization of a droplet containing the biological particle and precursors capable of being polymerized or gelled. A partition may comprise one or more solid or semi-solid particles. For example, a partition may comprise one or more beads, such as one or more gel beads. In some cases, a partition may include a single gel bead, a single cell bead, or both a single cell bead and single gel bead. A partition may include one or more reagents (e.g., as described herein). Unique identifiers, such as barcodes, may be injected into the droplets previous to, subsequent to, or concurrently with droplet generation, such as via a microcapsule (e.g., bead), as described elsewhere herein. The barcodes may comprise nucleic acid sequences. Such nucleic acid barcode sequences may be components of nucleic acid barcode molecules, which may be coupled (e.g., releasably coupled) to a solid or semi-solid particle such as a bead. In some cases, a partition may be unoccupied. For example, a partition may not comprise a bead or a biological particle. Microfluidic devices comprising one or more channels (e.g., microfluidic channel networks of a chip) can be utilized to generate partitions as described herein. For example, a first fluid and a second fluid that is immiscible with the first fluid may be flowed to a droplet generation junction, and a droplet of the first fluid may be generated within the second fluid. Alternative mechanisms may also be employed in the partitioning of individual biological particles, including porous membranes through which aqueous mixtures of cells are extruded into non-aqueous fluids.
The partitions can be flowable within fluid streams. The partitions may comprise, for example, micro-vesicles that have an outer barrier surrounding an inner fluid center or core. In some cases, the partitions may comprise a porous matrix that is capable of entraining and/or retaining materials within its matrix. The partitions can be droplets of a first phase within a second phase, wherein the first and second phases are immiscible. For example, the partitions can be droplets of aqueous fluid within a non-aqueous continuous phase (e.g., oil phase). In another example, the partitions can be droplets of a non-aqueous fluid within an aqueous phase. In some examples, the partitions may be provided in a water-in-oil emulsion or oil-in-water emulsion. A variety of different vessels are described in, for example, U.S. Patent Application Publication No. 2014/0155295, which is entirely incorporated herein by reference for all purposes. Emulsion systems for creating stable droplets in non-aqueous or oil continuous phases are described in, for example, U.S. Patent Application Publication No. 2010/0105112, which is entirely incorporated herein by reference for all purposes.
In the case of droplets in an emulsion, allocating individual particles to discrete partitions may in one non-limiting example be accomplished by introducing a flowing stream of particles in an aqueous fluid into a flowing stream of a non-aqueous fluid, such that droplets are generated at the junction of the two streams. Fluid properties (e.g., fluid flow rates, fluid viscosities, etc.), particle properties (e.g., volume fraction, particle size, particle concentration, etc.), microfluidic architectures (e.g., channel geometry, etc.), and other parameters may be adjusted to control the occupancy of the resulting partitions (e.g., number of biological particles per partition, number of beads per partition, etc.). For example, partition occupancy can be controlled by providing the aqueous stream at a certain concentration and/or flow rate of particles. To generate single biological particle partitions, the relative flow rates of the immiscible fluids can be selected such that, on average, the partitions may contain less than one biological particle per partition in order to ensure that those partitions that are occupied are primarily singly occupied. In some cases, partitions among a plurality of partitions may contain at most one biological particle (e.g., cell bead, chromatin, DNA, cell, cell nucleus, or other cellular material). In some embodiments, the various parameters (e.g., fluid properties, particle properties, microfluidic architectures, etc.) may be selected or adjusted such that a majority of partitions are occupied, for example, allowing for only a small percentage of unoccupied partitions. The flows and channel architectures can be controlled as to ensure a given number of singly occupied partitions, less than a certain level of unoccupied partitions and/or less than a certain level of multiply occupied partitions.
The second fluid 116 can comprise an oil, such as a fluorinated oil, that includes a fluorosurfactant for stabilizing the resulting droplets, for example, inhibiting subsequent coalescence of the resulting droplets 118, 120. Examples of particularly useful partitioning fluids and fluorosurfactants are described, for example, in U.S. Patent Application Publication No. 2010/0105112, which is entirely incorporated herein by reference for all purposes.
As will be appreciated, the channel segments described herein may be coupled to any of a variety of different fluid sources or receiving components, including reservoirs, tubing, manifolds, or fluidic components of other systems. As will be appreciated, the microfluidic channel structure 100 may have other geometries. For example, a microfluidic channel structure can have more than one channel junction. For example, a microfluidic channel structure can have 2, 3, 4, or 5 channel segments each carrying particles (e.g., biological particles, cell beads, and/or solid or semi-solid particles such as gel beads) that meet at a channel junction. Fluid may be directed to flow along one or more channels or reservoirs via one or more fluid flow units. A fluid flow unit can comprise compressors (e.g., providing positive pressure), pumps (e.g., providing negative pressure), actuators, and the like to control flow of the fluid. Fluid may also or otherwise be controlled via applied pressure differentials, centrifugal force, electrokinetic pumping, vacuum, capillary or gravity flow, or the like.
The generated droplets may comprise two subsets of droplets: (1) occupied droplets 118, containing one or more biological particles 114, and (2) unoccupied droplets 120, not containing any biological particles 114. Occupied droplets 118 may comprise singly occupied droplets (having one biological particle) and multiply occupied droplets (having more than one biological particle). As described elsewhere herein, in some cases, the majority of occupied partitions can include no more than one biological particle per occupied partition and some of the generated partitions can be unoccupied (of any biological particle). In some cases, though, some of the occupied partitions may include more than one biological particle. In some cases, the partitioning process may be controlled such that fewer than about 25% of the occupied partitions contain more than one biological particle, and in many cases, fewer than about 20% of the occupied partitions have more than one biological particle, while in some cases, fewer than about 10% or even fewer than about 5% of the occupied partitions include more than one biological particle per partition.
In some cases, it may be desirable to minimize the creation of excessive numbers of empty partitions, such as to reduce costs and/or increase efficiency. While this minimization may be achieved by providing a sufficient number of biological particles (e.g., biological particles 114) at the partitioning junction 110, such as to ensure that at least one biological particle is encapsulated in a partition, the Poissonian distribution may expectedly increase the number of partitions that include multiple biological particles. As such, where singly occupied partitions are to be obtained, at most about 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5% or less of the generated partitions can be unoccupied.
In some cases, the flow of one or more of the biological particles (e.g., in channel segment 102), or other fluids directed into the partitioning junction (e.g., in channel segments 104, 106) can be controlled such that, in many cases, no more than about 50% of the generated partitions, no more than about 25% of the generated partitions, or no more than about 10% of the generated partitions are unoccupied. These flows can be controlled so as to present a non-Poissonian distribution of singly-occupied partitions while providing lower levels of unoccupied partitions. The above noted ranges of unoccupied partitions can be achieved while still providing any of the single occupancy rates described above. For example, in many cases, the use of the systems and methods described herein may result in partitions that have multiple occupancy rates of less than about 25%, less than about 20%, less than about 15%, less than about 10%, and in many cases, less than about 5%, while having unoccupied partitions of less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 10%, less than about 5%, or less.
As will be appreciated, the above-described occupancy rates are also applicable to partitions that include both biological particles and additional reagents, including, but not limited to, microcapsules or beads (e.g., gel beads) carrying barcoded nucleic acid molecules (e.g., oligonucleotides) (described in relation to
In another aspect, in addition to or as an alternative to droplet based partitioning, biological particles (e.g., as described herein) may be encapsulated within a microcapsule that comprises an outer shell, layer or porous matrix in which is entrained one or more individual biological particles or small groups of biological particles. The microcapsule may include other reagents. Encapsulation of biological particles may be performed by a variety of processes. Such processes may combine an aqueous fluid containing the biological particles with a polymeric precursor material that may be capable of being formed into a gel or other solid or semi-solid matrix upon application of a particular stimulus to the polymer precursor. Such stimuli can include, for example, thermal stimuli (e.g., either heating or cooling), photo-stimuli (e.g., through photo-curing), chemical stimuli (e.g., through crosslinking, polymerization initiation of the precursor (e.g., through added initiators)), mechanical stimuli, or a combination thereof.
Preparation of microcapsules comprising biological particles may be performed by a variety of methods. For example, air knife droplet or aerosol generators may be used to dispense droplets of precursor fluids into gelling solutions in order to form microcapsules that include individual biological particles or small groups of biological particles. Likewise, membrane based encapsulation systems may be used to generate microcapsules comprising encapsulated biological particles as described herein. Microfluidic systems of the present disclosure, such as that shown in
For example, in the case where the polymer precursor material comprises a linear polymer material, such as a linear polyacrylamide, PEG, or other linear polymeric material, the activation agent may comprise a cross-linking agent, or a chemical that activates a cross-linking agent within the formed droplets. Likewise, for polymer precursors that comprise polymerizable monomers, the activation agent may comprise a polymerization initiator. For example, in certain cases, where the polymer precursor comprises a mixture of acrylamide monomer with a N,N′-bis-(acryloyl)cystamine (BAC) comonomer, an agent such as tetraethylmethylenediamine (TEMED) may be provided within the second fluid streams 116 in channel segments 104 and 106, which can initiate the copolymerization of the acrylamide and BAC into a cross-linked polymer network, or hydrogel.
Upon contact of the second fluid stream 116 with the first fluid stream 112 at junction 110, during formation of droplets, the TEMED may diffuse from the second fluid 116 into the aqueous fluid 112 comprising the linear polyacrylamide, which will activate the crosslinking of the polyacrylamide within the droplets 118, 120, resulting in the formation of gel (e.g., hydrogel) microcapsules, as solid or semi-solid beads or particles entraining the biological particles (e.g., cells) 114. Although described in terms of polyacrylamide encapsulation, other activatable' encapsulation compositions may also be employed in the context of the methods and compositions described herein. For example, formation of alginate droplets followed by exposure to divalent metal ions (e.g., Ca2+ ions), can be used as an encapsulation process using the described processes. Likewise, agarose droplets may also be transformed into capsules through temperature based gelling (e.g., upon cooling, etc.).
In some cases, encapsulated biological particles can be selectively releasable from the microcapsule, such as through passage of time or upon application of a particular stimulus, that degrades the microcapsule sufficiently to allow the biological particles (e.g., cell), or its other contents to be released from the microcapsule, such as into a partition (e.g., droplet). For example, in the case of the polyacrylamide polymer described above, degradation of the microcapsule may be accomplished through the introduction of an appropriate reducing agent, such as dithiothreitol (DTT) or the like, to cleave disulfide bonds that cross-link the polymer matrix. See, for example, U.S. Patent Application Publication No. 2014/0378345, which is entirely incorporated herein by reference for all purposes.
The biological particle can be subjected to other conditions sufficient to polymerize or gel the precursors. The conditions sufficient to polymerize or gel the precursors may comprise exposure to heating, cooling, electromagnetic radiation, and/or light. The conditions sufficient to polymerize or gel the precursors may comprise any conditions sufficient to polymerize or gel the precursors. Following polymerization or gelling, a polymer or gel may be formed around and/or within the biological particle. The polymer or gel may be diffusively permeable to chemical or biochemical reagents. The polymer or gel may be diffusively impermeable to macromolecular constituents of the biological particle. In this manner, the polymer or gel may act to allow the biological particle to be subjected to chemical or biochemical operations while spatially confining the macromolecular constituents to a region of the droplet defined by the polymer or gel. The polymer or gel may include one or more of disulfide cross-linked polyacrylamide, agarose, alginate, polyvinyl alcohol, polyethylene glycol (PEG)-diacrylate, PEG-acrylate, PEG-thiol, PEG-azide, PEG-alkyne, other acrylates, chitosan, hyaluronic acid, collagen, fibrin, gelatin, or elastin. The polymer or gel may comprise any other polymer or gel. A cell comprising a polymer or gel matrix may be referred to as a “cell bead.”
The polymer or gel may be functionalized to bind to targeted analytes, such as nucleic acids, proteins, carbohydrates, lipids or other analytes. The polymer or gel may be polymerized or gelled via a passive mechanism. For example, polymerization or gelling may be brought about by a change in salinity, pH, temperature, or pressure. The polymer or gel may be stable in alkaline conditions or at elevated temperature. The polymer or gel may have mechanical properties similar to the mechanical properties of the bead. For instance, a polymer or gel matrix may be of a similar size to the bead. The polymer or gel may have a mechanical strength (e.g. tensile strength) similar to that of the bead. The polymer or gel may be of a lower density than an oil. The polymer or gel may be of a density that is roughly similar to that of a buffer. The polymer or gel may have a tunable pore size. The pore size may be chosen to, for instance, retain denatured nucleic acids. The pore size may be chosen to maintain diffusive permeability to exogenous chemicals such as sodium hydroxide (NaOH) and/or endogenous chemicals such as inhibitors. The polymer or gel may be biocompatible. The polymer or gel may maintain or enhance cell viability. The polymer or gel may be biochemically compatible. The polymer or gel may be polymerized and/or depolymerized thermally, chemically, enzymatically, and/or optically.
The polymer or gel may comprise poly(acrylamide-co-acrylic acid) crosslinked with disulfide linkages. The preparation of the polymer or gel may comprise a two-step reaction. In the first activation step, poly(acrylamide-co-acrylic acid) may be exposed to an acylating agent to convert carboxylic acids to esters. For instance, the poly(acrylamide-co-acrylic acid) may be exposed to 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM). The polyacrylamide-co-acrylic acid may be exposed to other salts of 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium. In the second cross-linking step, the ester formed in the first step may be exposed to a disulfide crosslinking agent. For instance, the ester may be exposed to cystamine (2,2′-dithiobis(ethylamine)). Following the two steps, the biological particle may be surrounded by polyacrylamide strands linked together by disulfide bridges. In this manner, the biological particle may be encased inside of or comprise a gel or matrix (e.g., polymer matrix) to form a “cell bead.” A cell bead can contain biological particles (e.g., a cell) or macromolecular constituents (e.g., RNA, DNA, proteins, etc.) of biological particles. A cell bead may include a single cell or multiple cells, or a derivative of the single cell or multiple cells. For example after lysing and washing the cells, inhibitory components from cell lysates can be washed away and the macromolecular constituents can be bound as cell beads. Systems and methods disclosed herein can be applicable to both cell beads (and/or droplets or other partitions) containing biological particles and cell beads (and/or droplets or other partitions) containing macromolecular constituents of biological particles.
Encapsulated biological particles can provide certain potential advantages of being more storable and more portable than droplet-based partitioned biological particles. Furthermore, in some cases, it may be desirable to allow biological particles to incubate for a select period of time before analysis, such as in order to characterize changes in such biological particles over time, either in the presence or absence of different stimuli. In such cases, encapsulation may allow for longer incubation than partitioning in emulsion droplets, although in some cases, droplet partitioned biological particles may also be incubated for different periods of time, e.g., at least 10 seconds, at least 30 seconds, at least 1 minute, at least 5 minutes, at least 10 minutes, at least 30 minutes, at least 1 hour, at least 2 hours, at least 5 hours, or at least 10 hours or more. The encapsulation of biological particles may constitute the partitioning of the biological particles into which other reagents are co-partitioned. Alternatively or in addition, encapsulated biological particles may be readily deposited into other partitions (e.g., droplets) as described above.
Beads
A partition may comprise one or more unique identifiers, such as one or more barcodes. Barcodes may be previously, subsequently or concurrently delivered to the partitions that hold the compartmentalized or partitioned biological particle. For example, barcodes may be injected into droplets previous to, subsequent to, or concurrently with droplet generation. The delivery of the barcodes to a particular partition allows for the later attribution of the characteristics of the individual biological particle to the particular partition. Barcodes may be delivered, for example, as components of a nucleic acid molecule (e.g., an oligonucleotide). Barcodes may be delivered to a partition via any suitable mechanism. For example, barcoded nucleic acid molecules can be delivered to a partition such as a droplet or well via a microcapsule or bead. A microcapsule, in some instances, can comprise a bead. Beads are described in further detail below.
In some cases, barcoded nucleic acid molecules can be initially associated with the microcapsule or bead and then released from the microcapsule or bead. For example, a bead may comprise a plurality of nucleic acid barcode molecules releasably coupled thereto. Release of the barcoded nucleic acid molecules can be passive (e.g., by diffusion out of the microcapsule or bead). In addition or alternatively, release from the microcapsule or bead can be upon application of a stimulus which allows the barcoded nucleic acid nucleic acid molecules to dissociate or to be released from the microcapsule or bead. Such stimulus may disrupt the microcapsule or bead, an interaction that couples the barcoded nucleic acid molecules to or within the microcapsule or bead, or both. Such stimulus can include, for example, a thermal stimulus, photo-stimulus, chemical stimulus (e.g., change in pH or use of a reducing agent(s)), a mechanical stimulus, a radiation stimulus; a biological stimulus (e.g., enzyme), or any combination thereof.
As an alternative, the channel segments 201 and 202 may meet at another junction upstream of the junction 210. At such junction, beads and biological particles may form a mixture that is directed along another channel to the junction 210 to yield droplets 220. The mixture may provide the beads and biological particles in an alternating fashion, such that, for example, a droplet comprises a single bead and a single biological particle.
Beads, biological particles and droplets (e.g., droplets comprising beads and/or biological particles) may flow along channels at substantially regular flow profiles (e.g., at regular flow rates). Such regular flow profiles may permit a droplet to be formed such that it includes a single bead and a single biological particle. Such regular flow profiles may permit the droplets to have an occupancy (e.g., droplets having beads and biological particles) greater than 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%. Such regular flow profiles and devices that may be used to provide such regular flow profiles are provided in, for example, U.S. Patent Publication No. 2015/0292988, which is entirely incorporated herein by reference.
The second fluid 218 can comprise an oil, such as a fluorinated oil, that includes a fluorosurfactant for stabilizing the resulting droplets, for example, inhibiting subsequent coalescence of the resulting droplets 220.
A discrete droplet that is generated may include an individual biological particle 216. A discrete droplet that is generated may include a bead 214 comprising a barcode or other reagent. For example, bead 214 may comprise a plurality of nucleic acid barcode molecules each comprising a common barcode sequence. A discrete droplet generated may include both an individual biological particle and a barcode carrying bead, such as droplets 220. In some instances, a discrete droplet may include more than one individual biological particle or no biological particle. In some instances, a discrete droplet may include more than one bead or no bead. A discrete droplet may be unoccupied (e.g., no beads, no biological particles).
Beneficially, a discrete droplet partitioning a biological particle and a barcode carrying bead may effectively allow the attribution of the barcode to macromolecular constituents of the biological particle within the partition. The contents of a partition may remain discrete from the contents of other partitions.
As will be appreciated, the channel segments described herein may be coupled to any of a variety of different fluid sources or receiving components, including reservoirs, tubing, manifolds, or fluidic components of other systems. As will be appreciated, the microfluidic channel structure 200 may have other geometries. For example, a microfluidic channel structure can have more than one channel junctions. For example, a microfluidic channel structure can have 2, 3, 4, or 5 channel segments each carrying beads that meet at a channel junction. Fluid may be directed flow along one or more channels or reservoirs via one or more fluid flow units. A fluid flow unit can comprise compressors (e.g., providing positive pressure), pumps (e.g., providing negative pressure), actuators, and the like to control flow of the fluid. Fluid may also or otherwise be controlled via applied pressure differentials, centrifugal force, electrokinetic pumping, vacuum, capillary or gravity flow, or the like.
A bead may be porous, non-porous, solid, semi-solid, semi-fluidic, fluidic, and/or a combination thereof. In some instances, a bead may be dissolvable, disruptable, and/or degradable. In some cases, a bead may not be degradable. In some cases, the bead may be a gel bead. A gel bead may be a hydrogel bead. A gel bead may be formed from molecular precursors, such as a polymeric or monomeric species. A semi-solid bead may be a liposomal bead. Solid beads may comprise metals including iron oxide, gold, and silver. In some cases, the bead may be a silica bead. In some cases, the bead can be rigid. In other cases, the bead may be flexible and/or compressible.
A bead may be of any suitable shape. Examples of bead shapes include, but are not limited to, spherical, non-spherical, oval, oblong, amorphous, circular, cylindrical, and variations thereof.
Beads may be of uniform size or heterogeneous size. In some cases, the diameter of a bead may be at least about 10 nanometers (nm), 100 nm, 500 nm, 1 micrometer (μm), 5 μm, 10 μm, 20 μm, 30 μm, 40 μm, 50 μm, 60 μm, 70 μm, 80 μm, 90 μm, 100 μm, 250 μm, 500 μm, 1 mm, or greater. In some cases, a bead may have a diameter of less than about 10 nm, 100 nm, 500 nm, 1 μm, 5 μm, 10 μm, 20 μm, 30 μm, 40 μm, 50 μm, 60 μm, 70 μm, 80 μm, 90 μm, 100 μm, 250 μm, 500 μm, 1 mm, or less. In some cases, a bead may have a diameter in the range of about 40-75 μm, 30-75 μm, 20-75 μm, 40-85 μm, 40-95 μm, 20-100 μm, 10-100 μm, 1-100 μm, 20-250 μm, or 20-500 μm.
In certain aspects, beads can be provided as a population or plurality of beads having a relatively monodisperse size distribution. Where it may be desirable to provide relatively consistent amounts of reagents within partitions, maintaining relatively consistent bead characteristics, such as size, can contribute to the overall consistency. In particular, the beads described herein may have size distributions that have a coefficient of variation in their cross-sectional dimensions of less than 50%, less than 40%, less than 30%, less than 20%, and in some cases less than 15%, less than 10%, less than 5%, or less. A bead may comprise natural and/or synthetic materials. For example, a bead can comprise a natural polymer, a synthetic polymer or both natural and synthetic polymers. Examples of natural polymers include proteins and sugars such as deoxyribonucleic acid, rubber, cellulose, starch (e.g., amylose, amylopectin), proteins, enzymes, polysaccharides, silks, polyhydroxyalkanoates, chitosan, dextran, collagen, carrageenan, ispaghula, acacia, agar, gelatin, shellac, sterculia gum, xanthan gum, Corn sugar gum, guar gum, gum karaya, agarose, alginic acid, alginate, or natural polymers thereof. Examples of synthetic polymers include acrylics, nylons, silicones, spandex, viscose rayon, polycarboxylic acids, polyvinyl acetate, polyacrylamide, polyacrylate, polyethylene glycol, polyurethanes, polylactic acid, silica, polystyrene, polyacrylonitrile, polybutadiene, polycarbonate, polyethylene, polyethylene terephthalate, poly(chlorotrifluoroethylene), poly(ethylene oxide), poly(ethylene terephthalate), polyethylene, polyisobutylene, poly(methyl methacrylate), poly(oxymethylene), polyformaldehyde, polypropylene, polystyrene, poly(tetrafluoroethylene), poly(vinyl acetate), poly(vinyl alcohol), poly(vinyl chloride), poly(vinylidene dichloride), poly(vinylidene difluoride), poly(vinyl fluoride) and/or combinations (e.g., co-polymers) thereof. Beads may also be formed from materials other than polymers, including lipids, micelles, ceramics, glass-ceramics, material composites, metals, other inorganic materials, and others.
In some instances, the bead may contain molecular precursors (e.g., monomers or polymers), which may form a polymer network via polymerization of the molecular precursors. In some cases, a precursor may be an already polymerized species capable of undergoing further polymerization via, for example, a chemical cross-linkage. In some cases, a precursor can comprise one or more of an acrylamide or a methacrylamide monomer, oligomer, or polymer. In some cases, the bead may comprise prepolymers, which are oligomers capable of further polymerization. For example, polyurethane beads may be prepared using prepolymers. In some cases, the bead may contain individual polymers that may be further polymerized together. In some cases, beads may be generated via polymerization of different precursors, such that they comprise mixed polymers, co-polymers, and/or block co-polymers. In some cases, the bead may comprise covalent or ionic bonds between polymeric precursors (e.g., monomers, oligomers, linear polymers), nucleic acid molecules (e.g., oligonucleotides), primers, and other entities. In some cases, the covalent bonds can be carbon-carbon bonds, thioether bonds, or carbon-heteroatom bonds.
Cross-linking may be permanent or reversible, depending upon the particular cross-linker used. Reversible cross-linking may allow for the polymer to linearize or dissociate under appropriate conditions. In some cases, reversible cross-linking may also allow for reversible attachment of a material bound to the surface of a bead. In some cases, a cross-linker may form disulfide linkages. In some cases, the chemical cross-linker forming disulfide linkages may be cystamine or a modified cystamine.
In some cases, disulfide linkages can be formed between molecular precursor units (e.g., monomers, oligomers, or linear polymers) or precursors incorporated into a bead and nucleic acid molecules (e.g., oligonucleotides). Cystamine (including modified cystamines), for example, is an organic agent comprising a disulfide bond that may be used as a crosslinker agent between individual monomeric or polymeric precursors of a bead. Polyacrylamide may be polymerized in the presence of cystamine or a species comprising cystamine (e.g., a modified cystamine) to generate polyacrylamide gel beads comprising disulfide linkages (e.g., chemically degradable beads comprising chemically-reducible cross-linkers). The disulfide linkages may permit the bead to be degraded (or dissolved) upon exposure of the bead to a reducing agent.
In some cases, chitosan, a linear polysaccharide polymer, may be crosslinked with glutaraldehyde via hydrophilic chains to form a bead. Crosslinking of chitosan polymers may be achieved by chemical reactions that are initiated by heat, pressure, change in pH, and/or radiation.
In some cases, a bead may comprise an acrydite moiety, which in certain aspects may be used to attach one or more nucleic acid molecules (e.g., barcode sequence, barcoded nucleic acid molecule, barcoded oligonucleotide, primer, or other oligonucleotide) to the bead. In some cases, an acrydite moiety can refer to an acrydite analogue generated from the reaction of acrydite with one or more species, such as, the reaction of acrydite with other monomers and cross-linkers during a polymerization reaction. Acrydite moieties may be modified to form chemical bonds with a species to be attached, such as a nucleic acid molecule (e.g., barcode sequence, barcoded nucleic acid molecule, barcoded oligonucleotide, primer, or other oligonucleotide). Acrydite moieties may be modified with thiol groups capable of forming a disulfide bond or may be modified with groups already comprising a disulfide bond. The thiol or disulfide (via disulfide exchange) may be used as an anchor point for a species to be attached or another part of the acrydite moiety may be used for attachment. In some cases, attachment can be reversible, such that when the disulfide bond is broken (e.g., in the presence of a reducing agent), the attached species is released from the bead. In other cases, an acrydite moiety can comprise a reactive hydroxyl group that may be used for attachment.
Functionalization of beads for attachment of nucleic acid molecules (e.g., oligonucleotides) may be achieved through a wide range of different approaches, including activation of chemical groups within a polymer, incorporation of active or activatable functional groups in the polymer structure, or attachment at the pre-polymer or monomer stage in bead production.
For example, precursors (e.g., monomers, cross-linkers) that are polymerized to form a bead may comprise acrydite moieties, such that when a bead is generated, the bead also comprises acrydite moieties. The acrydite moieties can be attached to a nucleic acid molecule (e.g., oligonucleotide), which may include a priming sequence (e.g., a primer for amplifying target nucleic acids, random primer, primer sequence for messenger RNA) and/or one or more barcode sequences. The one more barcode sequences may include sequences that are the same for all nucleic acid molecules (e.g., nucleic acid barcode molecules) coupled to a given bead and/or sequences that are different across all nucleic acid molecules coupled to the given bead. The nucleic acid molecule may be incorporated into the bead and/or may be attached to a surface of the bead.
In some cases, the nucleic acid molecule_(e.g., nucleic acid barcode molecule) can comprise a functional sequence, for example, for attachment to a sequencing flow cell, such as, for example, a P5 sequence for Illumina® sequencing. In some cases, the nucleic acid molecule (e.g., nucleic acid barcode molecule) or derivative thereof (e.g., oligonucleotide or polynucleotide generated from the nucleic acid molecule) can comprise another functional sequence, such as, for example, a P7 sequence for attachment to a sequencing flow cell for Illumina sequencing. In some cases, the nucleic acid molecule can comprise a barcode sequence. In some cases, the primer can further comprise a unique molecular identifier (UMI). In some cases, the primer can comprise an R1 primer sequence for Illumina sequencing. In some cases, the primer can comprise an R2 primer sequence for Illumina sequencing. Examples of such nucleic acid molecules (e.g., oligonucleotides, polynucleotides, etc.) and uses thereof, as may be used with compositions, devices, methods and systems of the present disclosure, are provided in U.S. Patent Pub. Nos. 2014/0378345 and 2015/0376609, each of which is entirely incorporated herein by reference.
The nucleic acid molecule 802 may comprise a unique molecular identifying sequence 816 (e.g., unique molecular identifier (UMI)). In some cases, the unique molecular identifying sequence 816 may comprise from about 5 to about 8 nucleotides. Alternatively, the unique molecular identifying sequence 816 may compress less than about 5 or more than about 8 nucleotides. The unique molecular identifying sequence 816 may be a unique sequence that varies across individual nucleic acid molecules (e.g., 802, 818, 820, etc.) coupled to a single bead (e.g., bead 804). In some cases, the unique molecular identifying sequence 816 may be a random sequence (e.g., such as a random N-mer sequence). For example, the UMI may provide a unique identifier of the starting mRNA molecule that was captured, in order to allow quantitation of the number of original expressed RNA. As will be appreciated, although
In operation, a biological particle (e.g., cell, DNA, RNA, etc.) can be co-partitioned along with a barcode bearing bead 804. The barcoded nucleic acid molecules 802, 818, 820 can be released from the bead 804 in the partition. By way of example, in the context of analyzing sample RNA, the poly-T segment (e.g., 812) of one of the released nucleic acid molecules (e.g., 802) can hybridize to the poly-A tail of a mRNA molecule. Reverse transcription may result in a cDNA transcript of the mRNA, but which transcript includes each of the sequence segments 808, 810, 816 of the nucleic acid molecule 802. Because the nucleic acid molecule 802 comprises an anchoring sequence 814, it will more likely hybridize to and prime reverse transcription at the sequence end of the poly-A tail of the mRNA. Within any given partition, all of the cDNA transcripts of the individual mRNA molecules may include a common barcode sequence segment 810. However, the transcripts made from the different mRNA molecules within a given partition may vary at the unique molecular identifying sequence 812 segment (e.g., UMI segment). Beneficially, even following any subsequent amplification of the contents of a given partition, the number of different UMIs can be indicative of the quantity of mRNA originating from a given partition, and thus from the biological particle (e.g., cell). As noted above, the transcripts can be amplified, cleaned up and sequenced to identify the sequence of the cDNA transcript of the mRNA, as well as to sequence the barcode segment and the UMI segment. While a poly-T primer sequence is described, other targeted or random priming sequences may also be used in priming the reverse transcription reaction. Likewise, although described as releasing the barcoded oligonucleotides into the partition, in some cases, the nucleic acid molecules bound to the bead (e.g., gel bead) may be used to hybridize and capture the mRNA on the solid phase of the bead, for example, in order to facilitate the separation of the RNA from other cell contents.
In some cases, precursors comprising a functional group that is reactive or capable of being activated such that it becomes reactive can be polymerized with other precursors to generate gel beads comprising the activated or activatable functional group. The functional group may then be used to attach additional species (e.g., disulfide linkers, primers, other oligonucleotides, etc.) to the gel beads. For example, some precursors comprising a carboxylic acid (COOH) group can co-polymerize with other precursors to form a gel bead that also comprises a COOH functional group. In some cases, acrylic acid (a species comprising free COOH groups), acrylamide, and bis(acryloyl)cystamine can be co-polymerized together to generate a gel bead comprising free COOH groups. The COOH groups of the gel bead can be activated (e.g., via 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-Hydroxysuccinimide (NHS) or 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM)) such that they are reactive (e.g., reactive to amine functional groups where EDC/NHS or DMTMM are used for activation). The activated COOH groups can then react with an appropriate species (e.g., a species comprising an amine functional group where the carboxylic acid groups are activated to be reactive with an amine functional group) comprising a moiety to be linked to the bead.
Beads comprising disulfide linkages in their polymeric network may be functionalized with additional species via reduction of some of the disulfide linkages to free thiols. The disulfide linkages may be reduced via, for example, the action of a reducing agent (e.g., DTT, TCEP, etc.) to generate free thiol groups, without dissolution of the bead. Free thiols of the beads can then react with free thiols of a species or a species comprising another disulfide bond (e.g., via thiol-disulfide exchange) such that the species can be linked to the beads (e.g., via a generated disulfide bond). In some cases, free thiols of the beads may react with any other suitable group. For example, free thiols of the beads may react with species comprising an acrydite moiety. The free thiol groups of the beads can react with the acrydite via Michael addition chemistry, such that the species comprising the acrydite is linked to the bead. In some cases, uncontrolled reactions can be prevented by inclusion of a thiol capping agent such as N-ethylmalieamide or iodoacetate.
Activation of disulfide linkages within a bead can be controlled such that only a small number of disulfide linkages are activated. Control may be exerted, for example, by controlling the concentration of a reducing agent used to generate free thiol groups and/or concentration of reagents used to form disulfide bonds in bead polymerization. In some cases, a low concentration (e.g., molecules of reducing agent:gel bead ratios of less than or equal to about 1:100,000,000,000, less than or equal to about 1:10,000,000,000, less than or equal to about 1:1,000,000,000, less than or equal to about 1:100,000,000, less than or equal to about 1:10,000,000, less than or equal to about 1:1,000,000, less than or equal to about 1:100,000, less than or equal to about 1:10,000) of reducing agent may be used for reduction. Controlling the number of disulfide linkages that are reduced to free thiols may be useful in ensuring bead structural integrity during functionalization. In some cases, optically-active agents, such as fluorescent dyes may be coupled to beads via free thiol groups of the beads and used to quantify the number of free thiols present in a bead and/or track a bead.
In some cases, addition of moieties to a gel bead after gel bead formation may be advantageous. For example, addition of an oligonucleotide (e.g., barcoded oligonucleotide) after gel bead formation may avoid loss of the species during chain transfer termination that can occur during polymerization. Moreover, smaller precursors (e.g., monomers or cross linkers that do not comprise side chain groups and linked moieties) may be used for polymerization and can be minimally hindered from growing chain ends due to viscous effects. In some cases, functionalization after gel bead synthesis can minimize exposure of species (e.g., oligonucleotides) to be loaded with potentially damaging agents (e.g., free radicals) and/or chemical environments. In some cases, the generated gel may possess an upper critical solution temperature (UCST) that can permit temperature driven swelling and collapse of a bead. Such functionality may aid in oligonucleotide (e.g., a primer) infiltration into the bead during subsequent functionalization of the bead with the oligonucleotide. Post-production functionalization may also be useful in controlling loading ratios of species in beads, such that, for example, the variability in loading ratio is minimized. Species loading may also be performed in a batch process such that a plurality of beads can be functionalized with the species in a single batch.
A bead injected or otherwise introduced into a partition may comprise releasably, cleavably, or reversibly attached barcodes. A bead injected or otherwise introduced into a partition may comprise activatable barcodes. A bead injected or otherwise introduced into a partition may be degradable, disruptable, or dissolvable beads.
Barcodes can be releasably, cleavably or reversibly attached to the beads such that barcodes can be released or be releasable through cleavage of a linkage between the barcode molecule and the bead, or released through degradation of the underlying bead itself, allowing the barcodes to be accessed or be accessible by other reagents, or both. In non-limiting examples, cleavage may be achieved through reduction of di-sulfide bonds, use of restriction enzymes, photo-activated cleavage, or cleavage via other types of stimuli (e.g., chemical, thermal, pH, enzymatic, etc.) and/or reactions, such as described elsewhere herein. Releasable barcodes may sometimes be referred to as being activatable, in that they are available for reaction once released. Thus, for example, an activatable barcode may be activated by releasing the barcode from a bead (or other suitable type of partition described herein). Other activatable configurations are also envisioned in the context of the described methods and systems.
In addition to, or as an alternative to the cleavable linkages between the beads and the associated molecules, such as barcode containing nucleic acid molecules (e.g., barcoded oligonucleotides), the beads may be degradable, disruptable, or dissolvable spontaneously or upon exposure to one or more stimuli (e.g., temperature changes, pH changes, exposure to particular chemical species or phase, exposure to light, reducing agent, etc.). In some cases, a bead may be dissolvable, such that material components of the beads are solubilized when exposed to a particular chemical species or an environmental change, such as a change temperature or a change in pH. In some cases, a gel bead can be degraded or dissolved at elevated temperature and/or in basic conditions. In some cases, a bead may be thermally degradable such that when the bead is exposed to an appropriate change in temperature (e.g., heat), the bead degrades. Degradation or dissolution of a bead bound to a species (e.g., a nucleic acid molecule, e.g., barcoded oligonucleotide) may result in release of the species from the bead.
As will be appreciated from the above disclosure, the degradation of a bead may refer to the disassociation of a bound or entrained species from a bead, both with and without structurally degrading the physical bead itself. For example, the degradation of the bead may involve cleavage of a cleavable linkage via one or more species and/or methods described elsewhere herein. In another example, entrained species may be released from beads through osmotic pressure differences due to, for example, changing chemical environments. By way of example, alteration of bead pore sizes due to osmotic pressure differences can generally occur without structural degradation of the bead itself. In some cases, an increase in pore size due to osmotic swelling of a bead can permit the release of entrained species within the bead. In other cases, osmotic shrinking of a bead may cause a bead to better retain an entrained species due to pore size contraction.
A degradable bead may be introduced into a partition, such as a droplet of an emulsion or a well, such that the bead degrades within the partition and any associated species (e.g., oligonucleotides) are released within the droplet when the appropriate stimulus is applied. The free species (e.g., oligonucleotides, nucleic acid molecules) may interact with other reagents contained in the partition. For example, a polyacrylamide bead comprising cystamine and linked, via a disulfide bond, to a barcode sequence, may be combined with a reducing agent within a droplet of a water-in-oil emulsion. Within the droplet, the reducing agent can break the various disulfide bonds, resulting in bead degradation and release of the barcode sequence into the aqueous, inner environment of the droplet. In another example, heating of a droplet comprising a bead-bound barcode sequence in basic solution may also result in bead degradation and release of the attached barcode sequence into the aqueous, inner environment of the droplet.
Any suitable number of molecular tag molecules (e.g., primer, barcoded oligonucleotide) can be associated with a bead such that, upon release from the bead, the molecular tag molecules (e.g., primer, e.g., barcoded oligonucleotide) are present in the partition at a pre-defined concentration. Such pre-defined concentration may be selected to facilitate certain reactions for generating a sequencing library, e.g., amplification, within the partition. In some cases, the pre-defined concentration of the primer can be limited by the process of producing nucleic acid molecule (e.g., oligonucleotide) bearing beads.
In some cases, beads can be non-covalently loaded with one or more reagents. The beads can be non-covalently loaded by, for instance, subjecting the beads to conditions sufficient to swell the beads, allowing sufficient time for the reagents to diffuse into the interiors of the beads, and subjecting the beads to conditions sufficient to de-swell the beads. The swelling of the beads may be accomplished, for instance, by placing the beads in a thermodynamically favorable solvent, subjecting the beads to a higher or lower temperature, subjecting the beads to a higher or lower ion concentration, and/or subjecting the beads to an electric field. The swelling of the beads may be accomplished by various swelling methods. The de-swelling of the beads may be accomplished, for instance, by transferring the beads in a thermodynamically unfavorable solvent, subjecting the beads to lower or high temperatures, subjecting the beads to a lower or higher ion concentration, and/or removing an electric field. The de-swelling of the beads may be accomplished by various de-swelling methods. Transferring the beads may cause pores in the bead to shrink. The shrinking may then hinder reagents within the beads from diffusing out of the interiors of the beads. The hindrance may be due to steric interactions between the reagents and the interiors of the beads. The transfer may be accomplished microfluidically. For instance, the transfer may be achieved by moving the beads from one co-flowing solvent stream to a different co-flowing solvent stream. The swellability and/or pore size of the beads may be adjusted by changing the polymer composition of the bead.
In some cases, an acrydite moiety linked to a precursor, another species linked to a precursor, or a precursor itself can comprise a labile bond, such as chemically, thermally, or photo-sensitive bond e.g., disulfide bond, UV sensitive bond, or the like. Once acrydite moieties or other moieties comprising a labile bond are incorporated into a bead, the bead may also comprise the labile bond. The labile bond may be, for example, useful in reversibly linking (e.g., covalently linking) species (e.g., barcodes, primers, etc.) to a bead. In some cases, a thermally labile bond may include a nucleic acid hybridization based attachment, e.g., where an oligonucleotide is hybridized to a complementary sequence that is attached to the bead, such that thermal melting of the hybrid releases the oligonucleotide, e.g., a barcode containing sequence, from the bead or microcapsule.
The addition of multiple types of labile bonds to a gel bead may result in the generation of a bead capable of responding to varied stimuli. Each type of labile bond may be sensitive to an associated stimulus (e.g., chemical stimulus, light, temperature, enzymatic, etc.) such that release of species attached to a bead via each labile bond may be controlled by the application of the appropriate stimulus. Such functionality may be useful in controlled release of species from a gel bead. In some cases, another species comprising a labile bond may be linked to a gel bead after gel bead formation via, for example, an activated functional group of the gel bead as described above. As will be appreciated, barcodes that are releasably, cleavably or reversibly attached to the beads described herein include barcodes that are released or releasable through cleavage of a linkage between the barcode molecule and the bead, or that are released through degradation of the underlying bead itself, allowing the barcodes to be accessed or accessible by other reagents, or both.
The barcodes that are releasable as described herein may sometimes be referred to as being activatable, in that they are available for reaction once released. Thus, for example, an activatable barcode may be activated by releasing the barcode from a bead (or other suitable type of partition described herein). Other activatable configurations are also envisioned in the context of the described methods and systems.
In addition to thermally cleavable bonds, disulfide bonds and UV sensitive bonds, other non-limiting examples of labile bonds that may be coupled to a precursor or bead include an ester linkage (e.g., cleavable with an acid, a base, or hydroxylamine), a vicinal diol linkage (e.g., cleavable via sodium periodate), a Diels-Alder linkage (e.g., cleavable via heat), a sulfone linkage (e.g., cleavable via a base), a silyl ether linkage (e.g., cleavable via an acid), a glycosidic linkage (e.g., cleavable via an amylase), a peptide linkage (e.g., cleavable via a protease), or a phosphodiester linkage (e.g., cleavable via a nuclease (e.g., DNAase)). A bond may be cleavable via other nucleic acid molecule targeting enzymes, such as restriction enzymes (e.g., restriction endonucleases), as described further below.
Species may be encapsulated in beads during bead generation (e.g., during polymerization of precursors). Such species may or may not participate in polymerization. Such species may be entered into polymerization reaction mixtures such that generated beads comprise the species upon bead formation. In some cases, such species may be added to the gel beads after formation. Such species may include, for example, nucleic acid molecules (e.g., oligonucleotides), reagents for a nucleic acid amplification reaction (e.g., primers, polymerases, dNTPs, co-factors (e.g., ionic co-factors), buffers) including those described herein, reagents for enzymatic reactions (e.g., enzymes, co-factors, substrates, buffers), reagents for nucleic acid modification reactions such as polymerization, ligation, or digestion, and/or reagents for template preparation (e.g., tagmentation) for one or more sequencing platforms (e.g., Nextera® for Illumina®). Such species may include one or more enzymes described herein, including without limitation, polymerase, reverse transcriptase, restriction enzymes (e.g., endonuclease), transposase, ligase, proteinase K, DNAse, etc. Such species may include one or more reagents described elsewhere herein (e.g., lysis agents, inhibitors, inactivating agents, chelating agents, stimulus). Trapping of such species may be controlled by the polymer network density generated during polymerization of precursors, control of ionic charge within the gel bead (e.g., via ionic species linked to polymerized species), or by the release of other species. Encapsulated species may be released from a bead upon bead degradation and/or by application of a stimulus capable of releasing the species from the bead. Alternatively or in addition, species may be partitioned in a partition (e.g., droplet) during or subsequent to partition formation. Such species may include, without limitation, the abovementioned species that may also be encapsulated in a bead.
A degradable bead may comprise one or more species with a labile bond such that, when the bead/species is exposed to the appropriate stimuli, the bond is broken and the bead degrades. The labile bond may be a chemical bond (e.g., covalent bond, ionic bond) or may be another type of physical interaction (e.g., van der Waals interactions, dipole-dipole interactions, etc.). In some cases, a crosslinker used to generate a bead may comprise a labile bond. Upon exposure to the appropriate conditions, the labile bond can be broken and the bead degraded. For example, upon exposure of a polyacrylamide gel bead comprising cystamine crosslinkers to a reducing agent, the disulfide bonds of the cystamine can be broken and the bead degraded.
A degradable bead may be useful in more quickly releasing an attached species (e.g., a nucleic acid molecule, a barcode sequence, a primer, etc) from the bead when the appropriate stimulus is applied to the bead as compared to a bead that does not degrade. For example, for a species bound to an inner surface of a porous bead or in the case of an encapsulated species, the species may have greater mobility and accessibility to other species in solution upon degradation of the bead. In some cases, a species may also be attached to a degradable bead via a degradable linker (e.g., disulfide linker). The degradable linker may respond to the same stimuli as the degradable bead or the two degradable species may respond to different stimuli. For example, a barcode sequence may be attached, via a disulfide bond, to a polyacrylamide bead comprising cystamine. Upon exposure of the barcoded-bead to a reducing agent, the bead degrades and the barcode sequence is released upon breakage of both the disulfide linkage between the barcode sequence and the bead and the disulfide linkages of the cystamine in the bead.
As will be appreciated from the above disclosure, while referred to as degradation of a bead, in many instances as noted above, that degradation may refer to the disassociation of a bound or entrained species from a bead, both with and without structurally degrading the physical bead itself. For example, entrained species may be released from beads through osmotic pressure differences due to, for example, changing chemical environments. By way of example, alteration of bead pore sizes due to osmotic pressure differences can generally occur without structural degradation of the bead itself In some cases, an increase in pore size due to osmotic swelling of a bead can permit the release of entrained species within the bead. In other cases, osmotic shrinking of a bead may cause a bead to better retain an entrained species due to pore size contraction.
Where degradable beads are provided, it may be beneficial to avoid exposing such beads to the stimulus or stimuli that cause such degradation prior to a given time, in order to, for example, avoid premature bead degradation and issues that arise from such degradation, including for example poor flow characteristics and aggregation. By way of example, where beads comprise reducible cross-linking groups, such as disulfide groups, it will be desirable to avoid contacting such beads with reducing agents, e.g., DTT or other disulfide cleaving reagents. In such cases, treatment to the beads described herein will, in some cases be provided free of reducing agents, such as DTT. Because reducing agents are often provided in commercial enzyme preparations, it may be desirable to provide reducing agent free (or DTT free) enzyme preparations in treating the beads described herein. Examples of such enzymes include, e.g., polymerase enzyme preparations, reverse transcriptase enzyme preparations, ligase enzyme preparations, as well as many other enzyme preparations that may be used to treat the beads described herein. The terms “reducing agent free” or “DTT free” preparations can refer to a preparation having less than about 1/10th, less than about 1/50th, or even less than about 1/100th of the lower ranges for such materials used in degrading the beads. For example, for DTT, the reducing agent free preparation can have less than about 0.01 millimolar (mM), 0.005 mM, 0.001 mM DTT, 0.0005 mM DTT, or even less than about 0.0001 mM DTT. In many cases, the amount of DTT can be undetectable.
Numerous chemical triggers may be used to trigger the degradation of beads. Examples of these chemical changes may include, but are not limited to pH-mediated changes to the integrity of a component within the bead, degradation of a component of a bead via cleavage of cross-linked bonds, and depolymerization of a component of a bead.
In some embodiments, a bead may be formed from materials that comprise degradable chemical crosslinkers, such as BAC or cystamine. Degradation of such degradable crosslinkers may be accomplished through a number of mechanisms. In some examples, a bead may be contacted with a chemical degrading agent that may induce oxidation, reduction or other chemical changes. For example, a chemical degrading agent may be a reducing agent, such as dithiothreitol (DTT). Additional examples of reducing agents may include 13-mercaptoethanol, (2S)-2-amino-1,4-dimercaptobutane (dithiobutylamine or DTBA), tris(2-carboxyethyl) phosphine (TCEP), or combinations thereof. A reducing agent may degrade the disulfide bonds formed between gel precursors forming the bead, and thus, degrade the bead. In other cases, a change in pH of a solution, such as an increase in pH, may trigger degradation of a bead. In other cases, exposure to an aqueous solution, such as water, may trigger hydrolytic degradation, and thus degradation of the bead. In some cases, any combination of stimuli may trigger degradation of a bead. For example, a change in pH may enable a chemical agent (e.g., DTT) to become an effective reducing agent.
Beads may also be induced to release their contents upon the application of a thermal stimulus. A change in temperature can cause a variety of changes to a bead. For example, heat can cause a solid bead to liquefy. A change in heat may cause melting of a bead such that a portion of the bead degrades. In other cases, heat may increase the internal pressure of the bead components such that the bead ruptures or explodes. Heat may also act upon heat-sensitive polymers used as materials to construct beads.
Any suitable agent may degrade beads. In some embodiments, changes in temperature or pH may be used to degrade thermo-sensitive or pH-sensitive bonds within beads. In some embodiments, chemical degrading agents may be used to degrade chemical bonds within beads by oxidation, reduction or other chemical changes. For example, a chemical degrading agent may be a reducing agent, such as DTT, wherein DTT may degrade the disulfide bonds formed between a crosslinker and gel precursors, thus degrading the bead. In some embodiments, a reducing agent may be added to degrade the bead, which may or may not cause the bead to release its contents. Examples of reducing agents may include dithiothreitol (DTT), 13-mercaptoethanol, (2S)-2-amino-1,4-dimercaptobutane (dithiobutylamine or DTBA), tris(2-carboxyethyl) phosphine (TCEP), or combinations thereof. The reducing agent may be present at a concentration of about 0.1 mM, 0.5 mM, 1 mM, 5 mM, 10 mM. The reducing agent may be present at a concentration of at least about 0.1 mM, 0.5 mM, 1 mM, 5 mM, 10 mM, or greater than 10 mM. The reducing agent may be present at concentration of at most about 10 mM, 5 mM, 1 mM, 0.5 mM, 0.1 mM, or less.
Any suitable number of molecular tag molecules (e.g., primer, barcoded oligonucleotide) can be associated with a bead such that, upon release from the bead, the molecular tag molecules (e.g., primer, e.g., barcoded oligonucleotide) are present in the partition at a pre-defined concentration. Such pre-defined concentration may be selected to facilitate certain reactions for generating a sequencing library, e.g., amplification, within the partition. In some cases, the pre-defined concentration of the primer can be limited by the process of producing oligonucleotide bearing beads.
Although
In some cases, additional microcapsules can be used to deliver additional reagents to a partition. In such cases, it may be advantageous to introduce different beads into a common channel or droplet generation junction, from different bead sources (e.g., containing different associated reagents) through different channel inlets into such common channel or droplet generation junction (e.g., junction 210). In such cases, the flow and frequency of the different beads into the channel or junction may be controlled to provide for a certain ratio of microcapsules from each source, while ensuring a given pairing or combination of such beads into a partition with a given number of biological particles (e.g., one biological particle and one bead per partition).
The partitions described herein may comprise small volumes, for example, less than about 10 microliters (μL), 5 μL, 1 μL, 900 picoliters (pL), 800 pL, 700 pL, 600 pL, 500 pL, 400 pL, 300 pL, 200 pL, 100 pL, 50 pL, 20 pL, 10 pL, 1 pL, 500 nanoliters (nL), 100 nL, 50 nL, or less.
For example, in the case of droplet based partitions, the droplets may have overall volumes that are less than about 1000 pL, 900 pL, 800 pL, 700 pL, 600 pL, 500 pL, 400 pL, 300 pL, 200 pL, 100 pL, 50 pL, 20 pL, 10 pL, 1 pL, or less. Where co-partitioned with microcapsules, it will be appreciated that the sample fluid volume, e.g., including co-partitioned biological particles and/or beads, within the partitions may be less than about 90% of the above described volumes, less than about 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about 20%, or less than about 10% of the above described volumes.
As is described elsewhere herein, partitioning species may generate a population or plurality of partitions. In such cases, any suitable number of partitions can be generated or otherwise provided. For example, at least about 1,000 partitions, at least about 5,000 partitions, at least about 10,000 partitions, at least about 50,000 partitions, at least about 100,000 partitions, at least about 500,000 partitions, at least about 1,000,000 partitions, at least about 5,000,000 partitions at least about 10,000,000 partitions, at least about 50,000,000 partitions, at least about 100,000,000 partitions, at least about 500,000,000 partitions, at least about 1,000,000,000 partitions, or more partitions can be generated or otherwise provided. Moreover, the plurality of partitions may comprise both unoccupied partitions (e.g., empty partitions) and occupied partitions.
Reagents
In accordance with certain aspects, biological particles may be partitioned along with lysis reagents in order to release the contents of the biological particles within the partition. In such cases, the lysis agents can be contacted with the biological particle suspension concurrently with, or immediately prior to, the introduction of the biological particles into the partitioning junction/droplet generation zone (e.g., junction 210), such as through an additional channel or channels upstream of the channel junction. In accordance with other aspects, additionally or alternatively, biological particles may be partitioned along with other reagents, as will be described further below.
In an example operation, the channel segment 301 may transport an aqueous fluid 312 that includes a plurality of biological particles 314 along the channel segment 301 into the second junction 310. As an alternative or in addition to, channel segment 301 may transport beads (e.g., gel beads). The beads may comprise barcode molecules.
For example, the channel segment 301 may be connected to a reservoir comprising an aqueous suspension of biological particles 314. Upstream of, and immediately prior to reaching, the second junction 310, the channel segment 301 may meet the channel segment 302 at the first junction 309. The channel segment 302 may transport a plurality of reagents 315 (e.g., lysis agents) suspended in the aqueous fluid 312 along the channel segment 302 into the first junction 309. For example, the channel segment 302 may be connected to a reservoir comprising the reagents 315. After the first junction 309, the aqueous fluid 312 in the channel segment 301 can carry both the biological particles 314 and the reagents 315 towards the second junction 310. In some instances, the aqueous fluid 312 in the channel segment 301 can include one or more reagents, which can be the same or different reagents as the reagents 315. A second fluid 316 that is immiscible with the aqueous fluid 312 (e.g., oil) can be delivered to the second junction 310 from each of channel segments 304 and 306. Upon meeting of the aqueous fluid 312 from the channel segment 301 and the second fluid 316 from each of channel segments 304 and 306 at the second channel junction 310, the aqueous fluid 312 can be partitioned as discrete droplets 318 in the second fluid 316 and flow away from the second junction 310 along channel segment 308. The channel segment 308 may deliver the discrete droplets 318 to an outlet reservoir fluidly coupled to the channel segment 308, where they may be harvested.
The second fluid 316 can comprise an oil, such as a fluorinated oil, that includes a fluorosurfactant for stabilizing the resulting droplets, for example, inhibiting subsequent coalescence of the resulting droplets 318.
A discrete droplet generated may include an individual biological particle 314 and/or one or more reagents 315. In some instances, a discrete droplet generated may include a barcode carrying bead (not shown), such as via other microfluidics structures described elsewhere herein. In some instances, a discrete droplet may be unoccupied (e.g., no reagents, no biological particles).
Beneficially, when lysis reagents and biological particles are co-partitioned, the lysis reagents can facilitate the release of the contents of the biological particles within the partition. The contents released in a partition may remain discrete from the contents of other partitions.
As will be appreciated, the channel segments described herein may be coupled to any of a variety of different fluid sources or receiving components, including reservoirs, tubing, manifolds, or fluidic components of other systems. As will be appreciated, the microfluidic channel structure 300 may have other geometries. For example, a microfluidic channel structure can have more than two channel junctions. For example, a microfluidic channel structure can have 2, 3, 4, 5 channel segments or more each carrying the same or different types of beads, reagents, and/or biological particles that meet at a channel junction. Fluid flow in each channel segment may be controlled to control the partitioning of the different elements into droplets. Fluid may be directed flow along one or more channels or reservoirs via one or more fluid flow units. A fluid flow unit can comprise compressors (e.g., providing positive pressure), pumps (e.g., providing negative pressure), actuators, and the like to control flow of the fluid. Fluid may also or otherwise be controlled via applied pressure differentials, centrifugal force, electrokinetic pumping, vacuum, capillary or gravity flow, or the like.
Examples of lysis agents include bioactive reagents, such as lysis enzymes that are used for lysis of different cell types, e.g., gram positive or negative bacteria, plants, yeast, mammalian, etc., such as lysozymes, achromopeptidase, lysostaphin, labiase, kitalase, lyticase, and a variety of other lysis enzymes available from, e.g., Sigma-Aldrich, Inc. (St Louis, Mo.), as well as other commercially available lysis enzymes. Other lysis agents may additionally or alternatively be co-partitioned with the biological particles to cause the release of the biological particles's contents into the partitions. For example, in some cases, surfactant-based lysis solutions may be used to lyse cells, although these may be less desirable for emulsion based systems where the surfactants can interfere with stable emulsions. In some cases, lysis solutions may include non-ionic surfactants such as, for example, TritonX-100 and Tween 20. In some cases, lysis solutions may include ionic surfactants such as, for example, sarcosyl and sodium dodecyl sulfate (SDS). Electroporation, thermal, acoustic or mechanical cellular disruption may also be used in certain cases, e.g., non-emulsion based partitioning such as encapsulation of biological particles that may be in addition to or in place of droplet partitioning, where any pore size of the encapsulate is sufficiently small to retain nucleic acid fragments of a given size, following cellular disruption.
Alternatively or in addition to the lysis agents co-partitioned with the biological particles described above, other reagents can also be co-partitioned with the biological particles, including, for example, DNase and RNase inactivating agents or inhibitors, such as proteinase K, chelating agents, such as EDTA, and other reagents employed in removing or otherwise reducing negative activity or impact of different cell lysate components on subsequent processing of nucleic acids. In addition, in the case of encapsulated biological particles, the biological particles may be exposed to an appropriate stimulus to release the biological particles or their contents from a co-partitioned microcapsule. For example, in some cases, a chemical stimulus may be co-partitioned along with an encapsulated biological particle to allow for the degradation of the microcapsule and release of the cell or its contents into the larger partition. In some cases, this stimulus may be the same as the stimulus described elsewhere herein for release of nucleic acid molecules (e.g., oligonucleotides) from their respective microcapsule (e.g., bead). In alternative aspects, this may be a different and non-overlapping stimulus, in order to allow an encapsulated biological particle to be released into a partition at a different time from the release of nucleic acid molecules into the same partition.
Additional reagents may also be co-partitioned with the biological particles, such as endonucleases to fragment a biological particle's DNA, DNA polymerase enzymes and dNTPs used to amplify the biological particle's nucleic acid fragments and to attach the barcode molecular tags to the amplified fragments. Other enzymes may be co-partitioned, including without limitation, polymerase, transposase, ligase, proteinase K, DNAse, etc. Additional reagents may also include reverse transcriptase enzymes, including enzymes with terminal transferase activity, primers and oligonucleotides, and switch oligonucleotides (also referred to herein as “switch oligos” or “template switching oligonucleotides”) which can be used for template switching. In some cases, template switching can be used to increase the length of a cDNA. In some cases, template switching can be used to append a predefined nucleic acid sequence to the cDNA. In an example of template switching, cDNA can be generated from reverse transcription of a template, e.g., cellular mRNA, where a reverse transcriptase with terminal transferase activity can add additional nucleotides, e.g., polyC, to the cDNA in a template independent manner. Switch oligos can include sequences complementary to the additional nucleotides, e.g., polyG. The additional nucleotides (e.g., polyC) on the cDNA can hybridize to the additional nucleotides (e.g., polyG) on the switch oligo, whereby the switch oligo can be used by the reverse transcriptase as template to further extend the cDNA. Template switching oligonucleotides may comprise a hybridization region and a template region. The hybridization region can comprise any sequence capable of hybridizing to the target. In some cases, as previously described, the hybridization region comprises a series of G bases to complement the overhanging C bases at the 3′ end of a cDNA molecule. The series of G bases may comprise 1 G base, 2 G bases, 3 G bases, 4 G bases, 5 G bases or more than 5 G bases. The template sequence can comprise any sequence to be incorporated into the cDNA. In some cases, the template region comprises at least 1 (e.g., at least 2, 3, 4, 5 or more) tag sequences and/or functional sequences. Switch oligos may comprise deoxyribonucleic acids; ribonucleic acids; modified nucleic acids including 2-Aminopurine, 2,6-Diaminopurine (2-Amino-dA), inverted dT, 5-Methyl dC, 2′-deoxylnosine, Super T (5-hydroxybutynl-2′-deoxyuridine), Super G (8-aza-7-deazaguanosine), locked nucleic acids (LNAs), unlocked nucleic acids (UNAs, e.g., UNA-A, UNA-U, UNA-C, UNA-G), Iso-dG, Iso-dC, 2′ Fluoro bases (e.g., Fluoro C, Fluoro U, Fluoro A, and Fluoro G), or any combination.
In some cases, the length of a switch oligo may be at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,
96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249 or 250 nucleotides or longer.
In some cases, the length of a switch oligo may be at most about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249 or 250 nucleotides.
Once the contents of the cells are released into their respective partitions, the macromolecular components (e.g., macromolecular constituents of biological particles, such as RNA, DNA, or proteins) contained therein may be further processed within the partitions. In accordance with the methods and systems described herein, the macromolecular component contents of individual biological particles can be provided with unique identifiers such that, upon characterization of those macromolecular components they may be attributed as having been derived from the same biological particle or particles. The ability to attribute characteristics to individual biological particles or groups of biological particles is provided by the assignment of unique identifiers specifically to an individual biological particle or groups of biological particles. Unique identifiers, e.g., in the form of nucleic acid barcodes can be assigned or associated with individual biological particles or populations of biological particles, in order to tag or label the biological particle's macromolecular components (and as a result, its characteristics) with the unique identifiers. These unique identifiers can then be used to attribute the biological particle's components and characteristics to an individual biological particle or group of biological particles.
In some aspects, this is performed by co-partitioning the individual biological particle or groups of biological particles with the unique identifiers, such as described above (with reference to
The nucleic acid barcode sequences can include from about 6 to about 20 or more nucleotides within the sequence of the nucleic acid molecules (e.g., oligonucleotides). The nucleic acid barcode sequences can include from about 6 to about 20, 30, 40, 50, 60, 70, 80, 90, 100 or more nucleotides. In some cases, the length of a barcode sequence may be about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 nucleotides or longer. In some cases, the length of a barcode sequence may be at least about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 nucleotides or longer. In some cases, the length of a barcode sequence may be at most about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 nucleotides or shorter. These nucleotides may be completely contiguous, i.e., in a single stretch of adjacent nucleotides, or they may be separated into two or more separate subsequences that are separated by 1 or more nucleotides. In some cases, separated barcode subsequences can be from about 4 to about 16 nucleotides in length. In some cases, the barcode subsequence may be about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 nucleotides or longer. In some cases, the barcode subsequence may be at least about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 nucleotides or longer. In some cases, the barcode subsequence may be at most about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 nucleotides or shorter.
The co-partitioned nucleic acid molecules can also comprise other functional sequences useful in the processing of the nucleic acids from the co-partitioned biological particles. These sequences include, e.g., targeted or random/universal amplification primer sequences for amplifying the genomic DNA from the individual biological particles within the partitions while attaching the associated barcode sequences, sequencing primers or primer recognition sites, hybridization or probing sequences, e.g., for identification of presence of the sequences or for pulling down barcoded nucleic acids, or any of a number of other potential functional sequences. Other mechanisms of co-partitioning oligonucleotides may also be employed, including, e.g., coalescence of two or more droplets, where one droplet contains oligonucleotides, or microdispensing of oligonucleotides into partitions, e.g., droplets within microfluidic systems.
In an example, microcapsules, such as beads, are provided that each include large numbers of the above described barcoded nucleic acid molecules (e.g., barcoded oligonucleotides) releasably attached to the beads, where all of the nucleic acid molecules attached to a particular bead will include the same nucleic acid barcode sequence, but where a large number of diverse barcode sequences are represented across the population of beads used. In some embodiments, hydrogel beads, e.g., comprising polyacrylamide polymer matrices, are used as a solid support and delivery vehicle for the nucleic acid molecules into the partitions, as they are capable of carrying large numbers of nucleic acid molecules, and may be configured to release those nucleic acid molecules upon exposure to a particular stimulus, as described elsewhere herein. In some cases, the population of beads provides a diverse barcode sequence library that includes at least about 1,000 different barcode sequences, at least about 5,000 different barcode sequences, at least about 10,000 different barcode sequences, at least about 50,000 different barcode sequences, at least about 100,000 different barcode sequences, at least about 1,000,000 different barcode sequences, at least about 5,000,000 different barcode sequences, or at least about 10,000,000 different barcode sequences, or more. Additionally, each bead can be provided with large numbers of nucleic acid (e.g., oligonucleotide) molecules attached. In particular, the number of molecules of nucleic acid molecules including the barcode sequence on an individual bead can be at least about 1,000 nucleic acid molecules, at least about 5,000 nucleic acid molecules, at least about 10,000 nucleic acid molecules, at least about 50,000 nucleic acid molecules, at least about 100,000 nucleic acid molecules, at least about 500,000 nucleic acids, at least about 1,000,000 nucleic acid molecules, at least about 5,000,000 nucleic acid molecules, at least about 10,000,000 nucleic acid molecules, at least about 50,000,000 nucleic acid molecules, at least about 100,000,000 nucleic acid molecules, at least about 250,000,000 nucleic acid molecules and in some cases at least about 1 billion nucleic acid molecules, or more. Nucleic acid molecules of a given bead can include identical (or common) barcode sequences, different barcode sequences, or a combination of both. Nucleic acid molecules of a given bead can include multiple sets of nucleic acid molecules. Nucleic acid molecules of a given set can include identical barcode sequences. The identical barcode sequences can be different from barcode sequences of nucleic acid molecules of another set.
Moreover, when the population of beads is partitioned, the resulting population of partitions can also include a diverse barcode library that includes at least about 1,000 different barcode sequences, at least about 5,000 different barcode sequences, at least about 10,000 different barcode sequences, at least at least about 50,000 different barcode sequences, at least about 100,000 different barcode sequences, at least about 1,000,000 different barcode sequences, at least about 5,000,000 different barcode sequences, or at least about 10,000,000 different barcode sequences. Additionally, each partition of the population can include at least about 1,000 nucleic acid molecules, at least about 5,000 nucleic acid molecules, at least about 10,000 nucleic acid molecules, at least about 50,000 nucleic acid molecules, at least about 100,000 nucleic acid molecules, at least about 500,000 nucleic acids, at least about 1,000,000 nucleic acid molecules, at least about 5,000,000 nucleic acid molecules, at least about 10,000,000 nucleic acid molecules, at least about 50,000,000 nucleic acid molecules, at least about 100,000,000 nucleic acid molecules, at least about 250,000,000 nucleic acid molecules and in some cases at least about 1 billion nucleic acid molecules.
In some cases, it may be desirable to incorporate multiple different barcodes within a given partition, either attached to a single or multiple beads within the partition. For example, in some cases, a mixed, but known set of barcode sequences may provide greater assurance of identification in the subsequent processing, e.g., by providing a stronger address or attribution of the barcodes to a given partition, as a duplicate or independent confirmation of the output from a given partition.
The nucleic acid molecules (e.g., oligonucleotides) are releasable from the beads upon the application of a particular stimulus to the beads. In some cases, the stimulus may be a photo-stimulus, e.g., through cleavage of a photo-labile linkage that releases the nucleic acid molecules. In other cases, a thermal stimulus may be used, where elevation of the temperature of the beads environment will result in cleavage of a linkage or other release of the nucleic acid molecules form the beads. In still other cases, a chemical stimulus can be used that cleaves a linkage of the nucleic acid molecules to the beads, or otherwise results in release of the nucleic acid molecules from the beads. In one case, such compositions include the polyacrylamide matrices described above for encapsulation of biological particles, and may be degraded for release of the attached nucleic acid molecules through exposure to a reducing agent, such as DTT.
In some aspects, provided are systems and methods for controlled partitioning. Droplet size may be controlled by adjusting certain geometric features in channel architecture (e.g., microfluidics channel architecture). For example, an expansion angle, width, and/or length of a channel may be adjusted to control droplet size.
A discrete droplet generated may include a bead (e.g., as in occupied droplets 416). Alternatively, a discrete droplet generated may include more than one bead. Alternatively, a discrete droplet generated may not include any beads (e.g., as in unoccupied droplet 418). In some instances, a discrete droplet generated may contain one or more biological particles, as described elsewhere herein. In some instances, a discrete droplet generated may comprise one or more reagents, as described elsewhere herein.
In some instances, the aqueous fluid 408 can have a substantially uniform concentration or frequency of beads 412. The beads 412 can be introduced into the channel segment 402 from a separate channel (not shown in
In some instances, the aqueous fluid 408 in the channel segment 402 can comprise biological particles (e.g., described with reference to
The second fluid 410 can comprise an oil, such as a fluorinated oil, that includes a fluorosurfactant for stabilizing the resulting droplets, for example, inhibiting subsequent coalescence of the resulting droplets.
In some instances, the second fluid 410 may not be subjected to and/or directed to any flow in or out of the reservoir 404. For example, the second fluid 410 may be substantially stationary in the reservoir 404. In some instances, the second fluid 410 may be subjected to flow within the reservoir 404, but not in or out of the reservoir 404, such as via application of pressure to the reservoir 404 and/or as affected by the incoming flow of the aqueous fluid 408 at the junction 406. Alternatively, the second fluid 410 may be subjected and/or directed to flow in or out of the reservoir 404. For example, the reservoir 404 can be a channel directing the second fluid 410 from upstream to downstream, transporting the generated droplets.
The channel structure 400 at or near the junction 406 may have certain geometric features that at least partly determine the sizes of the droplets formed by the channel structure 400. The channel segment 402 can have a height, h0 and width, w, at or near the junction 406. By way of example, the channel segment 402 can comprise a rectangular cross-section that leads to a reservoir 404 having a wider cross-section (such as in width or diameter). Alternatively, the cross-section of the channel segment 402 can be other shapes, such as a circular shape, trapezoidal shape, polygonal shape, or any other shapes. The top and bottom walls of the reservoir 404 at or near the junction 406 can be inclined at an expansion angle, a. The expansion angle, a, allows the tongue (portion of the aqueous fluid 408 leaving channel segment 402 at junction 406 and entering the reservoir 404 before droplet formation) to increase in depth and facilitate decrease in curvature of the intermediately formed droplet. Droplet size may decrease with increasing expansion angle. The resulting droplet radius, Rd, may be predicted by the following equation for the aforementioned geometric parameters of ho, w, and α:
By way of example, for a channel structure with w=21 μm, h=21 μm, and α=3°, the predicted droplet size is 121 μm. In another example, for a channel structure with w=25 μm, h=25 μm, and α=5°, the predicted droplet size is 123 μm. In another example, for a channel structure with w=28 μm, h=28 μm, and α=7°, the predicted droplet size is 124 μm.
In some instances, the expansion angle, α, may be between a range of from about 0.5° to about 4°, from about 0.1° to about 10°, or from about 0° to about 90°. For example, the expansion angle can be at least about 0.01°, 0.1°, 0.2°, 0.3°, 0.4°, 0.5°, 0.6°, 0.7°, 0.8°, 0.9°, 1°, 2°, 3°, 4°, 5°, 6°, 7°, 8°, 9°, 10°, 15°, 20°, 25°, 30°, 35°, 40°, 45°, 50°, 55°, 60°, 65°, 70°, 75°, 80°, 85°, or higher. In some instances, the expansion angle can be at most about 89°, 88°, 87°, 86°, 85°, 84°, 83°, 82°, 81°, 80°, 75°, 70°, 65°, 60°, 55°, 50°, 45°, 40°, 35°, 30°, 25°, 20°, 15°, 10°, 9°, 8°, 7°, 6°, 5°, 4°, 3°, 2°, 1°, 0.1°, 0.01°, or less. In some instances, the width, w, can be between a range of from about 100 micrometers (μm) to about 500 μm. In some instances, the width, w, can be between a range of from about 10 μm to about 200 μm. Alternatively, the width can be less than about 10 μm. Alternatively, the width can be greater than about 500 μm. In some instances, the flow rate of the aqueous fluid 408 entering the junction 406 can be between about 0.04 microliters (μL)/minute (min) and about 40 μL/min. In some instances, the flow rate of the aqueous fluid 408 entering the junction 406 can be between about 0.01 microliters (μL)/minute (min) and about 100 μL/min. Alternatively, the flow rate of the aqueous fluid 408 entering the junction 406 can be less than about 0.01 μL/min. Alternatively, the flow rate of the aqueous fluid 408 entering the junction 406 can be greater than about 40 μL/min, such as 45 μL/min, 50 μL/min, 55 μL/min, 60 μL/min, 65 μL/min, 70 μL/min, 75 μL/min, 80 μL/min, 85 μL/min, 90 μL/min, 95 μL/min, 100 μL/min, 110 μL/min, 120 μL/min, 130 μL/min, 140 μL/min, 150 μL/min, or greater. At lower flow rates, such as flow rates of about less than or equal to 10 microliters/minute, the droplet radius may not be dependent on the flow rate of the aqueous fluid 408 entering the junction 406.
In some instances, at least about 50% of the droplets generated can have uniform size. In some instances, at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or greater of the droplets generated can have uniform size. Alternatively, less than about 50% of the droplets generated can have uniform size.
The throughput of droplet generation can be increased by increasing the points of generation, such as increasing the number of junctions (e.g., junction 406) between aqueous fluid 408 channel segments (e.g., channel segment 402) and the reservoir 404. Alternatively or in addition, the throughput of droplet generation can be increased by increasing the flow rate of the aqueous fluid 408 in the channel segment 402.
Each channel segment of the plurality of channel segments 502 may comprise an aqueous fluid 508 that includes suspended beads 512. The reservoir 504 may comprise a second fluid 510 that is immiscible with the aqueous fluid 508. In some instances, the second fluid 510 may not be subjected to and/or directed to any flow in or out of the reservoir 504. For example, the second fluid 510 may be substantially stationary in the reservoir 504. In some instances, the second fluid 510 may be subjected to flow within the reservoir 504, but not in or out of the reservoir 504, such as via application of pressure to the reservoir 504 and/or as affected by the incoming flow of the aqueous fluid 508 at the junctions. Alternatively, the second fluid 510 may be subjected and/or directed to flow in or out of the reservoir 504. For example, the reservoir 504 can be a channel directing the second fluid 510 from upstream to downstream, transporting the generated droplets.
In operation, the aqueous fluid 508 that includes suspended beads 512 may be transported along the plurality of channel segments 502 into the plurality of junctions 506 to meet the second fluid 510 in the reservoir 504 to create droplets 516, 518. A droplet may form from each channel segment at each corresponding junction with the reservoir 504. At the junction where the aqueous fluid 508 and the second fluid 510 meet, droplets can form based on factors such as the hydrodynamic forces at the junction, flow rates of the two fluids 508, 510, fluid properties, and certain geometric parameters (e.g., w, h0, a, etc.) of the channel structure 500, as described elsewhere herein. A plurality of droplets can be collected in the reservoir 504 by continuously injecting the aqueous fluid 508 from the plurality of channel segments 502 through the plurality of junctions 506. Throughput may significantly increase with the parallel channel configuration of channel structure 500. For example, a channel structure having five inlet channel segments comprising the aqueous fluid 508 may generate droplets five times as frequently than a channel structure having one inlet channel segment, provided that the fluid flow rate in the channel segments are substantially the same. The fluid flow rate in the different inlet channel segments may or may not be substantially the same. A channel structure may have as many parallel channel segments as is practical and allowed for the size of the reservoir. For example, the channel structure may have at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 500, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1500, 5000 or more parallel or substantially parallel channel segments.
The geometric parameters, w, h0, and a, may or may not be uniform for each of the channel segments in the plurality of channel segments 502. For example, each channel segment may have the same or different widths at or near its respective channel junction with the reservoir 504. For example, each channel segment may have the same or different height at or near its respective channel junction with the reservoir 504. In another example, the reservoir 504 may have the same or different expansion angle at the different channel junctions with the plurality of channel segments 502. When the geometric parameters are uniform, beneficially, droplet size may also be controlled to be uniform even with the increased throughput. In some instances, when it is desirable to have a different distribution of droplet sizes, the geometric parameters for the plurality of channel segments 502 may be varied accordingly.
In some instances, at least about 50% of the droplets generated can have uniform size. In some instances, at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or greater of the droplets generated can have uniform size. Alternatively, less than about 50% of the droplets generated can have uniform size.
Each channel segment of the plurality of channel segments 602 may comprise an aqueous fluid 608 that includes suspended beads 612. The reservoir 604 may comprise a second fluid 610 that is immiscible with the aqueous fluid 608. In some instances, the second fluid 610 may not be subjected to and/or directed to any flow in or out of the reservoir 604. For example, the second fluid 610 may be substantially stationary in the reservoir 604. In some instances, the second fluid 610 may be subjected to flow within the reservoir 604, but not in or out of the reservoir 604, such as via application of pressure to the reservoir 604 and/or as affected by the incoming flow of the aqueous fluid 608 at the junctions. Alternatively, the second fluid 610 may be subjected and/or directed to flow in or out of the reservoir 604. For example, the reservoir 604 can be a channel directing the second fluid 610 from upstream to downstream, transporting the generated droplets.
In operation, the aqueous fluid 608 that includes suspended beads 612 may be transported along the plurality of channel segments 602 into the plurality of junctions 606 to meet the second fluid 610 in the reservoir 604 to create a plurality of droplets 616. A droplet may form from each channel segment at each corresponding junction with the reservoir 604. At the junction where the aqueous fluid 608 and the second fluid 610 meet, droplets can form based on factors such as the hydrodynamic forces at the junction, flow rates of the two fluids 608, 610, fluid properties, and certain geometric parameters (e.g., widths and heights of the channel segments 602, expansion angle of the reservoir 604, etc.) of the channel structure 600, as described elsewhere herein. A plurality of droplets can be collected in the reservoir 604 by continuously injecting the aqueous fluid 608 from the plurality of channel segments 602 through the plurality of junctions 606. Throughput may significantly increase with the substantially parallel channel configuration of the channel structure 600. A channel structure may have as many substantially parallel channel segments as is practical and allowed for by the size of the reservoir. For example, the channel structure may have at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1500, 5000 or more parallel or substantially parallel channel segments. The plurality of channel segments may be substantially evenly spaced apart, for example, around an edge or perimeter of the reservoir. Alternatively, the spacing of the plurality of channel segments may be uneven.
The reservoir 604 may have an expansion angle, a (not shown in
The reservoir 604 may have the same or different expansion angle at the different channel junctions with the plurality of channel segments 602. For example, a circular reservoir (as shown in
In some instances, at least about 50% of the droplets generated can have uniform size. In some instances, at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or greater of the droplets generated can have uniform size. Alternatively, less than about 50% of the droplets generated can have uniform size. The beads and/or biological particle injected into the droplets may or may not have uniform size.
An aqueous fluid 712 comprising a plurality of particles 716 may be transported along the channel segment 702 into the junction 706 to meet a second fluid 714 (e.g., oil, etc.) that is immiscible with the aqueous fluid 712 in the reservoir 704 to create droplets 720 of the aqueous fluid 712 flowing into the reservoir 704. At the junction 706 where the aqueous fluid 712 and the second fluid 714 meet, droplets can form based on factors such as the hydrodynamic forces at the junction 706, relative flow rates of the two fluids 712, 714, fluid properties, and certain geometric parameters (e.g., zlh, etc.) of the channel structure 700. A plurality of droplets can be collected in the reservoir 704 by continuously injecting the aqueous fluid 712 from the channel segment 702 at the junction 706.
A discrete droplet generated may comprise one or more particles of the plurality of particles 716. As described elsewhere herein, a particle may be any particle, such as a bead, cell bead, gel bead, biological particle, macromolecular constituents of biological particle, or other particles. Alternatively, a discrete droplet generated may not include any particles.
In some instances, the aqueous fluid 712 can have a substantially uniform concentration or frequency of particles 716. As described elsewhere herein (e.g., with reference to
In some instances, the second fluid 714 may not be subjected to and/or directed to any flow in or out of the reservoir 704. For example, the second fluid 714 may be substantially stationary in the reservoir 704. In some instances, the second fluid 714 may be subjected to flow within the reservoir 704, but not in or out of the reservoir 704, such as via application of pressure to the reservoir 704 and/or as affected by the incoming flow of the aqueous fluid 712 at the junction 706. Alternatively, the second fluid 714 may be subjected and/or directed to flow in or out of the reservoir 704. For example, the reservoir 704 can be a channel directing the second fluid 714 from upstream to downstream, transporting the generated droplets.
The channel structure 700 at or near the junction 706 may have certain geometric features that at least partly determine the sizes and/or shapes of the droplets formed by the channel structure 700. The channel segment 702 can have a first cross-section height, h1, and the reservoir 704 can have a second cross-section height, h2. The first cross-section height, h1, and the second cross-section height, h2 may be different, such that at the junction 706, there is a height difference of Δh. The second cross-section height, h2, may be greater than the first cross-section height, h1. In some instances, the reservoir may thereafter gradually increase in cross-section height, for example, the more distant it is from the junction 706. In some instances, the cross-section height of the reservoir may increase in accordance with expansion angle, β, at or near the junction 706. The height difference, Δh, and/or expansion angle, β, can allow the tongue (portion of the aqueous fluid 712 leaving channel segment 702 at junction 706 and entering the reservoir 704 before droplet formation) to increase in depth and facilitate decrease in curvature of the intermediately formed droplet. For example, droplet size may decrease with increasing height difference and/or increasing expansion angle.
The height difference, Δh, can be at least about 1 μm. Alternatively, the height difference can be at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500 μm or more. Alternatively, the height difference can be at most about 500, 400, 300, 200, 100, 90, 80, 70, 60, 50, 45, 40, 35, 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 μm or less. In some instances, the expansion angle, (3, may be between a range of from about 0.5° to about 4°, from about 0.1° to about 10°, or from about 0° to about 90°. For example, the expansion angle can be at least about 0.01°, 0.1°, 0.2°, 0.3°, 0.4°, 0.5°, 0.6°, 0.7°, 0.8°, 0.9°, 1°, 2°, 3°, 4°, 5°, 6°, 7°, 8°, 9°, 10°, 15°, 20°, 25°, 30°, 35°, 40°, 45°, 50°, 55°, 60°, 65°, 70°, 75°, 80°, 85°, or higher. In some instances, the expansion angle can be at most about 89°, 88°, 87°, 86°, 85°, 84°, 83°, 82°, 81°, 80°, 75°, 70°, 65°, 60°, 55°, 50°, 45°, 40°, 35°, 30°, 25°, 20°, 15°, 10°, 9°, 8°, 7°, 6°, 5°, 4°, 3°, 2°, 1°, 0.1°, 0.01°, or less.
In some instances, the flow rate of the aqueous fluid 712 entering the junction 706 can be between about 0.04 microliters (μL)/minute (min) and about 40 μL/min. In some instances, the flow rate of the aqueous fluid 712 entering the junction 706 can be between about 0.01 microliters (μL)/minute (min) and about 100 μL/min. Alternatively, the flow rate of the aqueous fluid 712 entering the junction 706 can be less than about 0.01 μL/min. Alternatively, the flow rate of the aqueous fluid 712 entering the junction 706 can be greater than about 40 μL/min, such as 45 μL/min, 50 μL/min, 55 μL/min, 60 μL/min, 65 μL/min, 70 μL/min, 75 μL/min, 80 μL/min, 85 μL/min, 90 μL/min, 95 μL/min, 100 μL/min, 110 μL/min, 120 μL/min, 130 μL/min, 140 μL/min, 150 μL/min, or greater. At lower flow rates, such as flow rates of about less than or equal to 10 microliters/minute, the droplet radius may not be dependent on the flow rate of the aqueous fluid 712 entering the junction 706. The second fluid 714 may be stationary, or substantially stationary, in the reservoir 704. Alternatively, the second fluid 714 may be flowing, such as at the above flow rates described for the aqueous fluid 712.
In some instances, at least about 50% of the droplets generated can have uniform size. In some instances, at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or greater of the droplets generated can have uniform size. Alternatively, less than about 50% of the droplets generated can have uniform size.
While
The channel networks, e.g., as described above or elsewhere herein, can be fluidly coupled to appropriate fluidic components. For example, the inlet channel segments are fluidly coupled to appropriate sources of the materials they are to deliver to a channel junction. These sources may include any of a variety of different fluidic components, from simple reservoirs defined in or connected to a body structure of a microfluidic device, to fluid conduits that deliver fluids from off-device sources, manifolds, fluid flow units (e.g., actuators, pumps, compressors) or the like. Likewise, the outlet channel segment (e.g., channel segment 208, reservoir 604, etc.) may be fluidly coupled to a receiving vessel or conduit for the partitioned cells for subsequent processing. Again, this may be a reservoir defined in the body of a microfluidic device, or it may be a fluidic conduit for delivering the partitioned cells to a subsequent process operation, instrument or component.
The methods and systems described herein may be used to greatly increase the efficiency of single cell applications and/or other applications receiving droplet-based input. For example, following the sorting of occupied cells and/or appropriately-sized cells, subsequent operations that can be performed can include generation of amplification products, purification (e.g., via solid phase reversible immobilization (SPRI)), further processing (e.g., shearing, ligation of functional sequences, and subsequent amplification (e.g., via PCR)). These operations may occur in bulk (e.g., outside the partition). In the case where a partition is a droplet in an emulsion, the emulsion can be broken and the contents of the droplet pooled for additional operations. Additional reagents that may be co-partitioned along with the barcode bearing bead may include oligonucleotides to block ribosomal RNA (rRNA) and nucleases to digest genomic DNA from cells. Alternatively, rRNA removal agents may be applied during additional processing operations. The configuration of the constructs generated by such a method can help minimize (or avoid) sequencing of the poly-T sequence during sequencing and/or sequence the 5′ end of a polynucleotide sequence. The amplification products, for example, first amplification products and/or second amplification products, may be subject to sequencing for sequence analysis. In some cases, amplification may be performed using the Partial Hairpin Amplification for Sequencing (PHASE) method.
A variety of applications require the evaluation of the presence and quantification of different biological particle or organism types within a population of biological particles, including, for example, microbiome analysis and characterization, environmental testing, food safety testing, epidemiological analysis, e.g., in tracing contamination or the like.
Methods and Systems for Reducing or Removing Mitochondrial DNA
Cells comprise both nuclear DNA (e.g., DNA comprising chromatin) and mitochondrial DNA. In the tagmentation methods described herein, both nuclear DNA and mitochondrial DNA may be susceptible to tagmentation. Depending on the cell type, a method for measuring accessible chromatin may yield a plurality of sequencing reads, where between about 20 and 80% of the sequencing reads may be attributable to mitochondrial DNA. Such reads may be discarded if nuclear DNA (e.g., accessible chromatin) is of interest. Techniques to either eliminate or reduce mitochondrial DNA prior to tagmentation or to remove or reduce tagmented mitochondrial DNA fragments prior to sequencing may result in enhancement in chromatin-attributable data.
The present disclosure further provides a method of enhancing nuclear DNA within a sample. The method may comprise reducing or removing mitochondrial DNA. In some cases, the method may comprise providing a sample comprising both mitochondrial DNA and nuclear DNA, and removing mitochondrial DNA from or reducing the relative amount of mitochondrial DNA in the sample prior to analyzing cells or nuclei within the sample for accessible chromatin (e.g., tagmentation). In some cases, the method may comprise providing a sample comprising both mitochondrial DNA and nuclear DNA; subjecting the sample to analysis for accessible chromatin (e.g., as described herein), thereby generating a processed sample comprising both tagmented mitochondrial DNA fragments and tagmented nuclear DNA fragments; and removing tagmented mitochondrial DNA fragments from the processed sample or reducing the relative amount of tagmented mitochondrial DNA fragments within the processed sample.
In some cases, whole cells may be used as the input material for an ATAC-seq analysis (e.g., as described herein). In some cases, nuclei may be used as the input material for an ATAC-seq analysis. For example, nuclei may be used as the input material where mitochondrial DNA is removed prior to tagmentation of genomic DNA. In this approach, whole cells may be gently lysed to remove their cytoplasmic membrane whilst leaving the nuclear membrane and nucleoprotein packaging of the genome intact. In some cases, a lysis buffer used to lyse whole cells may comprise one or more of Tris-HCl, NaCl, magnesium ions (e.g., MgCl2), and a lysis agent. A lysis agent may be, for example, NP40, Tween-20, Digitonin, Nonident P40, or DBDM. Mitochondria may be washed away along with other cellular debris during subsequent centrifugation steps to yield a suspension of nuclei.
In some cases, mitochondrial membranes may be lysed along with their cytoplasmic counterparts. This may result in mitochondrial DNA non-specifically binding to nuclear membranes during this step and thus being carried into a subsequent tagmentation reaction. A blocking agent (e.g., a blocking protein) may be used to prevent nonspecific binding of mitochondrial DNA to nuclei membranes during cell lysis. A blocking agent may not inhibit downstream biochemistry. In some cases, a blocking agent may be selected from the group consisting of, for example, a single purified protein (e.g., bovine serum albumin or casein), a single purified glycoprotein, a milk protein, fish gelatin, a normal serum (e.g., fetal calf serum, rabbit serum, goat serum, or the like), a buffer such as ThermoFisher Scientific's SuperBlock, and polyvinylpyrrolidone (PVP). For example, the blocking agent (e.g., blocking protein) may be bovine serum albumin (BSA), an inexpensive and readily available isolated protein. The blocking protein (e.g., BSA) may be added to a detergent formulation used during cell lysis. The blocking protein (e.g., BSA) may block available binding sites on nuclei membrane, thereby preventing nonspecific binding of mitochondrial DNA. The blocking agent (e.g., blocking protein) may be provided in any useful concentration. The blocking agent may be provided in a solution comprising a buffer. After providing a blocking agent to a sample (e.g., a solution, partition, or plurality of partitions, such as a plurality of aqueous droplets) comprising one or more cells and/or nuclei, the sample may be agitated and/or centrifuged one or more times, and/or undergo one or more washing steps. During subsequent processing (e.g., centrifugation), cell debris and mitochondrial DNA may be washed away (e.g., in a supernatant). This approach may reduce the amount of sequencing reads associated with mitochondrial DNA in an ATAC-seq library by at least about 5%. For example, the amount of sequencing reads associated with mitochondrial DNA may be reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or by 100%. In an example, the amount of sequencing reads associated with mitochondrial DNA may be reduced by at least about 50%, such as from about 30% to about 60%. In some cases, the fraction of sequencing reads associated with mitochondrial DNA of a plurality of sequencing reads derived from a sample (e.g., a solution, partition, or plurality of partitions comprising one or more cells and/or nuclei) may be reduced to be less than about 60%. For example, the fraction of sequencing reads associated with mitochondrial DNA may be reduced to less than about 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 1%, or less of the total sequencing reads derived from a sample. In an example, the fraction of sequencing reads associated with mitochondrial DNA may be reduced to between about 1-5% of the total sequencing reads derived from a sample.
In some cases, a method of generating barcoded nucleic acid fragments comprises: (a) lysing a plurality of cells in the presence of a cell lysis agent and a blocking agent to generate a plurality of lysed cells; (b) separating a plurality of nuclei from the plurality of lysed cells to generate a plurality of biological particles, where an individual biological particle (e.g., cell) comprises a non-template nucleic acid and chromatin comprising a template nucleic acid; (c) providing (i) a plurality of transposon end nucleic acid molecules comprising a transposon end sequence and (ii) a plurality of transposase nucleic acid molecules; (d) generating a plurality of template nucleic acid fragments in a biological particle of the plurality of biological particles with the aid of a transposase-nucleic acid complex comprising a transposase nucleic acid molecule of the plurality of transposase nucleic acid molecules and a transposon end nucleic acid molecule of the plurality of transposon end nucleic acid molecules; (e) generating a partition (e.g., a droplet or well) comprising the biological particle comprising the plurality of template nucleic acid fragments and a plurality of barcode oligonucleotide molecules (e.g., nucleic acid barcode molecules) comprising a barcode sequence; and (1) generating a barcoded template nucleic acid fragment using a barcode oligonucleotide molecule (e.g., nucleic acid barcode molecule) of the plurality of barcode oligonucleotide molecule and a template nucleic acid fragment of the plurality of template nucleic acid fragments. In some cases, the blocking agent may comprise bovine serum albumin (BSA). For example, the blocking agent may comprise a solution of 3% BSA in phosphate buffered saline. Lysing the plurality of cells may comprise providing a lysis buffer comprising the cell lysis agent to the plurality of cells. In some cases, the biological particles may be nuclei, which may be isolated from lysed cells by, e.g., washing the lysed cells. In some cases, the method further comprises generating sequencing reads. Application of the method may reduce the fraction of sequencing reads deriving from mitochondrial DNA relative to the total number of sequencing reads generated. In some cases, the template nucleic acid may comprise chromatin.
In some cases, a method of generating barcoded nucleic acid fragments comprises: (a) lysing a plurality of cells in the presence of a cell lysis agent and a blocking agent to generate a plurality of lysed cells; (b) separating a plurality of nuclei from the plurality of lysed cells to generate a plurality of biological particles, where an individual biological particle comprises non-template DNA molecules (e.g., mitochondrial DNA molecules), template DNA molecules, and template RNA molecules; (c) providing (i) a plurality of transposon end nucleic acid molecules comprising a transposon end sequence and (ii) a plurality of transposase nucleic acid molecules; (d) generating a plurality of template DNA fragments in biological particles of the plurality of biological particles with the aid of a transposase-nucleic acid complex comprising a transposase nucleic acid molecule of the plurality of transposase nucleic acid molecules and a transposon end nucleic acid molecule of the plurality of transposon end nucleic acid molecules; (e) generating a partition (e.g., a droplet or well) comprising (i) the biological particle comprising the plurality of template nucleic acid fragments and template RNA molecules; (ii) a plurality of first barcode oligonucleotide molecules (e.g., first nucleic acid barcode molecules) comprising a barcode sequence; (iii) a plurality of second barcode oligonucleotide molecules (e.g., second nucleic acid molecules) comprising a barcode sequence and a capture sequence; and (iv) a plurality of reverse transcriptase molecules; (f) generating a barcoded template DNA fragment using a barcode oligonucleotide molecule of the plurality of first barcode oligonucleotide molecules and a template DNA fragment of the plurality of template DNA fragments; and (g) generating a barcoded cDNA molecule from the template RNA molecules by reverse transcription using a barcode oligonucleotide molecule of the plurality of second barcode oligonucleotide molecules. In some cases, the blocking agent may comprise bovine serum albumin (BSA). For example, the blocking agent may comprise a solution of 3% BSA in phosphate buffered saline. Lysing the plurality of cells may comprise providing a lysis buffer comprising the cell lysis agent to the plurality of cells. In some cases, the biological particles may be nuclei, which may be isolated from lysed cells by, e.g., washing the lysed cells. In some cases, the method further comprises generating sequencing reads. Application of the method may reduce the fraction of sequencing reads deriving from mitochondrial DNA relative to the total number of sequencing reads generated. In some cases, the template DNA molecules may comprise chromatin.
In some cases, a method of reducing or removing mitochondrial DNA from a sample may comprise providing a sample comprising a plurality of cells comprising nuclear DNA and mitochondrial DNA; subjecting the plurality of cells to analysis for accessible chromatin (e.g., tagmentation, as described herein), thereby generating tagmented mitochondrial DNA fragments and tagmented nuclear DNA fragments; and using an enzyme to deplete tagmented mitochondrial DNA fragments, thereby reducing the relative amount of tagmented mitochondrial DNA fragments within the total number of fragments. In some cases, the enzyme may be an endonuclease enzyme. For example, the enzyme may be an RNA-guided DNA endonuclease enzyme. The enzyme may be a clustered regularly interspaced short palindromic (CRISPR) associated protein (e.g., nuclease) such as Cas9. The enzyme (e.g., Cas9, such as recombinant Cas9) may be complexed with one or more guide RNAs (gRNAs). The Cas9-gRNA scheme may be used to target species for cleavage. For example, tagmented mitochondrial DNA fragments may be cleaved so that mitochondrial-derived DNA fragments will not be processed in subsequent sequencing. In this scheme, a gRNA may be specifically designed to target a species of interest (e.g., a tagmented mitochondrial DNA fragment). An enzyme (e.g., Cas9, such as recombinant Cas9) may be complexed with gRNAs to target loci of human mitochondrial chromosome. Application of the enzyme-gRNA system may result in a reduction in the fraction of mitochondrial DNA fragments relative to a total number of fragments. In an example, a plurality of gRNAs may be provided to a mixture comprising mitochondrial DNA fragments, where the plurality of gRNAs target different regions of mitochondrial DNA. For example, the plurality of gRNAs may target mitochondrial DNA (e.g., human mitochondrial chromosome) about every 250 base pairs.
In some cases, the amount of sequencing reads associated with mitochondrial DNA in an ATAC-seq library may be reduced by at least about 5%. For example, the amount of sequencing reads associated with mitochondrial DNA may be reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or more. In an example the amount of sequencing reads associated with mitochondrial DNA may be reduced by at least about 50%, such as from about 30% to about 60%. In some cases, the fraction of sequencing reads associated with mitochondrial DNA of a plurality of sequencing reads derived from a sample (e.g., a solution, partition, or plurality of partitions comprising one or more cells and/or nuclei) may be reduced to be less than about 60%. For example, the fraction of sequencing reads associated with mitochondrial DNA may be reduced to less than about 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 1%, or less of the total sequencing reads derived from a sample. In an example, the fraction of sequencing reads associated with mitochondrial DNA may be reduced to between about 1-5% of the total sequencing reads derived from a sample.
In some cases, ATAC-seq and RNA-seq methods may be combined with a method of reducing non-template (e.g., mitochondria]) fragments. For example, a method may comprise generating both barcoded template nucleic acid fragments and barcoded cDNA fragments (e.g., generated via reverse transcription of template RNA molecules) as well as using a blocking agent to reduce non-template fragments (e.g., as described herein). Alternatively or in addition, a method may comprise generating both barcoded template nucleic acid fragments and barcoded cDNA fragments (e.g., generated via reverse transcription of template RNA molecules) as well as using a CRISPR-associated protein to reduce non-template fragments (e.g., as described herein). In some cases, non-template fragments may comprise mitochondrial DNA. In some cases, non-template fragments may comprise mitochondrial RNA. In an example, a biological particle comprising a template DNA molecule, a non-template nucleic acid molecule comprising ribosomal RNA (rRNA, e.g., mitochondrial rRNA), and a template RNA molecule is provided, and a barcoded cDNA is generated from the template RNA molecule by reverse transcription using a barcode oligonucleotide (e.g., nucleic acid barcode molecule) (e.g., as described herein). Guide RNA molecules (e.g., sgRNAs) targeted to specific non-template rRNA (e.g., specific regions of mitochondrial rRNA) or cDNA molecule generated from rRNA molecules may be used in combination with a CRISPR associated protein such as Cas9 to selectively deplete sequences associated with rRNA, e.g., upon sequencing a plurality of sequences derived from the biological particle. Therefore, the methods described herein may allow for selective depletion of fragments and/or sequences (e.g., sequence reads) associated with a non-template species such as a non-template rRNA and corresponding enhancement of fragments and/or sequences (e.g., sequence reads) associated with template DNA and RNA species.
In some cases, a method for nucleic acid processing comprises: (a) generating a partition (e.g., a droplet or well), wherein the partition comprises: (i) a biological particle (e.g., cell); (ii) a plurality of barcode oligonucleotide molecules (e.g., nucleic acid barcode molecules) comprising a common barcode sequence; (iii) a plurality of transposon end oligonucleotide molecules (e.g., transposon end nucleic acid molecules) comprising a transposon end sequence; and (iv) a plurality of transposase molecules, wherein the biological particle (e.g., cell) comprises a template nucleic acid and a non-template nucleic acid; (b) generating a plurality of template nucleic acid fragments and a plurality of non-template nucleic acid fragments (e.g., mitochondrial nucleic acid fragments) with the aid of a transposase-nucleic acid complex comprising a transposase molecule of the plurality of transposase molecules and a transposon end oligonucleotide molecule of the plurality of transposon end oligonucleotide molecules; (c) generating a barcoded template nucleic acid fragment using a barcode oligonucleotide molecule of the plurality of barcode oligonucleotide molecules and a template nucleic acid fragment of the plurality of template nucleic acid fragments; and (d) cleaving one or more non-template nucleic acid fragments of the plurality of non-template nucleic acid fragments, or derivatives thereof, using (i) one or more guide ribonucleic acid molecules (gRNAs) targeted to the one or more non-template nucleic acid fragments, and (ii) a clustered regularly interspaced short palindromic (CRISPR) associated (Cas) nuclease. In some cases, one or more barcoded non-template nucleic acid fragments are generated using barcode oligonucleotide molecules of the plurality of barcode oligonucleotide molecules and one or more non-template nucleic acid fragments (e.g., mitochondrial nucleic acid fragments) of the plurality of non-template nucleic acid fragments. In some cases, the method may reduce the amount of fragments and/or barcoded fragments comprising and/or deriving from non-template nucleic acids. For example, the method may reduce the total number of non-template nucleic acid fragments and barcoded non-template nucleic acid fragments, e.g., in a mixture comprising one or more of template nucleic acid fragments, barcoded template nucleic acid fragments, non-template nucleic acid fragments, and barcoded non-template nucleic acid fragments. In some cases, the endonuclease may be Cas9, such as recombinant Cas9. In some cases, the non-template nucleic acid fragment may comprise a mitochondrial DNA fragment. In some cases, the template nucleic acid fragment may comprise a nuclear DNA fragment.
In some cases, a method of generating barcoded nucleic acid fragments comprises: (a) providing a plurality of biological particles (e.g., cells or nuclei), an individual biological particle (e.g., cell or nucleus) comprising a template nucleic acid (e.g., chromatin) and a non-template nucleic acid (e.g., mitochondrial nucleic acid); (b) generating a plurality of template nucleic acid fragments and a plurality of non-template nucleic acid fragments (e.g., mitochondrial nucleic acid fragments) in a biological particle of the plurality of biological particles with the aid of a transposase-nucleic acid complex comprising a transposase nucleic acid molecule and a transposon end nucleic acid molecule; (c) generating a partition (e.g., a droplet or well) comprising the biological particle comprising the plurality of template nucleic acid fragments and the plurality of non-template nucleic acid fragments, and a plurality of barcode oligonucleotide molecules (e.g., nucleic acid barcode molecules) comprising a barcode sequence; (d) generating a barcoded template nucleic acid fragment using a barcode oligonucleotide molecule of the plurality of barcode oligonucleotide molecules and a template nucleic acid fragment of the plurality of template nucleic acid fragments; and (e) cleaving one or more non-template DNA fragments of the plurality of non-template DNA fragments, or derivatives thereof, using (i) one or more guide ribonucleic acid molecules (gRNAs) targeted to the one or more non-template DNA fragments, and (ii) a clustered regularly interspaced short palindromic (CRISPR) associated (Cas) nuclease. In some cases, one or more barcoded non-template nucleic acid fragments are generated using barcode oligonucleotide molecules of the plurality of barcode oligonucleotide molecules and one or more non-template nucleic acid fragments (e.g., mitochondrial nucleic acid fragments) of the plurality of non-template nucleic acid fragments. In some cases, the method may reduce the amount of fragments and/or barcoded fragments comprising and/or deriving from non-template nucleic acids. For example, the method may reduce the total number of non-template nucleic acid fragments and barcoded non-template nucleic acid fragments, e.g., in a mixture comprising one or more of template nucleic acid fragments, barcoded template nucleic acid fragments, non-template nucleic acid fragments, and barcoded non-template nucleic acid fragments. In some cases, the endonuclease may be Cas9, such as recombinant Cas9. In some cases, the non-template nucleic acid fragment may comprise a mitochondrial DNA fragment. In some cases, the template nucleic acid fragment may comprise chromatin. In some cases, a method of generating barcoded nucleic acid fragments comprises: (a) generating a partition (e.g., a droplet or well), wherein the partition comprises: (i) a biological particle (e.g., cell or nucleus), wherein the biological particle comprises template DNA molecules (e.g., chromatin), non-template DNA molecules (e.g., mitochondrial DNA molecules), and template RNA molecules; (ii) a plurality of first barcode oligonucleotide molecules (e.g., first nucleic acid barcode molecules) comprising a barcode sequence; (iii) a plurality of transposon end nucleic acid molecules comprising a transposon end sequence; (iv) a plurality of transposase nucleic acid molecules; (v) a plurality of second barcode oligonucleotide molecules (e.g., second nucleic acid barcode molecules) comprising a barcode sequence and a capture sequence; and (vi) a plurality of reverse transcriptase molecules; (b) generating a plurality of template DNA fragments and a plurality of non-template DNA fragments (e.g., mitochondrial nucleic acid fragments) with the aid of a transposase-nucleic acid complex comprising a transposase nucleic acid molecule of the plurality of transposase nucleic acid molecules and a transposon end nucleic acid molecule of the plurality of transposon end nucleic acid molecules; (c) generating a barcoded template DNA fragment using a barcode oligonucleotide molecule of the plurality of first barcode oligonucleotide molecules and a template DNA fragment of the plurality of template DNA fragments; (d) generating a barcoded cDNA molecule from the template RNA molecules by reverse transcription using a barcode oligonucleotide molecule of the plurality of second barcode oligonucleotide molecules; and (e) cleaving one or more non-template DNA fragments of the plurality of non-template DNA fragments, or derivatives thereof, using (i) one or more guide ribonucleic acid molecules (gRNAs) targeted to the one or more non-template DNA fragments, and (ii) a clustered regularly interspaced short palindromic (CRISPR) associated (Cas) nuclease. In some cases, one or more barcoded non-template DNA fragments are generated using barcode oligonucleotide molecules of the plurality of barcode oligonucleotide molecules and one or more non-template DNA fragments (e.g., mitochondrial DNA fragments) of the plurality of non-template DNA fragments. In some cases, the method may reduce the amount of fragments and/or barcoded fragments comprising and/or deriving from non-template DNA. For example, the method may reduce the total number of non-template DNA fragments and barcoded non-template DNA fragments, e.g., in a mixture comprising one or more of template DNA fragments, barcoded template DNA fragments, non-template DNA fragments, and barcoded non-template DNA fragments. In some cases, the endonuclease may be Cas9, such as recombinant Cas9. In some cases, the non-template DNA fragment may comprise a mitochondrial DNA fragment. In some cases, the template DNA fragment may comprise chromatin.
In some cases, a method of generating barcoded nucleic acid fragments comprises: (a) providing a biological particle (e.g., cell) comprising template DNA molecules, non-template DNA molecules, and template RNA molecules; (b) generating a plurality of template DNA fragments and non-template DNA fragments in the biological particle with the aid of a transposase-nucleic acid complex comprising a transposase nucleic acid molecule and a transposon end nucleic acid molecule; (c) generating a partition (e.g., a droplet or well) comprising (i) the biological particle comprising template DNA fragments, non-template DNA fragments, and template RNA molecules; (ii) a plurality of first barcode oligonucleotide molecules (e.g., first nucleic acid barcode molecules) comprising a common barcode sequence; (iii) a plurality of second barcode oligonucleotide molecules (e.g., second nucleic acid molecules) comprising a barcode sequence and a capture sequence; and (iv) a plurality of reverse transcriptase molecules; (d) generating a barcoded template DNA fragment using a barcode oligonucleotide molecule of the plurality of first barcode oligonucleotide molecules and a template DNA fragment of the plurality of template DNA fragments; (e) generating a barcoded cDNA molecule from the template RNA molecules by reverse transcription using a barcode oligonucleotide molecule of the plurality of second barcode oligonucleotide molecules; and (f) cleaving one or more non-template DNA fragments of the plurality of non-template DNA fragments, or derivatives thereof, using (i) one or more guide ribonucleic acid molecules (gRNAs) targeted to the one or more non-template nucleic acid fragments, and (ii) a clustered regularly interspaced short palindromic (CRISPR) associated (Cas) nuclease. In some cases, one or more barcoded non-template DNA fragments are generated using barcode oligonucleotide molecules of the plurality of barcode oligonucleotide molecules and one or more non-template DNA fragments (e.g., mitochondrial DNA fragments) of the plurality of non-template DNA fragments. In some cases, the method may reduce the amount of fragments and/or barcoded fragments comprising and/or deriving from non-template DNA. For example, the method may reduce the total number of non-template DNA fragments and barcoded non-template DNA fragments, e.g., in a mixture comprising one or more of template DNA fragments, barcoded template DNA fragments, non-template DNA fragments, and barcoded non-template DNA fragments. In some cases, the endonuclease may be Cas9, such as recombinant Cas9. In some cases, the non-template DNA fragment may comprise a mitochondrial DNA fragment. In some cases, the template DNA fragment may comprise a nuclear DNA fragment.
In some cases, a method of generating barcoded nucleic acid fragments comprises: (a) providing a partition (e.g., a droplet or well), wherein the partition comprises (i) a biological particle (e.g., cell or nucleus), (ii) a single solid or semi-solid particle (e.g., bead, such as a gel bead), and (iii) a plurality of transposase nucleic acid molecules, wherein the single biological particle comprises a template nucleic acid molecule and a non-template nucleic acid molecule and wherein the single solid or semi-solid particle (e.g., bead) comprises a barcoded oligonucleotide (e.g., nucleic acid barcode molecule) releasably coupled thereto; (b) subjecting the partition to conditions sufficient to release the template nucleic acid molecule and the non-template nucleic acid molecule from the single biological particle; (c) subjecting the partition to conditions sufficient to release the barcoded oligonucleotide from the solid or semi-solid particle; (d) subjecting the partition to conditions sufficient to cause transposition of the barcoded oligonucleotides into the template nucleic acid molecule and the non-template nucleic acid molecule with the aid of a transposome complex generated from at least a subset of the plurality of transposase nucleic acid molecules; (e) fragmenting (i) the template nucleic acid molecule into a plurality of double-stranded template nucleic acid fragments comprising the barcoded oligonucleotides and (ii) the non-template nucleic acid molecule into a plurality of double-stranded non-template nucleic acid fragments comprising the barcoded oligonucleotides; and (f) cleaving one or more non-template nucleic acid fragments of the plurality of non-template nucleic acid fragments, or derivatives thereof, using (i) one or more guide ribonucleic acid molecules (gRNAs) targeted to the one or more non-template nucleic acid fragments, and (ii) a clustered regularly interspaced short palindromic (CRISPR) associated (Cas) nuclease. In some cases, the method may reduce the amount of fragments comprising and/or deriving from non-template nucleic acids. For example, the method may reduce the total number of non-template nucleic acid fragments, e.g., in a mixture comprising one or more of template nucleic acid fragments, barcoded template nucleic acid fragments, non-template nucleic acid fragments, and barcoded non-template nucleic acid fragments. In some cases, the endonuclease may be Cas9, such as recombinant Cas9. In some cases, the non-template nucleic acid fragment may comprise a mitochondrial DNA fragment. In some cases, the template nucleic acid fragment may comprise chromatin.
The present methods may have the effect of reducing or removing non-template nucleic acids (e.g., mitochondrial DNA) and/or enhancing accessible chromatin. The methods may be used with any cell type (e.g., as described herein). For example, the methods may be used with a human or a mammalian cell. The methods may also be used with any concentration of cells. For example, the methods of reducing or removing non-template nucleic acids (e.g., mitochondrial DNA) and/or enhancing accessible chromatin may be used with an isolated cell. In another example, the method of reducing or removing non-template nucleic acids (e.g., mitochondrial DNA) and/or enhancing accessible chromatin may be used with a plurality of cells, such as a plurality of cells within a plurality of droplets or a plurality of cells in a bulk solution. The method of reducing or removing non-template nucleic acids (e.g., mitochondrial DNA) and/or enhancing accessible chromatin may be applied to any library type that requires a reducing in sequencing reads associated with non-template nucleic acids (e.g., mitochondrial DNA) or RNA, including RNA-seq.
A method of reducing non-template (e.g., mitochondrial) reads and/or enhancing reads associated with accessible chromatin relative to a total number of reads associated with a sample (e.g., a cell or a plurality of cells) may be applied to any of the methods described herein. For example, a blocking agent (e.g., BSA) may be provided to any sample described herein. As described above, use of a blocking agent may reduce or prevent non-specific adsorption of mitochondrial DNA to nuclei such that mitochondrial DNA can be washed away during nuclei isolation. Similarly, an endonuclease may be provided after any tagmentation process described herein to reduce the relative fraction of tagmented mitochondrial DNA in a sample comprising tagmented DNA.
Additional details and methods regarding processing nucleic acid samples and reducing non-template (e.g., mitochondrial) reads can be found in, for example: Gu et al. (Gu, W.; Crawford, E. D.; O'Donovan, B. D., Wilson, M. R., Chow, E. D., Retallack, H., and DeRisi, J. L. “Depletion of Abundant Sequences by Hybridization (DASH): using Cas9 to remove unwanted high-abundance species in sequencing libraries and molecular counting applications,” Genome Biology (2016) 17:41), Montefiori et al. (Montefiori, L.; Hernandez, L.; Zhang, Z.; Gilad, Y.; Ober, C.; Crawford, G.; Nobrega, M.; and Sakabe, N. J. “Reducing mitochondrial reads in ATAC-seq using CRISPR/Cas9,” Scientific Reports (2017) 7:2451), and Corces et al. (Corces, M. R.; Trevino, A. E.; Hamilton, E. G.; Greenside, P. G.; Sinnott-Armstrong, N. A.; Vesuna, S.; Satpathy, A. T.; Rubin, A. J.; Montine, K. S.; Wu, B.; Kathiria, A.; Cho, S. W.; Mumbach, M. R.; Carter, A. C.; Kasowski, M.; Orloff, L. A.; Risca, V. I.; Kundaje, A.; Khavari, P. A.; Montine, T. J.; Greenleaf, W. J.; and Chang, H. Y. “An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues,” Nature Methods (2017)), each of which is herein incorporated by reference in its entirety.
Kits
Also provided herein are kits for analyzing the accessible chromatin (e.g., for ATAC-seq) and/or RNA transcripts of individual cells or small populations of cells. The kits may include one or more of the following: one, two, three, four, five or more, up to all of partitioning fluids, including both aqueous buffers and non-aqueous partitioning fluids or oils, nucleic acid barcode libraries that are releasably associated with beads, as described herein, microfluidic devices, reagents for disrupting cells amplifying nucleic acids, and providing additional functional sequences on fragments of cellular nucleic acids or replicates thereof, as well as instructions for using any of the foregoing in the methods described herein.
Computer Systems
The present disclosure provides computer systems that are programmed to implement methods of the disclosure.
The computer system 901 includes a central processing unit (CPU, also “processor” and “computer processor” herein) 905, which can be a single core or multi core processor, or a plurality of processors for parallel processing. The computer system 901 also includes memory or memory location 910 (e.g., random-access memory, read-only memory, flash memory), electronic storage unit 915 (e.g., hard disk), communication interface 920 (e.g., network adapter) for communicating with one or more other systems, and peripheral devices 925, such as cache, other memory, data storage and/or electronic display adapters. The memory 910, storage unit 915, interface 920 and peripheral devices 925 are in communication with the CPU 905 through a communication bus (solid lines), such as a motherboard. The storage unit 915 can be a data storage unit (or data repository) for storing data. The computer system 901 can be operatively coupled to a computer network (“network”) 930 with the aid of the communication interface 920. The network 930 can be the Internet, an internet and/or extranet, or an intranet and/or extranet that is in communication with the Internet. The network 930 in some cases is a telecommunication and/or data network. The network 930 can include one or more computer servers, which can enable distributed computing, such as cloud computing. The network 930, in some cases with the aid of the computer system 901, can implement a peer-to-peer network, which may enable devices coupled to the computer system 901 to behave as a client or a server.
The CPU 905 can execute a sequence of machine-readable instructions, which can be embodied in a program or software. The instructions may be stored in a memory location, such as the memory 910. The instructions can be directed to the CPU 905, which can subsequently program or otherwise configure the CPU 905 to implement methods of the present disclosure. Examples of operations performed by the CPU 905 can include fetch, decode, execute, and writeback.
The CPU 905 can be part of a circuit, such as an integrated circuit. One or more other components of the system 901 can be included in the circuit. In some cases, the circuit is an application specific integrated circuit (ASIC).
The storage unit 915 can store files, such as drivers, libraries and saved programs. The storage unit 915 can store user data, e.g., user preferences and user programs. The computer system 901 in some cases can include one or more additional data storage units that are external to the computer system 901, such as located on a remote server that is in communication with the computer system 901 through an intranet or the Internet.
The computer system 901 can communicate with one or more remote computer systems through the network 930. For instance, the computer system 901 can communicate with a remote computer system of a user (e.g., operator). Examples of remote computer systems include personal computers (e.g., portable PC), slate or tablet PC's (e.g., Apple® iPad, Samsung® Galaxy Tab), telephones, Smart phones (e.g., Apple® iPhone, Android-enabled device, Blackberry®), or personal digital assistants. The user can access the computer system 901 via the network 930.
Methods as described herein can be implemented by way of machine (e.g., computer processor) executable code stored on an electronic storage location of the computer system 901, such as, for example, on the memory 910 or electronic storage unit 915. The machine executable or machine readable code can be provided in the form of software. During use, the code can be executed by the processor 905. In some cases, the code can be retrieved from the storage unit 915 and stored on the memory 910 for ready access by the processor 905. In some situations, the electronic storage unit 915 can be precluded, and machine-executable instructions are stored on memory 910.
The code can be pre-compiled and configured for use with a machine having a processor adapted to execute the code, or can be compiled during runtime. The code can be supplied in a programming language that can be selected to enable the code to execute in a pre-compiled or as-compiled fashion.
Aspects of the systems and methods provided herein, such as the computer system 901, can be embodied in programming. Various aspects of the technology may be thought of as “products” or “articles of manufacture” typically in the form of machine (or processor) executable code and/or associated data that is carried on or embodied in a type of machine readable medium. Machine-executable code can be stored on an electronic storage unit, such as memory (e.g., read-only memory, random-access memory, flash memory) or a hard disk. “Storage” type media can include any or all of the tangible memory of the computers, processors or the like, or associated modules thereof, such as various semiconductor memories, tape drives, disk drives and the like, which may provide non-transitory storage at any time for the software programming. All or portions of the software may at times be communicated through the Internet or various other telecommunication networks. Such communications, for example, may enable loading of the software from one computer or processor into another, for example, from a management server or host computer into the computer platform of an application server. Thus, another type of media that may bear the software elements includes optical, electrical and electromagnetic waves, such as used across physical interfaces between local devices, through wired and optical landline networks and over various air-links. The physical elements that carry such waves, such as wired or wireless links, optical links or the like, also may be considered as media bearing the software. As used herein, unless restricted to non-transitory, tangible “storage” media, terms such as computer or machine “readable medium” refer to any medium that participates in providing instructions to a processor for execution.
Hence, a machine readable medium, such as computer-executable code, may take many forms, including but not limited to, a tangible storage medium, a carrier wave medium or physical transmission medium. Non-volatile storage media include, for example, optical or magnetic disks, such as any of the storage devices in any computer(s) or the like, such as may be used to implement the databases, etc. shown in the drawings. Volatile storage media include dynamic memory, such as main memory of such a computer platform. Tangible transmission media include coaxial cables; copper wire and fiber optics, including the wires that comprise a bus within a computer system. Carrier-wave transmission media may take the form of electric or electromagnetic signals, or acoustic or light waves such as those generated during radio frequency (RF) and infrared (IR) data communications. Common forms of computer-readable media therefore include for example: a floppy disk, a flexible disk, hard disk, magnetic tape, any other magnetic medium, a CD-ROM, DVD or DVD-ROM, any other optical medium, punch cards paper tape, any other physical storage medium with patterns of holes, a RAM, a ROM, a PROM and EPROM, a FLASH-EPROM, any other memory chip or cartridge, a carrier wave transporting data or instructions, cables or links transporting such a carrier wave, or any other medium from which a computer may read programming code and/or data. Many of these forms of computer readable media may be involved in carrying one or more sequences of one or more instructions to a processor for execution. [00243] The computer system 901 can include or be in communication with an electronic display 935 that comprises a user interface (UI) 940 for providing, for example, results of sequencing analysis, correlating sequencing reads to areas of accessible chromatin, etc. Examples of UIs include, without limitation, a graphical user interface (GUI) and web-based user interface. [00244] Methods and systems of the present disclosure can be implemented by way of one or more algorithms. An algorithm can be implemented by way of software upon execution by the central processing unit 905. The algorithm can, for example, perform sequencing reactions, correlating sequencing reads to areas of accessible chromatin, etc.
Devices, systems, compositions and methods of the present disclosure may be used for various applications, such as, for example, processing a single analyte (e.g., RNA, DNA, or protein) or multiple analytes (e.g., DNA and RNA, DNA and protein, RNA and protein, or RNA, DNA and protein) form a single cell. For example, a biological particle (e.g., a cell or cell bead) is partitioned in a partition (e.g., droplet), and multiple analytes from the biological particle are processed for subsequent processing. The multiple analytes may be from the single cell. This may enable, for example, simultaneous proteomic, transcriptomic and genomic analysis of the cell.
Although one or more of the Examples herein make use of partitions that comprise droplets in an emulsion (e.g., droplet emulsion partition), any of the above-described partitions (such as wells) can be utilized in the methods, systems, and compositions described below.
A plurality of transposase molecules, a plurality of cells of interest (or a plurality of nuclei harvested from cells of interest, e.g., by nonionic detergents such as NP-40 (IGEPAL CA-630) or Triton X-100), and a plurality of barcode oligonucleotides (e.g., nucleic acid barcode molecules) are partitioned such that at least some partitions (e.g., droplets or wells) comprise a plurality of transposase molecules, a single cell (or nucleus), and a plurality of barcode oligonucleotides comprising a sequencing primer sequence, a barcode sequence, and a transposon end sequence. In some embodiments, the plurality of barcode oligonucleotides are attached to a solid or semi-solid particle such as a gel bead and partitioned such that at least some partitions (e.g., droplets or wells) comprise transposase molecules, a single cell (or nucleus), and support (e.g., a single gel bead).
For example, in some embodiments, aqueous droplet emulsion partitions are generated as described herein such that at least some of the droplets formed will comprise transposase molecules, cell lysis reagents, a single cell, and a single bead (e.g., gel bead) comprising a plurality of barcoded forked adapter oligonucleotides. See, e.g.,
Specifically, a droplet is subjected to conditions such that the barcoded forked adaptor oligonucleotides are released from the bead (e.g., gel bead) into the aqueous droplet (e.g., by depolymerization or degradation of the bead using a reducing agent, such as DTT). Although the forked adaptors can be prepared in a variety of different configurations, an exemplary forked adaptor is illustrated in
In alternative embodiments (e.g.,
After forked adaptors are released from a bead (e.g., gel bead) into a droplet, the droplet is subjected to conditions such that a transposase-nucleic acid complex is formed comprising a transposase molecule and two forked adaptors. See
The double-stranded template nucleic acid fragments are then collected from the droplets and processed in bulk to fill any gaps created from the transposition reaction and to generate a library suitable for next generation high throughput sequencing (e.g., subjecting the fragments, or derivatives thereof, to one or more reactions (e.g., nucleic acid amplification) to add functional sequences to facilitate Illumina sequencing; see
A plurality of transposase-nucleic acid complexes, a plurality of cells of interest (or a plurality of nuclei harvested from cells of interest), and a plurality of barcode oligonucleotides are partitioned such that at least some partitions (e.g., droplets or wells) comprise a plurality of transposase-nucleic acid complexes, a single cell (or nucleus), and a plurality of barcode oligonucleotides (e.g., nucleic acid barcode molecules) comprising a sequencing primer sequence and a barcode sequence. In some embodiments, the plurality of barcode oligonucleotides are attached to a solid or semi-solid particle (e.g., a bead, such as a gel bead) and partitioned such that at least some partitions (e.g., droplets or wells) comprise transposase-nucleic acid complexes, a single cell (or nucleus), and a single solid or semi-solid particle (e.g., gel bead). In alternative embodiments, a plurality of transposase molecules and a plurality of transposon end sequence oligonucleotides are partitioned along with a single cell (or nucleus) and the barcode oligonucleotides and transposase-nucleic acid complexes are generated in the partition (e.g., droplet or well).
For example, in some embodiments, droplet emulsion partitions are generated as described herein such that at least some of the droplets comprise transposase-nucleic acid complexes, cell lysis reagents, T4 DNA ligase, a single cell or cell nucleus, and a single bead (e.g., gel bead) comprising a plurality of barcoded forked adapter oligonucleotides. See, e.g.,
An individual transposase-nucleic acid complex comprises a transposase and a pair of double-stranded oligonucleotides each comprising a transposon end sequence (e.g., an ME sequence). See
After droplet formation, single cells, if present, are lysed in a manner that releases template nucleic acid molecules from the nucleus into the droplet, but that substantially maintains native chromatin organization. Droplets are then generally processed as outlined in
Specifically, a droplet is subjected to conditions such that the forked adaptors are released from the bead (e.g., gel bead) into the aqueous droplet (e.g., by depolymerization or degradation of the bead using a reducing agent, such as DTT). See
After forked adaptors are released from a bead (e.g., gel bead) into a droplet, the droplet is subjected to conditions such that the transposase-nucleic acid complexes integrate the transposon end sequences into the template nucleic acid and fragment the template nucleic acid into double-stranded template nucleic acid fragments flanked by transposon end sequences. See
The double-stranded template nucleic acid fragments are then collected from the droplets and processed in bulk to fill any gaps created from the transposition reaction and to generate a library suitable for next generation high throughput sequencing (e.g., subjecting the fragments, or derivatives thereof, to one or more reactions (e.g., nucleic acid amplification) to add functional sequences to facilitate Illumina sequencing; see
A plurality of transposase molecules, a plurality of cells of interest (or a plurality of nuclei harvested from cells of interest), and a plurality of barcode oligonucleotides are partitioned such that at least some partitions (e.g., droplets or wells) comprise a plurality of transposase molecules, a single cell (or nucleus), and a plurality of barcode oligonucleotides (e.g., nucleic acid barcode molecules) comprising a T7 promoter sequence, a sequencing primer sequence, a barcode sequence, and a transposon end sequence. In some embodiments, the plurality of barcode oligonucleotides are attached to a solid or semi-solid particle (e.g., a bead, such as a gel bead) and partitioned such that at least some partitions (e.g., droplets or wells) comprise transposase molecules, a single cell (or nucleus), and a single solid or semi-solid particle (e.g., gel bead).
For example, in some embodiments, droplet emulsion partitions are generated as previously described such that at least some droplets (e.g., aqueous droplets) that comprise transposase molecules, cell lysis reagents, a single cell (or nucleus), and a single bead (e.g., gel bead) comprising partially double-stranded T7 promoter oligonucleotide adaptors. See, e.g.,
Specifically, a droplet (e.g., an aqueous droplet) is subjected to conditions such that the partially double-stranded adaptors are released from the gel bead into the droplet (e.g., by depolymerization or degradation of the bead using a reducing agent, such as DTT). See
After partially double-stranded adaptors are released from a bead (e.g., gel bead) into a droplet, the droplet is subjected to conditions such that a transposase-nucleic acid complex is formed comprising a transposase molecule and two partially double-stranded oligonucleotides adaptors. See
The double-stranded template nucleic acid fragments are then collected from the droplets and processed in bulk to fill any gaps created from the transposition reaction. RNA is generated from the double-stranded template nucleic acid fragments using an in vitro transcription reaction and T7 RNA polymerase. RNA is collected and purified, followed by first and second strand cDNA synthesis. Double-stranded cDNA molecules are then further processed (including fragmentation and adaptor insertion by, e.g., a second transposase-mediated fragmentation) to generate a library suitable for next generation high throughput sequencing (e.g., subjecting the fragments, or derivatives thereof, to one or more reactions (e.g., nucleic acid amplification) to add functional sequences to facilitate Illumina sequencing). The fully constructed library is then sequenced according to any suitable sequencing protocol.
A plurality of transposase molecules, a plurality of cells of interest (or a plurality of nuclei harvested from cells of interest), and a plurality of barcode oligonucleotides are partitioned such that at least some partitions (e.g., droplets or wells) comprise a plurality of transposase molecules, a single cell (or nucleus), and a plurality of barcode oligonucleotides (e.g., nucleic acid barcode molecules) comprising a sequencing primer sequence, a barcode sequence, and a transposon end sequence. In some embodiments, the plurality of barcode oligonucleotides are attached to a solid or semi-solid particle (e.g., a bead, such as a gel bead) and partitioned such that at least some partitions (e.g., droplets or wells) comprise transposase molecules, a single cell (or nucleus), and a single solid or semi-solid particle (e.g., gel bead).
For example, in some embodiments, droplet emulsion partitions are generated as previously described such that at least some droplets that comprise transposase molecules, cell lysis reagents, a single cell (or nucleus), and a single bead (e.g., gel bead) comprising partially double-stranded barcoded oligonucleotide adaptors. See, e.g.,
Specifically, a droplet (e.g., an aqueous droplet) is subjected to conditions such that partially double-stranded adaptors are released from a bead (e.g., gel bead) into the droplet (e.g., by depolymerization or degradation of the bead using a reducing agent, such as DTT). See
After partially double-stranded adaptors are released from a bead (e.g., gel bead) into a droplet (e.g., an aqueous droplet), the droplet is subjected to conditions such that a transposase-nucleic acid complex is formed comprising a transposase molecule and two partially double-stranded oligonucleotides. See
The double-stranded template nucleic acid fragments are then collected from the droplets and processed in bulk to generate a library suitable for next generation high throughput sequencing. In some embodiments, for example, double-stranded template nucleic acid fragments are processed in bulk in a random priming extension reaction. See, e,g,
In some embodiments, artificial transposons are designed to insert sequences of interest into a target DNA molecule (e.g., open chromatin). For example, an artificial transposon oligonucleotide comprising a barcode sequence and an adapter sequence is flanked by a transposon end sequence on each end of the oligonucleotide (see, e.g.,
For example, in some embodiments, droplet emulsion partitions are generated as previously described such that at least some droplets that comprise transposase molecules, cell lysis reagents, a single cell (or nucleus), and a single bead (e.g., gel bead). The cells are then lysed to release template nucleic acid molecules from the nucleus into the aqueous droplet. Droplets are then generally processed as outlined in
Specifically, a droplet (e.g., aqueous droplet) is subjected to conditions such that barcoded adaptors are released from a bead (e.g., gel bead) into the droplet (e.g., by depolymerization or degradation of the bead using a reducing agent, such as DTT). Although the barcoded adaptors can be prepared in a variety of different configurations, an exemplary barcoded adaptor is illustrated in
After barcoded adaptors are released from a bead (e.g., gel bead) into a droplet, the droplet is subjected to conditions such that a transposase-nucleic acid complex is formed comprising a transposase molecule and a barcoded adaptor comprising a pair of transposon end sequences. See
The barcode-transposed template nucleic acids are then collected from the droplets and processed in bulk to fragment the barcode-transposed template nucleic acids and to generate a library suitable for next generation high throughput sequencing (e.g., subjecting the fragments, or derivatives thereof, to one or more reactions (e.g., nucleic acid amplification) to add functional sequences to facilitate Illumina sequencing). The fully constructed library is then sequenced according to any suitable sequencing protocol.
A plurality of transposase nucleic acid complexes and a plurality of cells of interest (or a plurality of nuclei harvested from cells of interest) are partitioned such that at least some partitions (e.g., droplets or wells) comprise a single cell (or nucleus) and a plurality of transposase nucleic acid complexes comprising a transposase molecule and a barcode oligonucleotide (e.g., nucleic acid barcode molecule) comprising a sequencing primer sequence, a barcode sequence, and a transposon end sequence (see, e.g.,
For example, in some embodiments, droplet emulsion partitions are generated as previously described such that at least some droplets (e.g., aqueous droplets) comprise cell lysis reagents, a single cell (or nucleus), and a single bead (e.g., gel bead) functionalized with a transposase-nucleic acid complex. The cells are then lysed in a manner that releases template nucleic acid molecules from the nuclei into the respective droplets, but that substantially maintains native chromatin organization.
Droplets (e.g., aqueous droplets) are then subjected to conditions such that the transposase-nucleic acid complexes are released from beads (e.g., gel beads) into the respective droplets (e.g., by depolymerization or degradation of beads using a reducing agent, such as DTT). Although the transposase-nucleic acid complexes can be prepared in a variety of different configurations, a transposase-nucleic acid complex is illustrated in
Alternatively, bead (e.g., gel bead) functionalized transposase-nucleic acid complexes are prepared as illustrated in
After a transposase-nucleic acid complex is released from a bead (e.g., gel bead) into a droplet (or is formed in the partition in embodiments such as
The double-stranded template nucleic acid fragments are then collected from the droplets and processed in bulk to fill any gaps created from the transposition reaction and to generate a library suitable for next generation high throughput sequencing (e.g., subjecting the fragments, or derivatives thereof, to one or more reactions (e.g., nucleic acid amplification) to add functional sequences to facilitate Illumina sequencing; see, e.g.,
A plurality of transposase nucleic acid complexes and a plurality of cells of interest (or a plurality of nuclei harvested from cells of interest) are partitioned such that at least some partitions (e.g., droplets or wells) comprise a single cell (or nucleus), a plurality of transposase nucleic acid complexes comprising a transposon end sequence, and a plurality of barcoded oligonucleotides (e.g., nucleic acid barcode molecules) comprising a barcode sequence and a sequencing primer sequence (see, e.g.,
For example, in some embodiments, droplet emulsion partitions are generated as previously described such that at least some droplets (e.g., aqueous droplets) comprise a transposase-nucleic acid complex comprising a transposase and a pair of double-stranded oligonucleotides, cell lysis reagents, a single cell (or nucleus), and a single bead (e.g., gel bead) comprising a barcoded adaptor. Although the transposase-nucleic acid complexes can be prepared in a variety of different configurations, a transposase-nucleic acid complex is illustrated in
Cells, if present, are lysed in a manner that releases template nucleic acid molecules from into droplets (e.g., aqueous droplets), but that substantially maintains native chromatin organization. Droplets are then subjected to conditions such that barcoded adaptors are released from beads (e.g., gel beads) into the respective droplets. Although the barcoded adaptors can be prepared in a variety of different configurations, an exemplary barcoded adaptor is illustrated in
After barcoded adaptors are released from a bead (e.g., gel bead) into a droplet, the droplet is subjected to conditions such that the transposase-nucleic acid complexes integrate the transposon end sequences into the template nucleic acid and fragment the template nucleic acid into double-stranded template nucleic acid fragments. In alternative embodiments, cells (or nuclei) are permeabilized/permeable and the transposase-nucleic acid complexes enter the nuclei to fragment the template nucleic acids therein. Cells, if present, are then lysed to release the double-stranded template nucleic acid fragments. Because the transposase-nucleic acid complex can only act on a nucleosome-free template, the double-stranded template nucleic acid fragments are representative of genome-wide areas of accessible chromatin in a single cell or nucleus. After transposition and fragmentation, a PCR reaction is performed to fill any gaps created from the transposition reaction and to add the barcoded adaptors to the ends of the double-stranded template nucleic acid fragments.
The double-stranded template nucleic acid fragments are then collected from the droplets and processed in bulk to generate a library suitable for next generation high throughput sequencing (e.g., subjecting the fragments, or derivatives thereof, to one or more reactions (e.g., nucleic acid amplification) to add functional sequences to facilitate Illumina sequencing). The fully constructed library is then sequenced according to any suitable sequencing protocol.
Traditional tube-based implementations of Tn5-based tagmentation systems typically rely upon sample processing steps that take place in two independent reactions to generate the final transposase-fragmented nucleic acid sample. For example, in Reaction #1, oligonucleotide adaptors containing the Tn5 transposon end sequences and the Tn5 transposase enzyme are incubated to form a transposase-nucleic acid complex. Typically, magnesium (or other divalent cations) are omitted from the reaction buffer to keep the transposases catalytically inactive. In Reaction #2, the transposase-nucleic acid complex from Reaction #1 is combined with a target double-stranded DNA and an appropriate reaction buffer containing magnesium (or other divalent cations) to activate the transposase-nucleic acid complex and cause fragmentation of the target DNA and ligation of the adapter oligonucleotide sequences. While the above-described serial reaction workflow is straightforward, implementing a tagmentation reaction within a single reaction or reaction vessel (“one-pot reaction”) can be complicated.
A one-pot transposition reaction was performed on 50,000 HEK293T cells and compared to a traditional two-step tagmentation reaction. Sequencing libraries were prepared from each reaction type and sequenced on an Illumina sequencer. Sequencing data is presented in Table 1 below and demonstrates comparable sequencing metrics between the traditional and one-pot tagmentation methods.
The transposition methods described herein can be utilized in a one-pot reaction as described above. These one-pot reactions can be done either in bulk or in discrete partitions, such as a well or droplet.
Intact nuclei are harvested in bulk from cells in a cell population of interest in a manner that substantially maintains native chromatin organization (e.g., using IGEPAL CA-630 mediated cell lysis). Nuclei are then incubated in the presence of a transposase-nucleic acid complex comprising a transposase molecule and two partially double-stranded adaptor oligonucleotides. See, e.g.,
Nuclei (or cells) comprising the adapter-flanked template nucleic acid fragments are then partitioned into a plurality of partitions (e.g., droplets or wells) such that at least some partitions comprise (1) a single nucleus (or cell) comprising the adapter-flanked template nucleic acid fragments; and (2) a plurality of partially double-stranded barcode oligonucleotide molecules comprising a doubled stranded barcode sequence (“BC”), a double-stranded P5 adapter sequence (“P5”), and a single stranded sequence complementary to the Read 1 sequence (“R11,”). See
Single cell or nucleus-containing partitions (e.g., droplets or wells) are then subjected to conditions to release adapter-flanked template nucleic acid fragments from the nuclei (e.g., cell lysis). In certain embodiments, where barcode oligonucleotides (e.g., nucleic acid barcode molecules) are attached to a bead (e.g., gel bead), partitions (e.g., droplets or wells) are subjected to conditions to cause release of the barcode oligonucleotide molecules from the bead (e.g., gel bead) (e.g., depolymerization or degradation of the beads, for example, using a reducing agent such as DTT). After release from single nuclei, the adapter-flanked template nucleic acid fragments are subjected to conditions to phosphorylate the 5′ end of the Read1 sequence (e.g., using T4 polynucleotide kinase) for subsequent ligation steps. After phosphorylation, the barcode oligonucleotide molecules are ligated onto the adapter-flanked template nucleic acid fragments using a suitable DNA ligase enzyme (e.g., T4 or E. coli DNA ligase) and the complementary Read1 sequences in the barcode oligonucleotides and the adapter-flanked template nucleic acid fragments. See
After barcode ligation, gaps remaining from the transposition reaction are filled to produce barcoded, adapter-flanked template nucleic acid fragments. See
Cells from a cell population of interest (or nuclei from cells in a cell population of interest) are partitioned into a plurality of partitions (e.g., droplets or wells) such that at least some partitions comprise (1) a single cell (or a single nucleus) comprising a template nucleic acid; and (2) a plurality of partially double-stranded barcode oligonucleotide molecules (e.g., nucleic acid barcode molecules) comprising a doubled stranded barcode sequence (“BC”), a doubled stranded P5 adapter sequence (“P5”), and a single stranded sequence complementary to a Read 1 sequence (“R1rc”) (e.g.,
After partitioning into partitions (e.g., droplets or wells), the single cells (or nuclei) are lysed to release the template genomic DNA in a manner that substantially maintains native chromatin organization. Partitions (e.g., droplets or wells) are then subjected to conditions to generate a transposase-nucleic acid complex as described in Example 9 and shown in
Samples are then processed generally as described in Example 9. In certain embodiments, where barcode oligonucleotides (e.g., nucleic acid barcode molecules) are attached to a solid or semi-solid particle (e.g., bead, such as a gel bead), droplets are subjected to conditions to cause release of the barcode oligonucleotide molecules from the solid or semi-solid particle (e.g., gel bead) (e.g., depolymerization or degradation of beads, for example, using a reducing agent such as DTT). In some embodiments, the transposase molecules are inactivated (e.g., by heat inactivation) prior to further processing steps. The adapter-flanked template nucleic acid fragments are subjected to conditions to phosphorylate the 5′ end of the Read1 sequence (e.g., using T4 polynucleotide kinase) of the adapter-flanked template nucleic acid fragments. After phosphorylation, the barcode oligonucleotide molecules are ligated onto the adapter-flanked template nucleic acid fragments using a suitable DNA ligase enzyme (e.g., T4, 9° N, or E. coli DNA ligase) and the complementary Read1 sequences in the barcode oligonucleotides and the adapter-flanked template nucleic acid fragments. See
After barcode ligation, gaps remaining from the transposition reaction are filled to produce barcoded, adapter-flanked template nucleic acid fragments. See
Nuclei are harvested in bulk from cells in a cell population of interest in a manner that substantially maintains native chromatin organization. Alternatively, cells are permeabilized/permeable, allowing the transposase-nucleic acid complex to gain access to the nucleus. Nuclei (or permeabilized cells) are then incubated in the presence of a transposase-nucleic acid complex as described in Example 9. See
Nuclei (or cells) comprising the adapter-flanked template nucleic acid fragments are then partitioned into a plurality of partitions (e.g., droplets or wells) such that at least some partitions comprise (1) a single nucleus (or cell) comprising the adapter-flanked template nucleic acid fragments; and (2) a plurality of single-stranded barcode oligonucleotide molecules (e.g., nucleic acid barcode molecules) comprising a transposon end sequence (“ME”), a Read1 sequence (“R1”), or a portion thereof, a barcode sequence (“BC”), and a P5 adapter sequence (“P5”). See
Single cell- or nucleus-containing partitions (e.g., droplets or wells) are then subjected to conditions to release the adapter-flanked template nucleic acid fragments from the nuclei. After the adapter-flanked template nucleic acid fragments are released, gaps from the transposition reaction are filled with a suitable enzyme. See
The barcoded, adapter-flanked template nucleic acid fragments are then released from the partitions (e.g., droplets or wells) and processed in bulk to complete library preparation for next generation high throughput sequencing (e.g., to add sample index (SI) sequences (e.g., “i7”) and/or further adapter sequences (e.g., “P7”)). The fully constructed library is then sequenced according to a suitable next-generation sequencing protocol (e.g., Illumina sequencing).
Cells from a cell population of interest (or intact nuclei from cells in a cell population of interest) are partitioned into a plurality of partitions (e.g., droplets or wells) such that at least some partitions comprise (1) a single cell (or a single nucleus) comprising a template nucleic acid; and (2) a plurality of single-stranded barcode oligonucleotide molecules (e.g., nucleic acid barcode molecules) comprising a transposon end sequence (“ME”), a Read1 sequence (“R1”), a barcode sequence (“BC”), and a P5 adapter sequence (“P5”). See, e.g.,
After partitioning into partitions (e.g., droplets or wells), the single cells (or nuclei) are lysed to release the template genomic DNA in a manner that substantially maintains native chromatin organization. In certain embodiments, where barcode oligonucleotides (e.g., nucleic acid barcode molecules) are attached to a solid or semi-solid particle (e.g., bead, such as a gel bead), partitions (e.g., droplets or wells) are subjected to conditions to cause release of the barcode oligonucleotide molecules from the solid or semi-solid particle (e.g., bead, such as a gel bead) (e.g., depolymerization or degradation of beads, for example, using a reducing agent such as DTT). Partitions (e.g., droplets or wells) are then subjected to conditions to generate a transposase-nucleic acid complex as described in Example 9 and shown in
Samples are then processed generally as described in Example 11. After tagmentation, gaps from the transposition reaction are filled with a suitable gap-filling enzyme. See
The barcoded, adapter-flanked template nucleic acid fragments are then released from the partitions (e.g., droplets or wells) and processed in bulk to complete library preparation for next generation high throughput sequencing (e.g., to add sample index (SI) sequences (e.g., “i7”) and/or further adapter sequences (e.g., “P7”)). The fully constructed library is then sequenced according to a suitable next-generation sequencing protocol (e.g., Illumina sequencing).
Nuclei are harvested in bulk from cells in a cell population of interest in a manner that substantially maintains native chromatin organization. Alternatively, cells are permeabilized/permeable, allowing the transposase-nucleic acid complex to gain access to the nucleus. Nuclei are then incubated in the presence of a transposase-nucleic acid complex as described in Example 9. See
Nuclei (or cells) comprising the adapter-flanked template nucleic acid fragments are then partitioned into a plurality of partitions (e.g., droplets or wells) such that at least some partitions comprise (1) a single nucleus comprising the adapter-flanked template nucleic acid fragments; (2) a plurality of double-stranded barcode oligonucleotide molecules (e.g., nucleic acid barcode molecules) comprising a barcode sequence (BC) and a TruSeqR1 sequencing primer sequence (e.g.,
Single nucleus-containing partitions (e.g., droplets or wells) are then subjected to conditions to release the adapter-flanked template nucleic acid fragments from the nuclei. After the adapter-flanked template nucleic acid fragments are released, gaps from the transposition reaction are filled with a suitable gap-filling enzyme. Gap-filled adapter-flanked template nucleic acid fragments are then subjected to Cas9-mediated cleavage of the RI/ME adaptor, or some portion thereof. See
The barcoded, adapter-flanked template nucleic acid fragments are then released from the partitions (e.g., droplets or wells) and processed in bulk to complete library preparation for next generation high throughput sequencing (e.g., subjecting the fragments, or derivatives thereof, to one or more reactions (e.g., nucleic acid amplification) to add functional sequences to facilitate Illumina sequencing). In some embodiments, a second CRISPR/Cas9 mediated cleavage event using a synthetic guide RNA (gRNA) that targets the Read2/ME adapter sequence is performed either in the partitions or in bulk after release from the partitions. The fully constructed library is then sequenced according to any suitable sequencing protocol.
Cells from a cell population of interest (or intact nuclei from cells in a cell population of interest) are partitioned into a plurality of partitions (e.g., droplets or wells) such that at least some partitions comprise (1) a single cell (or a single nucleus) comprising a template nucleic acid; (2) a plurality of double-stranded barcode oligonucleotide molecules (e.g., nucleic acid barcode molecules) comprising a barcode sequence (“BC”) and a TruSeqR1 sequencing primer sequence (e.g.,
After partitioning into partitions (e.g., droplets or wells), the single cells (or nuclei) are lysed to release the template genomic DNA in a manner that substantially maintains native chromatin organization. Partitions (e.g., droplets or wells) are then subjected to conditions to generate a transposase-nucleic acid complex as described in Example 9 and shown in
Samples are then processed generally as described in Example 13. After tagmentation, gaps from the transposition reaction are filled with a suitable gap-filling enzyme. See
The barcoded, adapter-flanked template nucleic acid fragments are then released from the partitions (e.g., droplets or wells) and processed in bulk to complete library preparation for next generation high throughput sequencing (e.g., subjecting the fragments, or derivatives thereof, to one or more reactions (e.g., nucleic acid amplification) to add functional sequences to facilitate Illumina sequencing). In some embodiments, a second CRISPR/Cas9 mediated cleavage event using a synthetic guide RNA (gRNA) that targets the Read2/ME adapter sequence is performed either in the partitions or in bulk after release from the partitions. The fully constructed library is then sequenced according to any suitable sequencing protocol.
Nuclei are harvested in bulk from cells in a cell population of interest in a manner that substantially maintains native chromatin organization. Alternatively, cells are permeabilized/permable, allowing the transposase-nucleic acid complex to gain access to the nucleus. Nuclei are then incubated in the presence of a transposase-nucleic acid complex as described in Example 9. See
Nuclei (or cell) comprising the adapter-flanked template nucleic acid fragments are then partitioned into a plurality of partitions (e.g., droplets or wells) such that at least some partitions comprise (1) a single nucleus comprising the adapter-flanked template nucleic acid fragments; (2) a plurality of Y-adaptor barcode oligonucleotide molecules (e.g., nucleic acid barcode molecules) comprising a barcode sequence (“BC”), a Read1 sequencing primer sequence (“R1”), and a Read2 sequencing primer sequence (“R2”), e.g.,
Single nucleus containing partitions (e.g., droplets or wells) are then subjected to conditions to release the adapter-flanked template nucleic acid fragments from the nuclei. After the adapter-flanked template nucleic acid fragments are released, gaps from the transposition reaction are filled with a suitable gap-filling enzyme. Gap-filled adapter-flanked template nucleic acid fragments are then subjected to Cas9-mediated cleavage of the R1 and R2 adaptors, or a portion thereof. See
The barcoded, adapter-flanked template nucleic acid fragments are then released from the partitions (e.g., droplets or wells) and processed in bulk to complete library preparation for next generation high throughput sequencing (e.g., subjecting the fragments, or derivatives thereof, to one or more reactions (e.g., nucleic acid amplification) to add functional sequences to facilitate Illumina sequencing). The fully constructed library is then sequenced according to any suitable sequencing protocol.
Cells from a cell population of interest (or intact nuclei from cells in a cell population of interest) are partitioned into a plurality of partitions (e.g., droplets or wells) such that at least some partitions comprise (1) a single cell (or a single nucleus) comprising a template nucleic acid; (2) a plurality of Y-adaptor barcode oligonucleotide molecules (e.g., nucleic acid barcode molecules) comprising a barcode sequence (“BC”), a Read1 sequencing primer sequence (“R1”), and a Read2 sequencing primer sequence (“R2”) (e.g.,
After partitioning into partitions (e.g., droplets or wells), the single cells (or nuclei) are lysed to release the template genomic DNA in a manner that substantially maintains native chromatin organization. Partitions (e.g., droplets or wells) are then subjected to conditions to generate a transposase-nucleic acid complex as described in Example 9 and shown in
Samples are then processed generally as described in Example 15. After tagmentation, gaps from the transposition reaction are filled with a suitable gap-filling enzyme. See
The barcoded, adapter-flanked template nucleic acid fragments are then released from the partitions (e.g., droplets or wells) and processed in bulk to complete library preparation for next generation high throughput sequencing (e.g., subjecting the fragments, or derivatives thereof, to one or more reactions (e.g., nucleic acid amplification) to add functional sequences to facilitate Illumina sequencing). The fully constructed library is then sequenced according to any suitable sequencing protocol.
Cells from a cell population of interest (or intact nuclei from cells in a cell population of interest) are partitioned into a plurality of partitions (e.g., droplets or wells) such that at least some partitions comprise (1) a single cell (or a single nucleus) comprising template genomic DNA molecules and template RNA molecules; (2) a plurality of first barcoded oligonucleotide molecules (e.g., first nucleic acid barcode molecules) comprising a barcode sequence; (3) a plurality of transposase molecules, (4) a plurality of second barcode oligonucleotide molecules (e.g., second nucleic acid barcode molecules) comprising a barcode sequence and a capture sequence; and (5) a plurality of reverse transcriptase molecules. In some embodiments, the barcode sequence from the first barcoded oligonucleotide and the barcode sequence from the second barcoded oligonucleotide is the same. In some embodiments, the barcode sequence from the first barcoded oligonucleotide and the barcode sequence from the second barcoded oligonucleotide are different.
In some embodiments, the plurality of first barcoded oligonucleotides (e.g., first nucleic acid barcode molecules) and the plurality of second barcoded oligonucleotides (e.g., second nucleic acid barcode molecules) are attached to a solid or semi-solid particle (e.g., a bead, such as a gel bead) and partitioned such that at least some partitions (e.g., droplets or wells) comprise (1) a single cell (or single nucleus); (2) a single solid or semi-solid particle (e.g., gel bead) comprising the first and second plurality of barcoded oligonucleotides; (3) a plurality of transposase molecules; and (4) a plurality of reverse transcriptase molecules. In other embodiments, the plurality of first barcoded oligonucleotides (e.g., first nucleic acid barcode molecules) are attached to a first solid or semi-solid particle (e.g., bead, such as a gel bead) while the plurality of second barcoded oligonucleotides (e.g., second nucleic acid barcode molecules) are attached to a second solid or semi-solid particle (e.g., bead, such as a gel bead) and partitioned such that at least some partitions (e.g., droplets or wells) comprise (1) a single cell (or single nucleus); (2) a single first solid or semi-solid particle (e.g., gel bead); (2) a single second solid or semi-solid particle (e.g., gel bead); (3) a plurality of transposase molecules; and (4) a plurality of reverse transcriptase molecules.
In certain embodiments, the plurality of first barcoded oligonucleotides (e.g., first nucleic acid barcode molecules) are attached to a plurality of solid or semi-solid particles (e.g., beads, such as gel beads) while the plurality of second barcoded oligonucleotides (e.g., second nucleic acid barcode molecules) are attached to a plurality of magnetic particles (e.g., beads), wherein the plurality of magnetic particles are embedded within the solid or semi-solid particles (e.g., gel beads). Continuing these embodiments, the plurality of solid or semi-solid particles (e.g., gel beads) is partitioned such that at least some partitions (e.g., droplets or wells) comprise: (1) a single cell (or single nucleus); (2) a single solid or semi-solid particle (e.g., gel bead) comprising (i) a plurality of first barcoded oligonucleotides attached to the single solid or semisolid particle (e.g., gel bead); and (ii) a plurality of magnetic particles embedded within the single solid or semi-solid particle (e.g., gel bead), wherein the magnetic particles comprise the second barcode oligonucleotide attached thereto; (3) a plurality of transposase molecules; and (4) a plurality of reverse transcriptase molecules. See, e.g.,
The first barcoded oligonucleotide and related nucleic acid processing steps can take on the structure of any of the aforementioned Examples and may include additional components as described therein. For instance, in some embodiments, the first barcoded oligonucleotide comprises a barcode sequence and a transposon end sequence (e.g., a ME sequence) and is, for example, (1) a forked adapter such as those described in Example 1,
After partitioning into partitions (e.g., droplets or wells), the single cells (or nuclei) are lysed to release template genomic DNA and template RNA (e.g., cytoplasmic mRNA or nuclear mRNA) in a manner that substantially maintains native chromatin organization of the genomic DNA. In certain embodiments, where barcode oligonucleotides are attached to a solid or semi-solid particle (e.g., a bead, such as a gel bead), partitions (e.g., droplets or wells) are subjected to conditions to cause release of barcode oligonucleotide molecules from the solid or semi-solid particle (e.g., gel bead) (e.g., depolymerizati on or degradation of beads, for example, using a reducing agent such as DTT). Partitions (e.g., droplets or wells) are then subjected to conditions to generate a transposase-nucleic acid complex as described in the aforementioned examples. Alternatively, in some embodiments, a plurality of pre-formed transposase-nucleic acid complexes are partitioned into the plurality of (e.g., droplets or wells). Partitions (e.g., droplets or wells) are then subjected to conditions such that the transposase-nucleic acid complexes generate double-stranded template genomic DNA fragments. As described above, the transposition reaction can take on the structure of any of the aforementioned Examples to generate double-stranded template genomic DNA fragments flanked by a wide variety of functional sequences and suitable for a number of downstream processing steps. For example, as described herein, in some embodiments, the transposition reaction directly integrates the barcode sequence into the template genomic DNA fragments (e.g., Example 1) while, in other embodiments, the barcode sequence is added to template genomic DNA fragments subsequent to the transposition reaction (such as by ligation, e.g., Example 2). Because the transposase-nucleic acid complex can only act on nucleosome-free DNA, the template genomic DNA fragments are representative of genome-wide areas of accessible chromatin in a single cell or nucleus. Alternatively, in some embodiments, the tranposition reaction is performed in intact nuclei, and the nuclei are lysed to release the adapter-flanked template genomic DNA fragments. Alternatively, in some embodiments, the transposition reaction is performed in bulk in intact nuclei and a single nucleus comprising template genomic DNA fragments is partitioned and processed as described above. In some embodiments, gaps from the transposition reaction are filled in-droplet with a suitable gap-filling enzyme. In other embodiments, a gap-filling reaction is performed in bulk after the double-stranded, barcoded adapter-flanked DNA fragments have been released from the partitions.
In some cases, partitions (e.g., droplets or wells) may be subjected to conditions to capture template RNA (e.g., messenger RNA, mRNA) on second solid or semi-solid particles using a capture sequence of second barcoded oligonucleotides of the plurality of second barcoded oligonucleotides. Alternatively, second barcoded oligonucleotides of the plurality of second barcoded oligonucleotides may be released from the second solid or semi-solid particles (e.g., as described herein) and used to capture template RNA. Captured template RNA may be subsequently processed in bulk after removal from the partitions. Alternatively, in some cases, partitions (e.g., droplets or wells) may be subjected to conditions to generate single-stranded, barcoded cDNA molecules from the template RNA using the capture sequence from the second barcode oligonucleotide to prime the reverse transcription reaction (e.g., an oligo (dT) sequence). In some embodiments, second strand cDNA is produced (e.g., through a template switching oligonucleotide or through random priming) to generate double-stranded, barcoded cDNA molecules. In some embodiments, the template switching oligonucleotide also comprises a barcode sequence such that both the 5′ and 3′ end of the cDNA comprise a barcode sequence. The barcode sequence on the 5′ and 3′ end can be the same barcode sequence or the 5′ end can have a different barcode sequence than the 3′ end. In other embodiments, the plurality of second barcode oligonucleotide molecules are omitted and replaced with plurality of second oligonucleotide molecules comprising a capture sequence and no barcode sequence. Continuing with these embodiments, first strand cDNA molecules are generated using the capture sequence while second strand cDNA is generated through use of a barcoded template switching oligonucleotide to barcode the 5′ end of the template RNA. In some embodiments, an in-partition (e.g., in-droplet or in-well) amplification reaction, such as linear amplification, is performed on the adapter-flanked DNA fragments, the barcoded cDNA molecules, or both the adapter-flanked DNA fragments and the barcoded cDNA molecules. In some embodiments, a barcode oligonucleotide is directly ligated onto the template RNA.
Exemplary Scheme 1—scATAC-Seq+3′ scRNA-Seq Using Ligation
In an exemplary barcoding scheme, cells from a cell population of interest (or intact nuclei from cells in a cell population of interest) are partitioned into a plurality of partitions (e.g., droplets or wells) such that at least some partitions comprise: (1) a single cell (or a single nucleus) comprising template genomic DNA molecules and template RNA molecules (e.g., mRNA or nuclear pre-mRNA); (2) a solid or semi-solid particle (e.g., bead, such as a gel bead) comprising (i) a plurality of partially double-stranded nucleic acid barcode molecules as shown in
Continuing these embodiments, after partitioning, the single cells (or nuclei) are lysed to release template genomic DNA and template RNA (e.g., cytoplasmic mRNA or nuclear mRNA) in a manner that substantially maintains native chromatin organization of the genomic DNA. In certain embodiments, the plurality of nucleic acid barcode molecules of
Continuing this embodiment, after fragmentation, template genomic DNA fragments are processed generally as outlined in
Exemplary Scheme 2—scATAC-Seq-H 5′ scRATA-Seq Using Ligation
In another barcoding scheme, cells from a cell population of interest (or intact nuclei from cells in a cell population of interest) are partitioned into a plurality of partitions (e.g., droplets or wells) such that at least some partitions comprise: (1) a single cell (or a single nucleus) comprising template genomic DNA molecules and template RNA molecules (e.g., mRNA or nuclear pre-mRNA); (2) a solid or semi-solid particle (e.g., bead, such as a gel bead) comprising (i) a plurality of partially double-stranded nucleic acid barcode molecules as shown in
Continuing these embodiments, after partitioning, the single cells (or nuclei) are lysed to release template genomic DNA and template RNA (e.g., cytoplasmic mRNA or nuclear mRNA) in a manner that substantially maintains native chromatin organization of the genomic DNA. In certain embodiments, the plurality of nucleic acid barcode molecules of
Exemplary Scheme 3 scATAC-Seq 3′ scR1VA-Seq Using Linear Amplification
In certain barcoding schemes, cells from a cell population of interest (or intact nuclei from cells in a cell population of interest) are partitioned into a plurality of partitions (e.g., droplets) such that at least some partitions comprise: (1) a single cell (or a single nucleus) comprising template genomic DNA molecules and template RNA molecules (e.g., mRNA or nuclear pre-mRNA); (2) a solid or semi-solid particle (e.g., a bead, such as a gel bead) comprising (i) a plurality of single-stranded nucleic acid barcode molecules as shown in
Continuing these embodiments, after partitioning, the single cells (or nuclei) are lysed to release template genomic DNA and template RNA (e.g., cytoplasmic mRNA or nuclear mRNA) in a manner that substantially maintains native chromatin organization of the genomic DNA. In certain embodiments, the plurality of nucleic acid barcode molecules of
Exemplary Scheme 4—scATAC-Seq-H 5′ scIZNA-Seq Using Linear Amplification
In another barcoding scheme, cells from a cell population of interest (or intact nuclei from cells in a cell population of interest) are partitioned into a plurality of partitions (e.g., droplets or wells) such that at least some partitions comprise: (1) a single cell (or a single nucleus) comprising template genomic DNA molecules and template RNA molecules (e.g., mRNA or nuclear pre-mRNA); (2) a solid or semi-solid particle (e.g., bead, such as a gel bead) comprising (i) a plurality of single-stranded nucleic acid barcode molecules as shown in
Continuing these embodiments, after partitioning, the single cells (or nuclei) are lysed to release template genomic DNA and template RNA (e.g., cytoplasmic mRNA or nuclear mRNA) in a manner that substantially maintains native chromatin organization of the genomic DNA. In certain embodiments, the plurality of nucleic acid barcode molecules of
Alternatively, in some embodiments, the transposition reaction is performed in bulk in intact nuclei which are partitioned such that at least some partitions comprise (1) a single cell (or a single nucleus) comprising template genomic DNA fragments and template RNA molecules; (2) a solid or semi-solid particle (e.g., bead, such as a gel bead) comprising (i) a plurality of single-stranded nucleic acid barcode molecules as shown in
In the aforementioned embodiments, after barcoding, the barcoded, adapter-flanked DNA fragments and the barcoded cDNA molecules are then released from the partitions (e.g., droplets or wells) to provide a released mixture and processed in bulk to complete library preparation for next generation high throughput sequencing (e.g., subjecting the fragments, or derivatives thereof, to one or more reactions (e.g., nucleic acid amplification) to add functional sequences to facilitate Illumina sequencing). In some embodiments, a first portion of the released mixture comprising the adapter-flanked DNA fragments and the barcoded cDNA is taken and processed in bulk to complete library preparation for the barcoded, adapter-flanked DNA fragments while a second portion of the released mixture is taken and processed in bulk to complete library preparation for the barcoded cDNA molecules. In other embodiments, a first portion of the partitions (e.g., droplets or wells) comprising the barcoded, adapter-flanked DNA fragments and the barcoded cDNA molecules is taken and processed in bulk to complete library preparation for the barcoded, adapter-flanked DNA fragments while a second portion of the partitions (e.g., droplets or wells) comprising the barcoded, adapter-flanked DNA fragments and the barcoded cDNA molecules is taken and processed in bulk to complete library preparation for the barcoded cDNA molecules. In embodiments that utilize a magnetic particle (e.g., bead), the barcoded template molecules (e.g., barcoded template DNA fragments or barcoded cDNA molecules, or derivatives thereof) attached thereto can be magnetically separated and further processed to complete library preparation. The fully constructed library or libraries are then sequenced according to a suitable next-generation sequencing protocol (e.g., Illumina sequencing).
Nuclei from mice and humans were tagmented and barcoded by ligation (see, e.g., Example 9 and
Compared to the separation of the different cell types seen in the barcodes with standard R1 sequences, the barcodes with the shortened R1 sequence and barcodes with a uracil showed greater separation of mice and human nuclei, indicating a reduced rate of barcode exchange (
A plurality of cells is provided in which each cell comprises a template nucleic acid (e.g., nuclear DNA, such as chromatin) and a non-template nucleic acid (e.g., mitochondrial DNA). The plurality of cells is lysed in the presence of a cell lysis agent and a blocking agent (e.g., bovine serum albumin) to generate a plurality of lysed cells. A plurality of nucleic is then separated from the plurality of lysed cells to generate a plurality of biological particles (e.g., nuclei), where a given biological particle of the plurality of biological particles comprises non-template nucleic acid molecules (e.g., mitochondrial DNA molecules) and template nucleic acid molecules. The template nucleic acid molecules may comprise, for example, DNA molecules and RNA molecules. A plurality of template nucleic acid fragments may then be generated in biological particles of the plurality of biological particles with the aid of a transposase-nucleic acid complex comprising a transposase nucleic acid molecule and a transposon end nucleic acid molecule. A plurality of partitions may then be generated, where a given partition comprises (i) a single biological particle comprising the plurality of template nucleic acid fragments and template RNA molecules and (ii) a plurality of first barcode oligonucleotide molecules (e.g., first nucleic acid barcode molecules) comprising a barcode sequence. The partitions may further comprise (iii) a plurality of second barcode oligonucleotide molecules (e.g., second nucleic acid molecules) comprising a barcode sequence and a capture sequence; and (iv) a plurality of reverse transcriptase molecules. The partitions may be, for example, droplets or wells.
Barcoded template DNA fragments may then be generated within the partitions using barcode oligonucleotide molecules of the plurality of first barcode oligonucleotide molecules and template nucleic acid fragments of the plurality of template DNA fragments. If template RNA molecules are present, barcoded cDNA molecules may be generated from the template RNA molecules by reverse transcription using barcode oligonucleotide molecules of the plurality of second barcode oligonucleotide molecules. In some cases, the biological particles may be nuclei, which may be isolated from lysed cells by, e.g., washing the lysed cells. In some cases, the method further comprises generating sequencing reads. Application of the method may reduce the fraction of sequencing reads deriving from non-template nucleic acid molecules (e.g., mitochondrial DNA molecules) relative to the total number of sequencing reads generated.
A plurality of partitions (e.g., droplets or wells) is provided. A given partition of the plurality of partitions comprises: (i) a single biological particle (e.g., cell) from a plurality of biological particles (e.g., cells), wherein the single biological particle comprises template nucleic acid molecules (e.g., nuclear DNA molecules, such as chromatin) and non-template DNA molecules (e.g., mitochondrial DNA molecules); (ii) a plurality of barcode oligonucleotide molecules (e.g., nucleic acid barcode molecules) comprising a barcode sequence; (iii) a plurality of transposon end oligonucleotide molecules comprising a transposon end sequence; and (iv) a plurality of transposase molecules. The given partition may further comprise reverse transcriptases and a plurality of second barcode oligonucleotide molecules (e.g., second nucleic acid barcode molecules) comprising a barcode sequence and a capture sequence. Barcoded template nucleic acid fragments and barcoded non-template nucleic acid fragments may be generated as described in the preceding examples. One or more non-template nucleic acid fragments of the plurality of non-template DNA fragments, or derivatives thereof, may then be cleaved using (i) one or more guide ribonucleic acid molecules (gRNAs) targeted to the one or more non-template nucleic acid fragments, and (ii) a clustered regularly interspaced short palindromic (CRISPR) associated (Cas) nuclease. In some cases, the method may reduce the amount of fragments and/or barcoded fragments comprising and/or deriving from non-template nucleic acid molecules. For example, the method may reduce the total number of non-template nucleic acid fragments and barcoded non-template nucleic acid fragments, e.g., in a mixture comprising one or more of template nucleic acid fragments, barcoded template nucleic acid fragments, non-template nucleic acid fragments, and barcoded non-template nucleic acid fragments. In some cases, the endonuclease may be Cas9, such as recombinant Cas9. In some cases, the non-template nucleic acid fragment may comprise a mitochondrial DNA or RNA fragment. In some cases, the template nucleic acid fragment may comprise a nuclear DNA fragment.
Sample libraries may be generated using any of the methods described in the preceding examples. In some cases, a library may be generated using a linear amplification method. In other cases, a library may be generated using a ligation method. A linear amplification method may comprise, within a partition, generating template nucleic acid fragments and performing a gap filling extension process within the partition. Linear amplification may then be performed using, for example, a heat resistant polymerase. Barcodes may be incorporated into sequences comprising template nucleic acid sequences, or complements thereof. The barcoded nucleic acid fragments may then be released from their respective partitions into the bulk for additional processing including, for example, PCR. A ligation method may comprise, within a partition, generating template nucleic acid fragments and ligating barcodes to the fragments with a ligase such as a T4 DNA ligase, thereby generating barcoded nucleic acid fragments. The barcoded nucleic acid fragments may then be released from their respective partitions into the bulk for additional processing including, for example, gap filling and addition of additional sequences.
In order to compare linear amplification and ligation methods, various mouse and human cells were processed according to the methods described herein.
As shown in
“Wasted” Reads
As shown in
Insert Size Distribution
Linear amplification and ligation library preparation methods were also compared to examine insert size distributions.
As shown in
Peripheral blood mononuclear cells (PBMCs) are subjected to single cell RNA-seq and ATAC-seq analyses as described herein.
While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. It is not intended that the invention be limited by the specific examples provided within the specification. While the invention has been described with reference to the aforementioned specification, the descriptions and illustrations of the embodiments herein are not meant to be construed in a limiting sense. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. Furthermore, it shall be understood that all aspects of the invention are not limited to the specific depictions, configurations or relative proportions set forth herein which depend upon a variety of conditions and variables. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is therefore contemplated that the invention shall also cover any such alternatives, modifications, variations or equivalents. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
This application is a continuation application of U.S. patent application Ser. No. 16/206,168, filed Nov. 30, 2018, which is a continuation application of U.S. patent application Ser. No. 15/842,687, filed Dec. 14, 2017, which claims priority to U.S. Provisional Patent Application No. 62/511,905, filed May 26, 2017, and to U.S. Provisional Patent Application No. 62/527,529, filed Jun. 30, 2017, each of which applications is entirely incorporated herein by reference. This application is also a continuation-in-part application of PCT Patent Application No. PCT/US2018/034774, filed May 25, 2018, which claims priority to U.S. patent application Ser. No. 15/848,714, filed on Dec. 20, 2017, and which claims priority to U.S. patent application Ser. No. 15/842,550, filed on Dec. 14, 2017, and which claims priority to U.S. patent application Ser. No. 15/842,713, filed on Dec. 14, 2017, and which claims priority to U.S. Provisional Patent Application No. 62/650,223, filed on Mar. 29, 2018, each of which applications is entirely incorporated herein by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2797149 | Skeggs | Jun 1957 | A |
| 3047367 | Kessler | Jul 1962 | A |
| 3479141 | Smythe et al. | Nov 1969 | A |
| 4124638 | Hansen | Nov 1978 | A |
| 4253846 | Smythe et al. | Mar 1981 | A |
| 4582802 | Zimmerman et al. | Apr 1986 | A |
| 5137829 | Nag et al. | Aug 1992 | A |
| 5149625 | Church et al. | Sep 1992 | A |
| 5185099 | Delpuech et al. | Feb 1993 | A |
| 5202231 | Drmanac et al. | Apr 1993 | A |
| 5270183 | Corbett et al. | Dec 1993 | A |
| 5413924 | Kosak et al. | May 1995 | A |
| 5418149 | Gelfand et al. | May 1995 | A |
| 5436130 | Mathies et al. | Jul 1995 | A |
| 5478893 | Ghosh et al. | Dec 1995 | A |
| 5489523 | Mathur | Feb 1996 | A |
| 5512131 | Kumar et al. | Apr 1996 | A |
| 5558071 | Ward et al. | Sep 1996 | A |
| 5585069 | Zanzucchi et al. | Dec 1996 | A |
| 5587128 | Wilding et al. | Dec 1996 | A |
| 5605793 | Stemmer et al. | Feb 1997 | A |
| 5618711 | Gelfand et al. | Apr 1997 | A |
| 5695940 | Drmanac et al. | Dec 1997 | A |
| 5700642 | Monforte et al. | Dec 1997 | A |
| 5705628 | Hawkins et al. | Jan 1998 | A |
| 5708153 | Dower et al. | Jan 1998 | A |
| 5736330 | Fulton | Apr 1998 | A |
| 5739036 | Parris | Apr 1998 | A |
| 5744311 | Fraiser et al. | Apr 1998 | A |
| 5756334 | Perler et al. | May 1998 | A |
| 5830663 | Embleton et al. | Nov 1998 | A |
| 5834197 | Parton | Nov 1998 | A |
| 5842787 | Kopf-Sill et al. | Dec 1998 | A |
| 5846719 | Brenner et al. | Dec 1998 | A |
| 5846727 | Soper et al. | Dec 1998 | A |
| 5851769 | Gray et al. | Dec 1998 | A |
| 5856174 | Lipshutz et al. | Jan 1999 | A |
| 5872010 | Karger et al. | Feb 1999 | A |
| 5897783 | Howe et al. | Apr 1999 | A |
| 5900481 | Lough et al. | May 1999 | A |
| 5942609 | Hunkapiller et al. | Aug 1999 | A |
| 5958703 | Dower et al. | Sep 1999 | A |
| 5965443 | Reznikoff et al. | Oct 1999 | A |
| 5994056 | Higuchi | Nov 1999 | A |
| 5997636 | Gamarnik et al. | Dec 1999 | A |
| 6033880 | Haff et al. | Mar 2000 | A |
| 6046003 | Mandecki | Apr 2000 | A |
| 6051377 | Mandecki | Apr 2000 | A |
| 6057107 | Fulton | May 2000 | A |
| 6057149 | Burns et al. | May 2000 | A |
| 6103537 | Ullman et al. | Aug 2000 | A |
| 6110678 | Weisburg et al. | Aug 2000 | A |
| 6123798 | Gandhi et al. | Sep 2000 | A |
| 6133436 | Koester et al. | Oct 2000 | A |
| 6143496 | Brown et al. | Nov 2000 | A |
| 6159717 | Savakis et al. | Dec 2000 | A |
| 6171850 | Nagle et al. | Jan 2001 | B1 |
| 6172218 | Brenner | Jan 2001 | B1 |
| 6207384 | Mekalanos et al. | Mar 2001 | B1 |
| 6258571 | Chumakov et al. | Jul 2001 | B1 |
| 6265552 | Schatz | Jul 2001 | B1 |
| 6291243 | Fogarty et al. | Sep 2001 | B1 |
| 6294385 | Goryshin et al. | Sep 2001 | B1 |
| 6296020 | McNeely et al. | Oct 2001 | B1 |
| 6297006 | Drmanac et al. | Oct 2001 | B1 |
| 6297017 | Schmidt et al. | Oct 2001 | B1 |
| 6303343 | Kopf-Sill | Oct 2001 | B1 |
| 6306590 | Mehta et al. | Oct 2001 | B1 |
| 6327410 | Walt et al. | Dec 2001 | B1 |
| 6355198 | Kim et al. | Mar 2002 | B1 |
| 6361950 | Mandecki | Mar 2002 | B1 |
| 6372813 | Johnson et al. | Apr 2002 | B1 |
| 6379929 | Burns et al. | Apr 2002 | B1 |
| 6406848 | Bridgham et al. | Jun 2002 | B1 |
| 6409832 | Weigl et al. | Jun 2002 | B2 |
| 6432290 | Harrison et al. | Aug 2002 | B1 |
| 6432360 | Church | Aug 2002 | B1 |
| 6485944 | Church et al. | Nov 2002 | B1 |
| 6492118 | Abrams et al. | Dec 2002 | B1 |
| 6511803 | Church et al. | Jan 2003 | B1 |
| 6524456 | Ramsey et al. | Feb 2003 | B1 |
| 6569631 | Pantoliano et al. | May 2003 | B1 |
| 6579851 | Goeke et al. | Jun 2003 | B2 |
| 6586176 | Trnovsky et al. | Jul 2003 | B1 |
| 6593113 | Tenkanen et al. | Jul 2003 | B1 |
| 6613752 | Kay et al. | Sep 2003 | B2 |
| 6632606 | Ullman et al. | Oct 2003 | B1 |
| 6632655 | Mehta et al. | Oct 2003 | B1 |
| 6670133 | Knapp et al. | Dec 2003 | B2 |
| 6723513 | Lexow | Apr 2004 | B2 |
| 6767731 | Hannah | Jul 2004 | B2 |
| 6800298 | Burdick et al. | Oct 2004 | B1 |
| 6806052 | Bridgham et al. | Oct 2004 | B2 |
| 6806058 | Jesperson et al. | Oct 2004 | B2 |
| 6859570 | Walt et al. | Feb 2005 | B2 |
| 6880576 | Karp et al. | Apr 2005 | B2 |
| 6884788 | Bulpitt et al. | Apr 2005 | B2 |
| 6913935 | Thomas | Jul 2005 | B1 |
| 6929859 | Chandler et al. | Aug 2005 | B2 |
| 6969488 | Bridgham et al. | Nov 2005 | B2 |
| 6974669 | Mirkin et al. | Dec 2005 | B2 |
| 7041481 | Anderson et al. | May 2006 | B2 |
| 7115400 | Adessi et al. | Oct 2006 | B1 |
| 7129091 | Ismagilov et al. | Oct 2006 | B2 |
| 7138267 | Jendrisak et al. | Nov 2006 | B1 |
| 7211654 | Gao et al. | May 2007 | B2 |
| 7262056 | Wooddell et al. | Aug 2007 | B2 |
| 7268167 | Higuchi et al. | Sep 2007 | B2 |
| 7282370 | Bridgham et al. | Oct 2007 | B2 |
| 7294503 | Quake et al. | Nov 2007 | B2 |
| 7297485 | Bornarth et al. | Nov 2007 | B2 |
| 7316903 | Yanagihara et al. | Jan 2008 | B2 |
| 7323305 | Leamon et al. | Jan 2008 | B2 |
| 7329493 | Chou et al. | Feb 2008 | B2 |
| 7425431 | Church et al. | Sep 2008 | B2 |
| 7536928 | Kazuno | May 2009 | B2 |
| 7544473 | Brenner | Jun 2009 | B2 |
| 7604938 | Takahashi et al. | Oct 2009 | B2 |
| 7608434 | Reznikoff et al. | Oct 2009 | B2 |
| 7608451 | Cooper et al. | Oct 2009 | B2 |
| 7622280 | Holliger et al. | Nov 2009 | B2 |
| 7638276 | Griffiths et al. | Dec 2009 | B2 |
| 7645596 | Williams et al. | Jan 2010 | B2 |
| 7666664 | Sarofim et al. | Feb 2010 | B2 |
| 7700325 | Cantor et al. | Apr 2010 | B2 |
| 7708949 | Stone et al. | May 2010 | B2 |
| 7709197 | Drmanac | May 2010 | B2 |
| 7745178 | Dong | Jun 2010 | B2 |
| 7745218 | Kim et al. | Jun 2010 | B2 |
| 7776927 | Chu et al. | Aug 2010 | B2 |
| RE41780 | Anderson et al. | Sep 2010 | E |
| 7799553 | Mathies et al. | Sep 2010 | B2 |
| 7842457 | Berka et al. | Nov 2010 | B2 |
| 7901891 | Drmanac | Mar 2011 | B2 |
| 7910354 | Drmanac et al. | Mar 2011 | B2 |
| 7947477 | Schroeder et al. | May 2011 | B2 |
| 7960104 | Drmanac et al. | Jun 2011 | B2 |
| 7968287 | Griffiths et al. | Jun 2011 | B2 |
| 7972778 | Brown et al. | Jul 2011 | B2 |
| 8003312 | Krutzik et al. | Aug 2011 | B2 |
| 8008018 | Quake et al. | Aug 2011 | B2 |
| 8053192 | Bignell et al. | Nov 2011 | B2 |
| 8067159 | Brown et al. | Nov 2011 | B2 |
| 8101346 | Takahama | Jan 2012 | B2 |
| 8124404 | Alphey et al. | Feb 2012 | B2 |
| 8133719 | Drmanac et al. | Mar 2012 | B2 |
| 8137563 | Ma et al. | Mar 2012 | B2 |
| 8168385 | Brenner et al. | May 2012 | B2 |
| 8252539 | Quake et al. | Aug 2012 | B2 |
| 8268564 | Roth et al. | Sep 2012 | B2 |
| 8273573 | Ismagilov et al. | Sep 2012 | B2 |
| 8278071 | Brown et al. | Oct 2012 | B2 |
| 8298767 | Brenner et al. | Oct 2012 | B2 |
| 8304193 | Ismagilov et al. | Nov 2012 | B2 |
| 8318433 | Brenner | Nov 2012 | B2 |
| 8318460 | Cantor et al. | Nov 2012 | B2 |
| 8329407 | Ismagilov et al. | Dec 2012 | B2 |
| 8337778 | Stone et al. | Dec 2012 | B2 |
| 8361299 | Sabin et al. | Jan 2013 | B2 |
| 8420386 | Ivics et al. | Apr 2013 | B2 |
| 8461129 | Bolduc et al. | Jun 2013 | B2 |
| 8563274 | Brenner et al. | Oct 2013 | B2 |
| 8592150 | Drmanac et al. | Nov 2013 | B2 |
| 8598328 | Koga et al. | Dec 2013 | B2 |
| 8603749 | Gillevet et al. | Dec 2013 | B2 |
| 8679756 | Brenner et al. | Mar 2014 | B1 |
| 8748094 | Weitz et al. | Jun 2014 | B2 |
| 8748102 | Berka et al. | Jun 2014 | B2 |
| 8765380 | Berka et al. | Jul 2014 | B2 |
| 8822148 | Ismagliov et al. | Sep 2014 | B2 |
| 8829171 | Steemers et al. | Sep 2014 | B2 |
| 8835358 | Fodor et al. | Sep 2014 | B2 |
| 8871444 | Griffiths et al. | Oct 2014 | B2 |
| 8889083 | Ismagilov et al. | Nov 2014 | B2 |
| 8927218 | Forsyth | Jan 2015 | B2 |
| 8975302 | Light et al. | Mar 2015 | B2 |
| 8986286 | Tanghoj et al. | Mar 2015 | B2 |
| 8986628 | Stone et al. | Mar 2015 | B2 |
| 9005935 | Belyaev | Apr 2015 | B2 |
| 9012390 | Holtze et al. | Apr 2015 | B2 |
| 9017948 | Agresti et al. | Apr 2015 | B2 |
| 9029083 | Griffiths et al. | May 2015 | B2 |
| 9029085 | Agresti et al. | May 2015 | B2 |
| 9040256 | Grunenwald et al. | May 2015 | B2 |
| 9068210 | Agresti et al. | Jun 2015 | B2 |
| 9074251 | Steemers et al. | Jul 2015 | B2 |
| 9080211 | Grunenwald et al. | Jul 2015 | B2 |
| 9102980 | Brenner et al. | Aug 2015 | B2 |
| 9150916 | Christen et al. | Oct 2015 | B2 |
| 9175295 | Kaminaka et al. | Nov 2015 | B2 |
| 9238671 | Goryshin et al. | Jan 2016 | B2 |
| 9249460 | Pushkarev et al. | Feb 2016 | B2 |
| 9273349 | Nguyen et al. | Mar 2016 | B2 |
| 9290808 | Fodor et al. | Mar 2016 | B2 |
| 9328382 | Drmanac et al. | May 2016 | B2 |
| 9347059 | Saxonov | May 2016 | B2 |
| 9388465 | Hindson et al. | Jul 2016 | B2 |
| 9410201 | Hindson et al. | Aug 2016 | B2 |
| 9436088 | Seul et al. | Sep 2016 | B2 |
| 9567631 | Hindson et al. | Feb 2017 | B2 |
| 9574226 | Gormley et al. | Feb 2017 | B2 |
| 9637799 | Fan et al. | May 2017 | B2 |
| 9644204 | Hindson et al. | May 2017 | B2 |
| 9689024 | Hindson et al. | Jun 2017 | B2 |
| 9694361 | Bharadwaj et al. | Jul 2017 | B2 |
| 9695468 | Hindson et al. | Jul 2017 | B2 |
| 9701998 | Hindson et al. | Jul 2017 | B2 |
| 9856530 | Hindson et al. | Jan 2018 | B2 |
| 9951386 | Hindson et al. | Apr 2018 | B2 |
| 9957558 | Leamon et al. | May 2018 | B2 |
| 10011872 | Belgrader et al. | Jul 2018 | B1 |
| 10017759 | Kaper et al. | Jul 2018 | B2 |
| 10030267 | Hindson et al. | Jul 2018 | B2 |
| 10041116 | Hindson et al. | Aug 2018 | B2 |
| 10053723 | Hindson et al. | Aug 2018 | B2 |
| 10059989 | Giresi et al. | Aug 2018 | B2 |
| 10071377 | Bharadwaj et al. | Sep 2018 | B2 |
| 10119167 | Srinivasan et al. | Nov 2018 | B2 |
| 10137449 | Bharadwaj et al. | Nov 2018 | B2 |
| 10144950 | Nolan | Dec 2018 | B2 |
| 10150117 | Bharadwaj et al. | Dec 2018 | B2 |
| 10150963 | Hindson et al. | Dec 2018 | B2 |
| 10150964 | Hindson et al. | Dec 2018 | B2 |
| 10150995 | Giresi et al. | Dec 2018 | B1 |
| 10174310 | Nolan | Jan 2019 | B2 |
| 10208343 | Hindson et al. | Feb 2019 | B2 |
| 10221436 | Hardenbol et al. | Mar 2019 | B2 |
| 10221442 | Hindson et al. | Mar 2019 | B2 |
| 10227648 | Hindson et al. | Mar 2019 | B2 |
| 10253364 | Hindson et al. | Apr 2019 | B2 |
| 10273541 | Hindson et al. | Apr 2019 | B2 |
| 10400235 | Belhocine | Sep 2019 | B2 |
| 20010020588 | Adourian et al. | Sep 2001 | A1 |
| 20010036669 | Jedrzejewski et al. | Nov 2001 | A1 |
| 20010041357 | Fouillet et al. | Nov 2001 | A1 |
| 20010044109 | Mandecki | Nov 2001 | A1 |
| 20010048900 | Bardell et al. | Dec 2001 | A1 |
| 20010053519 | Fodor et al. | Dec 2001 | A1 |
| 20020001856 | Chow et al. | Jan 2002 | A1 |
| 20020005354 | Spence et al. | Jan 2002 | A1 |
| 20020034737 | Drmanac | Mar 2002 | A1 |
| 20020043463 | Shenderov | Apr 2002 | A1 |
| 20020051971 | Stuelpnagel et al. | May 2002 | A1 |
| 20020051992 | Bridgham et al. | May 2002 | A1 |
| 20020058332 | Quake et al. | May 2002 | A1 |
| 20020065609 | Ashby et al. | May 2002 | A1 |
| 20020068278 | Giese et al. | Jun 2002 | A1 |
| 20020089100 | Kawasaki | Jul 2002 | A1 |
| 20020092767 | Bjornson et al. | Jul 2002 | A1 |
| 20020113009 | O'Connor et al. | Aug 2002 | A1 |
| 20020119455 | Chan et al. | Aug 2002 | A1 |
| 20020119536 | Stern | Aug 2002 | A1 |
| 20020131147 | Paolini et al. | Sep 2002 | A1 |
| 20020160518 | Hayenga et al. | Oct 2002 | A1 |
| 20020164820 | Brown | Nov 2002 | A1 |
| 20020166582 | O'Connor et al. | Nov 2002 | A1 |
| 20020172965 | Kamb et al. | Nov 2002 | A1 |
| 20020175079 | Christel et al. | Nov 2002 | A1 |
| 20020179849 | Maher et al. | Dec 2002 | A1 |
| 20030005967 | Karp | Jan 2003 | A1 |
| 20030007898 | Bohm et al. | Jan 2003 | A1 |
| 20030008285 | Fischer | Jan 2003 | A1 |
| 20030008323 | Ravkin et al. | Jan 2003 | A1 |
| 20030022231 | Wangh et al. | Jan 2003 | A1 |
| 20030027214 | Kamb | Feb 2003 | A1 |
| 20030027221 | Scott et al. | Feb 2003 | A1 |
| 20030028981 | Chandler et al. | Feb 2003 | A1 |
| 20030032141 | Nguyen et al. | Feb 2003 | A1 |
| 20030036206 | Chien et al. | Feb 2003 | A1 |
| 20030039978 | Hannah | Feb 2003 | A1 |
| 20030044777 | Beattie | Mar 2003 | A1 |
| 20030044836 | Levine et al. | Mar 2003 | A1 |
| 20030075446 | Culbertson et al. | Apr 2003 | A1 |
| 20030082587 | Seul et al. | May 2003 | A1 |
| 20030089605 | Timperman | May 2003 | A1 |
| 20030104466 | Knapp et al. | Jun 2003 | A1 |
| 20030108897 | Drmanac | Jun 2003 | A1 |
| 20030124509 | Kenis et al. | Jul 2003 | A1 |
| 20030149307 | Hai et al. | Aug 2003 | A1 |
| 20030170698 | Gascoyne et al. | Sep 2003 | A1 |
| 20030182068 | Battersby et al. | Sep 2003 | A1 |
| 20030207260 | Trnovsky et al. | Nov 2003 | A1 |
| 20030215862 | Parce et al. | Nov 2003 | A1 |
| 20040063138 | McGinnis et al. | Apr 2004 | A1 |
| 20040081962 | Chen et al. | Apr 2004 | A1 |
| 20040101680 | Barber et al. | May 2004 | A1 |
| 20040101880 | Rozwadowski et al. | May 2004 | A1 |
| 20040132122 | Banerjee et al. | Jul 2004 | A1 |
| 20040224331 | Cantor et al. | Nov 2004 | A1 |
| 20040258701 | Dominowski et al. | Dec 2004 | A1 |
| 20050019839 | Jespersen et al. | Jan 2005 | A1 |
| 20050042625 | Schmidt et al. | Feb 2005 | A1 |
| 20050079510 | Berka et al. | Apr 2005 | A1 |
| 20050130188 | Walt et al. | Jun 2005 | A1 |
| 20050172476 | Stone et al. | Aug 2005 | A1 |
| 20050181379 | Su et al. | Aug 2005 | A1 |
| 20050202429 | Trau et al. | Sep 2005 | A1 |
| 20050202489 | Cho et al. | Sep 2005 | A1 |
| 20050221339 | Griffiths et al. | Oct 2005 | A1 |
| 20050244850 | Huang et al. | Nov 2005 | A1 |
| 20050272159 | Ismagilov et al. | Dec 2005 | A1 |
| 20050287572 | Mathies et al. | Dec 2005 | A1 |
| 20060002890 | Hersel et al. | Jan 2006 | A1 |
| 20060008799 | Cai et al. | Jan 2006 | A1 |
| 20060020371 | Ham et al. | Jan 2006 | A1 |
| 20060040382 | Heffron et al. | Feb 2006 | A1 |
| 20060073487 | Oliver et al. | Apr 2006 | A1 |
| 20060078888 | Griffiths et al. | Apr 2006 | A1 |
| 20060153924 | Griffiths et al. | Jul 2006 | A1 |
| 20060163385 | Link et al. | Jul 2006 | A1 |
| 20060177832 | Brenner | Aug 2006 | A1 |
| 20060177833 | Brenner | Aug 2006 | A1 |
| 20060199193 | Koo et al. | Sep 2006 | A1 |
| 20060240506 | Kushmaro et al. | Oct 2006 | A1 |
| 20060257893 | Takahashi et al. | Nov 2006 | A1 |
| 20060263888 | Fritz et al. | Nov 2006 | A1 |
| 20060275782 | Gunderson et al. | Dec 2006 | A1 |
| 20060286570 | Rowlen et al. | Dec 2006 | A1 |
| 20060292583 | Schneider et al. | Dec 2006 | A1 |
| 20070003442 | Link et al. | Jan 2007 | A1 |
| 20070020617 | Trnovsky et al. | Jan 2007 | A1 |
| 20070020640 | McCloskey et al. | Jan 2007 | A1 |
| 20070026401 | Hofmann et al. | Feb 2007 | A1 |
| 20070031829 | Yasuno et al. | Feb 2007 | A1 |
| 20070042400 | Choi et al. | Feb 2007 | A1 |
| 20070042419 | Barany et al. | Feb 2007 | A1 |
| 20070054119 | Garstecki et al. | Mar 2007 | A1 |
| 20070072208 | Drmanac | Mar 2007 | A1 |
| 20070077572 | Tawfik et al. | Apr 2007 | A1 |
| 20070092914 | Griffiths et al. | Apr 2007 | A1 |
| 20070099208 | Drmanac et al. | May 2007 | A1 |
| 20070134277 | Chen et al. | Jun 2007 | A1 |
| 20070154903 | Marla et al. | Jul 2007 | A1 |
| 20070160503 | Sethu et al. | Jul 2007 | A1 |
| 20070172873 | Brenner et al. | Jul 2007 | A1 |
| 20070190543 | Livak | Aug 2007 | A1 |
| 20070195127 | Ahn et al. | Aug 2007 | A1 |
| 20070207060 | Zou et al. | Sep 2007 | A1 |
| 20070228588 | Noritomi et al. | Oct 2007 | A1 |
| 20070231823 | McKernan et al. | Oct 2007 | A1 |
| 20070238113 | Kanda et al. | Oct 2007 | A1 |
| 20070259357 | Brenner | Nov 2007 | A1 |
| 20070264320 | Lee et al. | Nov 2007 | A1 |
| 20080003142 | Link et al. | Jan 2008 | A1 |
| 20080004436 | Tawfik et al. | Jan 2008 | A1 |
| 20080014589 | Link et al. | Jan 2008 | A1 |
| 20080124726 | Monforte | May 2008 | A1 |
| 20080138878 | Kubu et al. | Jun 2008 | A1 |
| 20080213766 | Brown et al. | Sep 2008 | A1 |
| 20080228268 | Shannon et al. | Sep 2008 | A1 |
| 20080241820 | Krutzik et al. | Oct 2008 | A1 |
| 20080242560 | Gunderson et al. | Oct 2008 | A1 |
| 20080268450 | Nam et al. | Oct 2008 | A1 |
| 20090005252 | Drmanac et al. | Jan 2009 | A1 |
| 20090011943 | Drmanac et al. | Jan 2009 | A1 |
| 20090012187 | Chu et al. | Jan 2009 | A1 |
| 20090025277 | Takanashi | Jan 2009 | A1 |
| 20090035770 | Mathies et al. | Feb 2009 | A1 |
| 20090048124 | Leamon et al. | Feb 2009 | A1 |
| 20090053169 | Castillo et al. | Feb 2009 | A1 |
| 20090062129 | McKernan et al. | Mar 2009 | A1 |
| 20090068170 | Weitz et al. | Mar 2009 | A1 |
| 20090098555 | Roth et al. | Apr 2009 | A1 |
| 20090099041 | Church et al. | Apr 2009 | A1 |
| 20090105959 | Braverman et al. | Apr 2009 | A1 |
| 20090118488 | Drmanac et al. | May 2009 | A1 |
| 20090134027 | Jary | May 2009 | A1 |
| 20090137404 | Drmanac et al. | May 2009 | A1 |
| 20090137414 | Drmanac et al. | May 2009 | A1 |
| 20090143244 | Bridgham et al. | Jun 2009 | A1 |
| 20090148961 | Luchini et al. | Jun 2009 | A1 |
| 20090155780 | Xiao et al. | Jun 2009 | A1 |
| 20090155781 | Drmanac et al. | Jun 2009 | A1 |
| 20090197248 | Griffiths et al. | Aug 2009 | A1 |
| 20090197772 | Griffiths et al. | Aug 2009 | A1 |
| 20090202984 | Cantor | Aug 2009 | A1 |
| 20090203531 | Kurn | Aug 2009 | A1 |
| 20090264299 | Drmanac et al. | Oct 2009 | A1 |
| 20090286687 | Dressman et al. | Nov 2009 | A1 |
| 20090325260 | Otto et al. | Dec 2009 | A1 |
| 20100021973 | Makarov et al. | Jan 2010 | A1 |
| 20100021984 | Edd et al. | Jan 2010 | A1 |
| 20100022414 | Link et al. | Jan 2010 | A1 |
| 20100035254 | Williams | Feb 2010 | A1 |
| 20100062494 | Church et al. | Mar 2010 | A1 |
| 20100069263 | Shendure et al. | Mar 2010 | A1 |
| 20100086914 | Bentley et al. | Apr 2010 | A1 |
| 20100105112 | Holtze et al. | Apr 2010 | A1 |
| 20100113296 | Myerson | May 2010 | A1 |
| 20100120098 | Grunenwald et al. | May 2010 | A1 |
| 20100130369 | Shenderov et al. | May 2010 | A1 |
| 20100136544 | Agresti et al. | Jun 2010 | A1 |
| 20100137163 | Link et al. | Jun 2010 | A1 |
| 20100173394 | Colston, Jr. et al. | Jul 2010 | A1 |
| 20100187705 | Lee et al. | Jul 2010 | A1 |
| 20100210479 | Griffiths et al. | Aug 2010 | A1 |
| 20100216153 | Lapidus et al. | Aug 2010 | A1 |
| 20100248237 | Froehlich et al. | Sep 2010 | A1 |
| 20100248991 | Roesler et al. | Sep 2010 | A1 |
| 20100304982 | Hinz et al. | Dec 2010 | A1 |
| 20110000560 | Miller et al. | Jan 2011 | A1 |
| 20110008775 | Gao et al. | Jan 2011 | A1 |
| 20110028412 | Cappello et al. | Feb 2011 | A1 |
| 20110033548 | Lai et al. | Feb 2011 | A1 |
| 20110033854 | Drmanac et al. | Feb 2011 | A1 |
| 20110053798 | Hindson et al. | Mar 2011 | A1 |
| 20110059556 | Strey et al. | Mar 2011 | A1 |
| 20110071053 | Drmanac et al. | Mar 2011 | A1 |
| 20110086780 | Colston, Jr. et al. | Apr 2011 | A1 |
| 20110092376 | Colston, Jr. et al. | Apr 2011 | A1 |
| 20110092392 | Colston, Jr. et al. | Apr 2011 | A1 |
| 20110160078 | Fodor et al. | Jun 2011 | A1 |
| 20110166034 | Kwong et al. | Jul 2011 | A1 |
| 20110195496 | Muraguchi et al. | Aug 2011 | A1 |
| 20110201526 | Berka et al. | Aug 2011 | A1 |
| 20110212090 | Pedersen et al. | Sep 2011 | A1 |
| 20110217736 | Hindson | Sep 2011 | A1 |
| 20110218123 | Weitz et al. | Sep 2011 | A1 |
| 20110263457 | Krutzik et al. | Oct 2011 | A1 |
| 20110267457 | Weitz et al. | Nov 2011 | A1 |
| 20110281736 | Drmanac et al. | Nov 2011 | A1 |
| 20110281738 | Drmanac et al. | Nov 2011 | A1 |
| 20110287435 | Grunenwald et al. | Nov 2011 | A1 |
| 20110305761 | Shum et al. | Dec 2011 | A1 |
| 20110306141 | Bronchetti et al. | Dec 2011 | A1 |
| 20110319281 | Drmanac | Dec 2011 | A1 |
| 20120000777 | Garrell et al. | Jan 2012 | A1 |
| 20120003657 | Myllykangas et al. | Jan 2012 | A1 |
| 20120010091 | Linnarson et al. | Jan 2012 | A1 |
| 20120010098 | Griffiths et al. | Jan 2012 | A1 |
| 20120010107 | Griffiths et al. | Jan 2012 | A1 |
| 20120014977 | Furihata et al. | Jan 2012 | A1 |
| 20120015382 | Weitz et al. | Jan 2012 | A1 |
| 20120015822 | Weitz et al. | Jan 2012 | A1 |
| 20120071331 | Casbon et al. | Mar 2012 | A1 |
| 20120121481 | Romanowsky et al. | May 2012 | A1 |
| 20120132288 | Weitz et al. | May 2012 | A1 |
| 20120135893 | Drmanac et al. | May 2012 | A1 |
| 20120165219 | Van Der Zaag et al. | Jun 2012 | A1 |
| 20120172259 | Rigatti et al. | Jul 2012 | A1 |
| 20120184449 | Hixson et al. | Jul 2012 | A1 |
| 20120190032 | Ness et al. | Jul 2012 | A1 |
| 20120190037 | Durin et al. | Jul 2012 | A1 |
| 20120196288 | Beer et al. | Aug 2012 | A1 |
| 20120208705 | Steemers et al. | Aug 2012 | A1 |
| 20120208724 | Steemers et al. | Aug 2012 | A1 |
| 20120211084 | Weitz et al. | Aug 2012 | A1 |
| 20120220494 | Samuels et al. | Aug 2012 | A1 |
| 20120220497 | Jacobson et al. | Aug 2012 | A1 |
| 20120222748 | Weitz et al. | Sep 2012 | A1 |
| 20120231972 | Golyshin et al. | Sep 2012 | A1 |
| 20120252012 | Armougom et al. | Oct 2012 | A1 |
| 20120253689 | Rogan et al. | Oct 2012 | A1 |
| 20120297493 | Cooper et al. | Nov 2012 | A1 |
| 20120309002 | Link | Dec 2012 | A1 |
| 20120316074 | Saxonov et al. | Dec 2012 | A1 |
| 20130017978 | Kavanagh et al. | Jan 2013 | A1 |
| 20130018970 | Woundy et al. | Jan 2013 | A1 |
| 20130022682 | Lee et al. | Jan 2013 | A1 |
| 20130028812 | Prieto et al. | Jan 2013 | A1 |
| 20130041004 | Drager et al. | Feb 2013 | A1 |
| 20130046030 | Rotem et al. | Feb 2013 | A1 |
| 20130059310 | Brenner et al. | Mar 2013 | A1 |
| 20130078638 | Berka et al. | Mar 2013 | A1 |
| 20130079231 | Pushkarev et al. | Mar 2013 | A1 |
| 20130079251 | Boles | Mar 2013 | A1 |
| 20130084243 | Goetsch et al. | Apr 2013 | A1 |
| 20130096073 | Sidelman | Apr 2013 | A1 |
| 20130109575 | Kleinschmidt et al. | May 2013 | A1 |
| 20130109576 | Shuber et al. | May 2013 | A1 |
| 20130121893 | Delamarche et al. | May 2013 | A1 |
| 20130130919 | Chen et al. | May 2013 | A1 |
| 20130157870 | Pushkarev et al. | Jun 2013 | A1 |
| 20130157899 | Adler, Jr. et al. | Jun 2013 | A1 |
| 20130178368 | Griffiths et al. | Jul 2013 | A1 |
| 20130189700 | So et al. | Jul 2013 | A1 |
| 20130203605 | Shendure et al. | Aug 2013 | A1 |
| 20130203675 | Desimone et al. | Aug 2013 | A1 |
| 20130210639 | Link et al. | Aug 2013 | A1 |
| 20130210991 | Fonnum et al. | Aug 2013 | A1 |
| 20130211055 | Raines et al. | Aug 2013 | A1 |
| 20130225418 | Watson | Aug 2013 | A1 |
| 20130225623 | Buxbaum et al. | Aug 2013 | A1 |
| 20130273640 | Krishnan et al. | Oct 2013 | A1 |
| 20130274117 | Church et al. | Oct 2013 | A1 |
| 20130296173 | Callow et al. | Nov 2013 | A1 |
| 20130343317 | Etemad et al. | Dec 2013 | A1 |
| 20140030350 | Ashrafi et al. | Jan 2014 | A1 |
| 20140038178 | Otto et al. | Feb 2014 | A1 |
| 20140057799 | Johnson et al. | Feb 2014 | A1 |
| 20140065234 | Shum et al. | Mar 2014 | A1 |
| 20140080717 | Li et al. | Mar 2014 | A1 |
| 20140093916 | Belyaev et al. | Apr 2014 | A1 |
| 20140120529 | Andersen et al. | May 2014 | A1 |
| 20140155274 | Xie et al. | Jun 2014 | A1 |
| 20140155295 | Hindson et al. | Jun 2014 | A1 |
| 20140194323 | Gillevet et al. | Jul 2014 | A1 |
| 20140199730 | Agresti et al. | Jul 2014 | A1 |
| 20140199731 | Agresti et al. | Jul 2014 | A1 |
| 20140206554 | Hindson et al. | Jul 2014 | A1 |
| 20140227684 | Hindson et al. | Aug 2014 | A1 |
| 20140227706 | Kato et al. | Aug 2014 | A1 |
| 20140228255 | Hindson et al. | Aug 2014 | A1 |
| 20140235506 | Hindson et al. | Aug 2014 | A1 |
| 20140242664 | Zhang et al. | Aug 2014 | A1 |
| 20140274740 | Srinivasan et al. | Sep 2014 | A1 |
| 20140287963 | Hindson et al. | Sep 2014 | A1 |
| 20140302503 | Lowe et al. | Oct 2014 | A1 |
| 20140315725 | Faham et al. | Oct 2014 | A1 |
| 20140315755 | Chen et al. | Oct 2014 | A1 |
| 20140357500 | Vigneault et al. | Dec 2014 | A1 |
| 20140378322 | Hindson et al. | Dec 2014 | A1 |
| 20140378345 | Hindson et al. | Dec 2014 | A1 |
| 20140378349 | Hindson et al. | Dec 2014 | A1 |
| 20150005188 | Levner et al. | Jan 2015 | A1 |
| 20150005199 | Hindson et al. | Jan 2015 | A1 |
| 20150005200 | Hindson et al. | Jan 2015 | A1 |
| 20150011430 | Saxonov | Jan 2015 | A1 |
| 20150011432 | Saxonov et al. | Jan 2015 | A1 |
| 20150031037 | Li et al. | Jan 2015 | A1 |
| 20150057163 | Rotem et al. | Feb 2015 | A1 |
| 20150072899 | Ward et al. | Mar 2015 | A1 |
| 20150111256 | Church et al. | Apr 2015 | A1 |
| 20150111788 | Fernandez et al. | Apr 2015 | A1 |
| 20150119280 | Srinivas et al. | Apr 2015 | A1 |
| 20150211056 | Um et al. | Jul 2015 | A1 |
| 20150218633 | Hindson et al. | Aug 2015 | A1 |
| 20150224466 | Hindson et al. | Aug 2015 | A1 |
| 20150225777 | Hindson et al. | Aug 2015 | A1 |
| 20150247182 | Faham et al. | Sep 2015 | A1 |
| 20150259736 | Steemers et al. | Sep 2015 | A1 |
| 20150267191 | Steelman et al. | Sep 2015 | A1 |
| 20150291942 | Gloeckner et al. | Oct 2015 | A1 |
| 20150298091 | Weitz et al. | Oct 2015 | A1 |
| 20150299772 | Zhang | Oct 2015 | A1 |
| 20150299784 | Fan et al. | Oct 2015 | A1 |
| 20150329617 | Winther et al. | Nov 2015 | A1 |
| 20150329852 | Nolan et al. | Nov 2015 | A1 |
| 20150329891 | Tan et al. | Nov 2015 | A1 |
| 20150337298 | Xi et al. | Nov 2015 | A1 |
| 20150353999 | Agresti et al. | Dec 2015 | A1 |
| 20150361418 | Reed et al. | Dec 2015 | A1 |
| 20150368638 | Steemers et al. | Dec 2015 | A1 |
| 20150368694 | Pan et al. | Dec 2015 | A1 |
| 20150376605 | Jarosz et al. | Dec 2015 | A1 |
| 20150376608 | Kaper et al. | Dec 2015 | A1 |
| 20150376609 | Hindson et al. | Dec 2015 | A1 |
| 20150376700 | Schnall-Levin et al. | Dec 2015 | A1 |
| 20150379196 | Schnall-Levin et al. | Dec 2015 | A1 |
| 20160024558 | Hardenbol | Jan 2016 | A1 |
| 20160025726 | Altin et al. | Jan 2016 | A1 |
| 20160032282 | Vigneault et al. | Feb 2016 | A1 |
| 20160053253 | Salathia et al. | Feb 2016 | A1 |
| 20160060621 | Agresti et al. | Mar 2016 | A1 |
| 20160115474 | Jelinek et al. | Apr 2016 | A1 |
| 20160122753 | Mikkelsen et al. | May 2016 | A1 |
| 20160122817 | Jarosz et al. | May 2016 | A1 |
| 20160145683 | Fan et al. | May 2016 | A1 |
| 20160153005 | Zhang et al. | Jun 2016 | A1 |
| 20160160235 | Solodushko et al. | Jun 2016 | A1 |
| 20160177359 | Ukanis et al. | Jun 2016 | A1 |
| 20160201125 | Samuels et al. | Jul 2016 | A1 |
| 20160208323 | Bernstein et al. | Jul 2016 | A1 |
| 20160231324 | Zhao et al. | Aug 2016 | A1 |
| 20160244742 | Linnarsson et al. | Aug 2016 | A1 |
| 20160244809 | Belgrader et al. | Aug 2016 | A1 |
| 20160244825 | Vigneault et al. | Aug 2016 | A1 |
| 20160251697 | Nolan et al. | Sep 2016 | A1 |
| 20160281160 | Jarosz et al. | Sep 2016 | A1 |
| 20160289769 | Schwartz et al. | Oct 2016 | A1 |
| 20160304860 | Hindson et al. | Oct 2016 | A1 |
| 20160326583 | Johnson et al. | Nov 2016 | A1 |
| 20160348093 | Price et al. | Dec 2016 | A1 |
| 20160376663 | Brown | Dec 2016 | A1 |
| 20170009274 | Abate et al. | Jan 2017 | A1 |
| 20170016041 | Greenfield et al. | Jan 2017 | A1 |
| 20170114390 | Hindson et al. | Apr 2017 | A1 |
| 20170145476 | Ryvkin et al. | May 2017 | A1 |
| 20170183701 | Agresti et al. | Jun 2017 | A1 |
| 20170211127 | Mikkelsen et al. | Jul 2017 | A1 |
| 20170260584 | Zheng et al. | Sep 2017 | A1 |
| 20170268056 | Vigneault et al. | Sep 2017 | A1 |
| 20170321252 | Hindson et al. | Nov 2017 | A1 |
| 20170343545 | Hadrup et al. | Nov 2017 | A1 |
| 20170348691 | Bharadwaj et al. | Dec 2017 | A1 |
| 20170356027 | Hindson et al. | Dec 2017 | A1 |
| 20180008984 | Bharadwaj et al. | Jan 2018 | A1 |
| 20180016634 | Hindson et al. | Jan 2018 | A1 |
| 20180030515 | Regev et al. | Feb 2018 | A1 |
| 20180051321 | Hindson et al. | Feb 2018 | A1 |
| 20180057868 | Walder et al. | Mar 2018 | A1 |
| 20180080021 | Reuter | Mar 2018 | A1 |
| 20180087050 | Zheng et al. | Mar 2018 | A1 |
| 20180088112 | Fan et al. | Mar 2018 | A1 |
| 20180094298 | Hindson et al. | Apr 2018 | A1 |
| 20180094313 | Hindson | Apr 2018 | A1 |
| 20180094315 | Hindson et al. | Apr 2018 | A1 |
| 20180105808 | Mikkelsen et al. | Apr 2018 | A1 |
| 20180112253 | Hindson et al. | Apr 2018 | A1 |
| 20180112266 | Hindson et al. | Apr 2018 | A1 |
| 20180179580 | Hindson et al. | Jun 2018 | A1 |
| 20180179591 | Belgrader et al. | Jun 2018 | A1 |
| 20180180601 | Pedersen et al. | Jun 2018 | A1 |
| 20180195060 | Wang et al. | Jul 2018 | A1 |
| 20180195112 | Lebofsky et al. | Jul 2018 | A1 |
| 20180216162 | Belhocine et al. | Aug 2018 | A1 |
| 20180237951 | Bock et al. | Aug 2018 | A1 |
| 20180258466 | Hindson et al. | Sep 2018 | A1 |
| 20180265928 | Schnall-Levin et al. | Sep 2018 | A1 |
| 20180267036 | Fan et al. | Sep 2018 | A1 |
| 20180273933 | Gunderson et al. | Sep 2018 | A1 |
| 20180274027 | Hindson et al. | Sep 2018 | A1 |
| 20180282804 | Hindson et al. | Oct 2018 | A1 |
| 20180305685 | Li et al. | Oct 2018 | A1 |
| 20180327839 | Hindson et al. | Nov 2018 | A1 |
| 20180340169 | Belhocine et al. | Nov 2018 | A1 |
| 20180340170 | Belhocine et al. | Nov 2018 | A1 |
| 20180340171 | Belhocine et al. | Nov 2018 | A1 |
| 20180340172 | Belhocine et al. | Nov 2018 | A1 |
| 20180340939 | Gaublomme et al. | Nov 2018 | A1 |
| 20180363029 | Hindson et al. | Dec 2018 | A1 |
| 20180371538 | Blauwkamp et al. | Dec 2018 | A1 |
| 20180371540 | Hindson et al. | Dec 2018 | A1 |
| 20190002967 | Chen et al. | Jan 2019 | A1 |
| 20190024166 | Hindson et al. | Jan 2019 | A1 |
| 20190032129 | Hindson et al. | Jan 2019 | A1 |
| 20190032130 | Giresi et al. | Jan 2019 | A1 |
| 20190040382 | Steemers et al. | Feb 2019 | A1 |
| 20190040464 | Giresi et al. | Feb 2019 | A1 |
| 20190071656 | Chang et al. | Mar 2019 | A1 |
| 20190078150 | Chen et al. | Mar 2019 | A1 |
| 20190085391 | Hindson et al. | Mar 2019 | A1 |
| 20190127731 | McDermott | May 2019 | A1 |
| 20190136316 | Hindson et al. | May 2019 | A1 |
| 20190136317 | Hindson et al. | May 2019 | A1 |
| 20190136319 | Hindson et al. | May 2019 | A1 |
| Number | Date | Country |
|---|---|---|
| 102292455 | Dec 2011 | CN |
| 103202812 | Jul 2013 | CN |
| 0249007 | Dec 1987 | EP |
| 0271281 | Jun 1988 | EP |
| 0637996 | Jul 1997 | EP |
| 1019496 | Sep 2004 | EP |
| 1672064 | Jun 2006 | EP |
| 1482036 | Oct 2007 | EP |
| 1841879 | Oct 2007 | EP |
| 1944368 | Jul 2008 | EP |
| 1594980 | Nov 2009 | EP |
| 1967592 | Apr 2010 | EP |
| 2258846 | Dec 2010 | EP |
| 2145955 | Feb 2012 | EP |
| 1905828 | Aug 2012 | EP |
| 2136786 | Oct 2012 | EP |
| 1908832 | Dec 2012 | EP |
| 2540389 | Jan 2013 | EP |
| 2635679 | Sep 2013 | EP |
| 2752664 | Jul 2014 | EP |
| 2097692 | May 1985 | GB |
| 2485850 | May 2012 | GB |
| S5949832 | Mar 1984 | JP |
| S60227826 | Nov 1985 | JP |
| 2006507921 | Mar 2006 | JP |
| 2006289250 | Oct 2006 | JP |
| 2007015990 | Jan 2007 | JP |
| 2007268350 | Oct 2007 | JP |
| 2009513948 | Apr 2009 | JP |
| 2009208074 | Sep 2009 | JP |
| 2012131798 | Jul 2012 | JP |
| 2012522517 | Sep 2012 | JP |
| WO-8402000 | May 1984 | WO |
| WO-9301498 | Jan 1993 | WO |
| WO-9418218 | Aug 1994 | WO |
| WO-9419101 | Sep 1994 | WO |
| WO-9423699 | Oct 1994 | WO |
| WO-9530782 | Nov 1995 | WO |
| WO-9629629 | Sep 1996 | WO |
| WO-9641011 | Dec 1996 | WO |
| WO-9802237 | Jan 1998 | WO |
| WO-9852691 | Nov 1998 | WO |
| WO-9909217 | Feb 1999 | WO |
| WO-9942597 | Aug 1999 | WO |
| WO-9952708 | Oct 1999 | WO |
| WO-0008212 | Feb 2000 | WO |
| WO-0023181 | Apr 2000 | WO |
| WO-0026412 | May 2000 | WO |
| WO-0034527 | Jun 2000 | WO |
| WO-0043766 | Jul 2000 | WO |
| WO-0070095 | Nov 2000 | WO |
| WO-0102850 | Jan 2001 | WO |
| WO-0114589 | Mar 2001 | WO |
| WO-0189787 | Nov 2001 | WO |
| WO-0190418 | Nov 2001 | WO |
| WO-0127610 | Mar 2002 | WO |
| WO-0231203 | Apr 2002 | WO |
| WO-02086148 | Oct 2002 | WO |
| WO-0218949 | Jan 2003 | WO |
| WO-03062462 | Jul 2003 | WO |
| WO-2004002627 | Jan 2004 | WO |
| WO-2004010106 | Jan 2004 | WO |
| WO-2004061083 | Jul 2004 | WO |
| WO-2004065617 | Aug 2004 | WO |
| WO-2004069849 | Aug 2004 | WO |
| WO-2004091763 | Oct 2004 | WO |
| WO-2004102204 | Nov 2004 | WO |
| WO-2004103565 | Dec 2004 | WO |
| WO-2004105734 | Dec 2004 | WO |
| WO-2005002730 | Jan 2005 | WO |
| WO-2005021151 | Mar 2005 | WO |
| WO-2005023331 | Mar 2005 | WO |
| WO-2005040406 | May 2005 | WO |
| WO-2005049787 | Jun 2005 | WO |
| WO-2005082098 | Sep 2005 | WO |
| WO-2006030993 | Mar 2006 | WO |
| WO-2006071770 | Jul 2006 | WO |
| WO-2006078841 | Jul 2006 | WO |
| WO-2006086210 | Aug 2006 | WO |
| WO-2006096571 | Sep 2006 | WO |
| WO-2007001448 | Jan 2007 | WO |
| WO-2007002490 | Jan 2007 | WO |
| WO-2007012638 | Feb 2007 | WO |
| WO-2007018601 | Feb 2007 | WO |
| WO-2007024840 | Mar 2007 | WO |
| WO-2007081385 | Jul 2007 | WO |
| WO-2007081387 | Jul 2007 | WO |
| WO-2007084192 | Jul 2007 | WO |
| WO-2007089541 | Aug 2007 | WO |
| WO-2007093819 | Aug 2007 | WO |
| WO-2007111937 | Oct 2007 | WO |
| WO-2007114794 | Oct 2007 | WO |
| WO-2007121489 | Oct 2007 | WO |
| WO-2007133710 | Nov 2007 | WO |
| WO-2007138178 | Dec 2007 | WO |
| WO-2007139766 | Dec 2007 | WO |
| WO-2007140015 | Dec 2007 | WO |
| WO-2007147079 | Dec 2007 | WO |
| WO-2007149432 | Dec 2007 | WO |
| WO-2008021123 | Feb 2008 | WO |
| WO-2008091792 | Jul 2008 | WO |
| WO-2008102057 | Aug 2008 | WO |
| WO-2008109176 | Sep 2008 | WO |
| WO-2008121342 | Oct 2008 | WO |
| WO-2008061193 | Nov 2008 | WO |
| WO-2008134153 | Nov 2008 | WO |
| WO-2008150432 | Dec 2008 | WO |
| WO-2009005680 | Jan 2009 | WO |
| WO-2009011808 | Jan 2009 | WO |
| WO-2009015296 | Jan 2009 | WO |
| WO-2009048532 | Apr 2009 | WO |
| WO-2009061372 | May 2009 | WO |
| WO-2009085215 | Jul 2009 | WO |
| WO-2009147386 | Dec 2009 | WO |
| WO-2010004018 | Jan 2010 | WO |
| WO-2010009735 | Jan 2010 | WO |
| WO-2010033200 | Mar 2010 | WO |
| WO-2010048605 | Apr 2010 | WO |
| WO-2010104604 | Sep 2010 | WO |
| WO-2010115154 | Oct 2010 | WO |
| WO-2010148039 | Dec 2010 | WO |
| WO-2010151776 | Dec 2010 | WO |
| WO-2010117620 | Feb 2011 | WO |
| WO-2011028539 | Mar 2011 | WO |
| WO-2011047870 | Apr 2011 | WO |
| WO-2011056546 | May 2011 | WO |
| WO-2011066476 | Jun 2011 | WO |
| WO-2011074960 | Jun 2011 | WO |
| WO-2011106314 | Sep 2011 | WO |
| WO-2011140627 | Nov 2011 | WO |
| WO-2011156529 | Dec 2011 | WO |
| WO-2012012037 | Jan 2012 | WO |
| WO-2011140510 | Mar 2012 | WO |
| WO-2012047889 | Apr 2012 | WO |
| WO-2012048340 | Apr 2012 | WO |
| WO-2012048341 | Apr 2012 | WO |
| WO-2012061832 | May 2012 | WO |
| WO-2012083225 | Jun 2012 | WO |
| WO-2012087736 | Jun 2012 | WO |
| WO-2012106546 | Aug 2012 | WO |
| WO-2012112804 | Aug 2012 | WO |
| WO-2012112970 | Aug 2012 | WO |
| WO-2012136734 | Oct 2012 | WO |
| WO-2012142611 | Oct 2012 | WO |
| WO-2012148497 | Nov 2012 | WO |
| WO-2012149042 | Nov 2012 | WO |
| WO-2012150317 | Nov 2012 | WO |
| WO-2012166425 | Dec 2012 | WO |
| WO-2013019751 | Feb 2013 | WO |
| WO-2013036929 | Mar 2013 | WO |
| WO-2013055955 | Apr 2013 | WO |
| WO-2013096643 | Jun 2013 | WO |
| WO-2013122996 | Aug 2013 | WO |
| WO-2013123125 | Aug 2013 | WO |
| WO-2013126741 | Aug 2013 | WO |
| WO-2013134261 | Sep 2013 | WO |
| WO-2013150083 | Oct 2013 | WO |
| WO-2013177220 | Nov 2013 | WO |
| WO-2013188872 | Dec 2013 | WO |
| WO-2014018460 | Jan 2014 | WO |
| WO-2014028537 | Feb 2014 | WO |
| WO-2014053854 | Apr 2014 | WO |
| WO-2014071361 | May 2014 | WO |
| WO-2014072703 | May 2014 | WO |
| WO-2014074611 | May 2014 | WO |
| WO-2014093676 | Jun 2014 | WO |
| WO-2014108810 | Jul 2014 | WO |
| WO-2014140309 | Sep 2014 | WO |
| WO-2014144495 | Sep 2014 | WO |
| WO-2014145047 | Sep 2014 | WO |
| WO-2014150931 | Sep 2014 | WO |
| WO-2014182835 | Nov 2014 | WO |
| WO-2014189957 | Nov 2014 | WO |
| WO-2014200767 | Dec 2014 | WO |
| WO-2014210353 | Dec 2014 | WO |
| WO-2015031691 | Mar 2015 | WO |
| WO-2015044428 | Apr 2015 | WO |
| WO-2015164212 | Oct 2015 | WO |
| WO-2015185067 | Dec 2015 | WO |
| WO-2015188839 | Dec 2015 | WO |
| WO-2015200893 | Dec 2015 | WO |
| WO-2016040476 | Mar 2016 | WO |
| WO-2016033251 | Apr 2016 | WO |
| WO-2016061517 | Apr 2016 | WO |
| WO-2016100976 | Jun 2016 | WO |
| WO-2016126871 | Aug 2016 | WO |
| WO-2016138496 | Sep 2016 | WO |
| WO-2016149661 | Sep 2016 | WO |
| WO-2016168584 | Oct 2016 | WO |
| WO-2016187256 | Nov 2016 | WO |
| WO-2016187717 | Dec 2016 | WO |
| WO-2016191618 | Dec 2016 | WO |
| WO-2016207647 | Dec 2016 | WO |
| WO-2016207653 | Dec 2016 | WO |
| WO-2016207661 | Dec 2016 | WO |
| WO-2017015075 | Jan 2017 | WO |
| WO-2017025594 | Feb 2017 | WO |
| WO-2017034970 | Mar 2017 | WO |
| WO-2017053905 | Mar 2017 | WO |
| WO-2017075265 | May 2017 | WO |
| WO-2017075294 | May 2017 | WO |
| WO-2017079593 | May 2017 | WO |
| WO-2017096158 | Jun 2017 | WO |
| WO-2017117358 | Jul 2017 | WO |
| WO-2017156336 | Sep 2017 | WO |
| WO-2018031631 | Feb 2018 | WO |
| WO-2018039969 | Mar 2018 | WO |
| WO-2018045186 | Mar 2018 | WO |
| WO-2018058073 | Mar 2018 | WO |
| WO-2018103025 | Jun 2018 | WO |
| WO-2018119301 | Jun 2018 | WO |
| WO-2018119447 | Jun 2018 | WO |
| WO-2018125982 | Jul 2018 | WO |
| WO-2018129368 | Jul 2018 | WO |
| WO-2018132635 | Jul 2018 | WO |
| WO-2018172726 | Sep 2018 | WO |
| WO-2018174827 | Sep 2018 | WO |
| WO-2018191701 | Oct 2018 | WO |
| WO-2019028166 | Feb 2019 | WO |
| WO-2019084328 | May 2019 | WO |
| Entry |
|---|
| 10X Genomics. 10x Genomics Chromium™ Single Cell 3′ Solution Utilized for Perturb-seq Approach. Press Release. Dec. 19, 2016. Retrieved from https://www.10xgenomics.com/news/10x-genomics-chromium-single-cell-3-solution-utilized-perturb-seq-approach/. |
| Abate, et al. Beating Poisson encapsulation statistics using close-packed ordering. Lab Chip. Sep. 21, 2009;9(18):2628-31 . doi: 10.1039/b909386a. Epub Jul. 28, 2009. |
| Abate, et al. High-throughput injection with microfluidics using picoinjectors. Proc Natl Acad Sci U S A. Nov. 9, 2010;107(45):19163-6. doi: 10.1073/pNas.1006888107. Epub Oct. 20, 2010. |
| Abate et al., Valve-based flow focusing for drop formation. Appl Phys Lett. 2009;94. 3 pages. |
| Adamson, et al. A Multiplexed Single-Cell CRISPR Screening Platform Enables Systematic Dissection of the Unfolded Protein Response. Cell. Dec. 15, 2016;167(7):1867-1882.e21 . doi: 10.1016/j.cell.2016.11.048. |
| Adamson et al., “Production of arrays of chemically distinct nanolitre plugs via repeated splitting in microfluidic devices”, Lab Chip 6(9): 1178-1186 (Sep. 2006). |
| Adey, et al. Rapid, low-input, low-bias construction of shotgun fragment libraries by high-density in vitro transposition. Genome Biology 11:R119 (2010). |
| Adey, et al., “Ultra-low-input, tagmentation-based whole-genome bisulfite sequencing”, Genome Research, 2012, 22 ;6): 1139-1143. |
| Agasti, et al. Photocleavable DNA barcode-antibody conjugates allow sensitive and multiplexed protein analysis in single cells. J Amer Chem Soc ePub, Nov. 2, 2012, vol. 134, No. 45, pp. 18499-18502. |
| Agresti, et al. Selection of ribozymes that catalyse multiple-turnover Diels-Alder cycloadditions by using in vitro compartmentalization. Proc Natl Acad Sci U S A. Nov. 8, 2005;102(45):16170-5. Epub Oct. 31, 2005. |
| AH006633.3 (Homo sapiens clone P1 and PAC max interactor 1 (MXI1) gene, complete cds, NCBI Reference Sequence, priority to Jun. 10, 2016, 5 pages) (Year:2016). |
| Ahern, “Biochemical, Reagents Kits Offer Scientists Good Return on Investment” The Scientist (1995) 9(15):1-7. |
| Ailenberg, et al. (2000) Controlled Hot Start and Improved Specificity in Carrying Out PCR Utilizing Touch-Up and Loop Incorporated Primers (TULIPS). BioTechniques, 29:1018-1024. (Year: 2000). |
| Aitman, et al. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature. Feb. 16, 2006;439(7078):851-5. |
| Akselband, “Enrichment of slow-growing marine microorganisms from mixed cultures using gel microdrop (GMD) growth assay and fluorescence-activated cell sorting”, J. Exp. Marine Bioi., 329: 196-205 (2006). |
| Akselband, “Rapid mycobacteria drug susceptibility testing using gel microdrop (GMD) growth assay and flow cytometry”, J. Microbiol. Methods, 62:181-197 (2005). |
| Altemos et al., “Genomic Characterization of Large Heterochromatic Gaps in the Human Genome Assembly,” PLOS Computational Biology, May 15, 2014, vol. 10, Issue 5, 14 pages. |
| Amini, S. et al. “Haplotype-resolved whole-genome sequencing by contiguity-preserving transposition and combinatorial indexing” Nature Genetics (2014) 46:1343-1349 doi:10.1038/ng.3119. |
| Anna, S.L., et al., “Formation of dispersions using “flow focusing” in microchannels,” Applied Physics Letters, vol. 82, No. 3, pp. 364-366 (2003). |
| Anonymous, “Oligo(dT)25 cellulose beads” NEB (2012) Retrieved from the Internet:https://www.neb.com/˜/media/Catalog/All-Products/286CA51268E24DE1B06F1CB288698B54/Datacards%20or%Manuals/S1408Datasheet-Lot0011205.pdf. |
| Anonymous, “Oligotex Handbook” Qiagen (2012) XP055314680, Retrieved from the Internet: URL:http://www.qiagen.com/de/resources/download.apsx?id=f9fald98-d54d-47e7-a20b-8b0cb8975009&lang=en. |
| Anonymous: “TCEP=HCI” Thermo Scientific, Dec. 31, 2013 (Dec. 31, 2013), XP055508461, Retrieved from the Internet: URL:https://assets.thermofisher.com/TFS-Assets/LSG/manuals/MAN0011306_TCEP_HCI_UG.pdf. |
| Anonymous: “Three Ways to Get Intimate with Epigenetic Marks”. Oct. 24, 2012. Retrieved from Internet: https://epigenie.com/three-ways-to-get-intimate-with-epigenetic-marks/. |
| Anonymous: “Viscosity-Basic concepts” (2004) XP055314117, Retrieved from the Internet: URL:http://lhtc.epfl.ch/webdav/site/lhtc/shared/import/migration/2 VISCOSITY.pdf. |
| Ason et al. DNA sequence bias during Tn5 transposition. Journal of molecular biology 335.5 (2004): 1213-1225. |
| Attia, et al. Micro-injection moulding of polymer microfluidic devices. Microfluidics and nanofluidics. 2009; 7(1):1-28. |
| Balikova, et al. Autosomal-dominant microtia linked to five tandem copies of a copy-number-variable region at chromosome 4p16. Am J Hum Genet. Jan. 2008;82(1):181-7. doi: 10.1016/j.ajhg.2007.08.001. |
| Banchelli, et al. Phospholipid membranes decorated by cholesterol-based oligonucleotides as soft hybrid nanostructures. J Phys Chem B. Sep. 4, 2008;112(35):10942-52. doi: 10.1021/jp802415t. Epub Aug. 9, 2008. |
| Baret, et al. Fluorescence-activated droplet sorting (FADS): efficient microfluidic cell sorting based on enzymatic activity. Lab Chip. Jul. 7, 2009;9(13):1850-8. doi: 10.1039/b902504a. Epub Apr. 23, 2009. |
| BD. BD Rhapsody™ Single-Cell Analysis System: Analyze hundreds of genes across tens of thousands of single cells in parallel. BD, Becton, Dickinson and Company. BDGM1012 Rev. 1. 2017. 8 pages. |
| Bentley, et al. 2008. Supplementary Information. pp. 1-55 Nature. Nov. 6, 2008; 456(7218):53-9. |
| Bentolila, et al. Single-step multicolor fluorescence in situ hybridization using semiconductor quantum dot-DNA conjugates. Cell Biochem Biophys. 2006;45(1):59-70. |
| Bentzen, et al. Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes. Nat Biotechnol. Oct. 2016;34(10):1037-1045. doi: 10.1038/nbt.3662. Epub Aug. 29, 2016. |
| Berkum, et al. Hi-C: a method to study the three-dimensional architecture of genomes. J Vis Exp. May 6, 2010;(39). pii: 1869. doi: 10.3791/1869. |
| Biles et al., Low-fidelity Pyrococcus furiosis DNA polymerase mutants useful in error-prone PCR. Nucl. Acids Res. 32(22):e176 2004. |
| Bjornsson et al., Intra-individual change over time in DNA methylation with familial clustering, JAMA, Jun. 25, 2008, vol. 299 No. 24, pp. 2877-2883. |
| Bodi, K. et al. “Comparison of Commercially Available Target Enrichment Methods for Next-Generation Sequencing” J Biomolecular Techniques (2013) 24:73-86. |
| Boone, et al. Plastic advances microfluidic devices. The devices debuted in silicon and glass, but plastic fabrication may make them hugely successful in biotechnology application. Analytical Chemistry. Feb. 2002; 78A-86A. |
| Boulanger, et al, “Massively parallel haplotyping on microscopic beads for the high-throughput phase analysis of single molecules”, PLoS One, vol. 7:1-10, 2012. |
| Boyle, et al. “High-resolution genome-wide in vivo footprinting of diverse transcription factors in human cells”, Genome Res. Mar. 2011;21(3):456-64. |
| Braeckmans et al., Scanning the Code. Modern Drug Discovery. 2003:28-32. |
| Bransky, et al. A microfluidic droplet generator based on a piezoelectric actuator. Lab Chip. Feb. 21, 2009;9(4):516-20. doi: 10.1039/b814810d. Epub Nov. 20, 2008. |
| Brenner, et al. In vitro cloning of complex mixtures of DNA on microbeads: physical separation of differentially expressed cDNAs. Proc Natl Acad Sci U S A. Feb. 15, 2000;97(4):1665-70. |
| Briggs, et al. “Tumor-infiltrating immune repertoires captures by single-cell barcoding in emulsion” with Supplementary material. bioRxiv 134841; doi: https://doi.org/10.1101/134841. Posted May 5, 2017. |
| Brouzes, et al. Droplet microfluidic technology for single-cell high-throughput screening. Proc Natl Acad Sci U S A. Aug. 25, 2009;106(34):14195-200. doi: 10.1073/pnas.0903542106. Epub Jul. 15, 2009. |
| Brown, K., Targeted Sequencing Using Droplet-Based Microfluidics, RainDance Technologies, 2009, 1-18. |
| Browning, et al. Haplotype phasing: existing methods and new developments. Nat Rev Genet. Sep. 16, 2011;12(10):703-14. doi: 10.1038/nrg3054. Review. |
| Buchman GW, et al. Selective RNA amplification: a novel method using dUMP-containing primers and uracil DNA glycosylase. PCR Methods Appl. Aug. 1993; 3(1):28-31. |
| Buenrostro, et al. ATAC-seq: A Method for Assaying Chromatin Accessibility Genome-Wide. Curr Protoc Mol Biol.; 109: 21.29.1-21.29.9. doi:10.1002/0471142727.mb2129s109. |
| Buenrostro, et al. Single-cell chromatin accessibility reveals principles of regulatory variation. Nature. Jul. 23, 2015;523(7561):486-90. doi: 10.1038/nature14590. Epub Jun. 17, 2015. |
| Buenrostro, et al. “Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position.” Nat Methods. Dec. 2013;10(12):1213-8. doi: 10.1038/nmeth.2688. Epub Oct. 6, 2013. |
| Burns, et al. An Integrated Nanoliter DNA Analysis Device. Science. Oct. 16, 1998;282(5388):484-7. |
| Burns, et al. Microfabricated structures for integrated DNA analysis. Proc Natl Acad Sci U S A. May 28, 1996; 93(11): 5556-5561. |
| Burns, et al. The intensification of rapid reactions in multiphase systems using slug flow in capillaries. Lab Chip. Sep. 2001;1(1):10-5. Epub Aug. 9, 2001. |
| Bystrykh, et al. Generalized DNA barcode design based on Hamming codes. PLoS One. 2012;7(5):e36852. doi: 10.1371/journal.pone.0036852. Epub May 17, 2012. |
| Cappuzzo, et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol. Aug. 1, 2005;23(22):5007-18. |
| Carroll, “The selection of high-producing cell lines using flow cytometry and cell sorting”, Exp. Op. Bioi. Therp., 4:11 1821-1829 (2004). |
| Caruccio, et al. Nextera Technology for NGS DNA Library Preparation: Simultaneous Fragmentation and Tagging by In Vitro Transposition, Nextera Technology, 2009, 16-3, 1-3. (Year: 2009). |
| Caruccio N., Preparation of Next-Generation Sequencing Libraries Using Nextera Technology: Simultaneous DNA Fragmentation and Adaptor Tagging by In Vitro Transposition. Ch. 17 Methods in Microbiology 733:241 (2011). |
| Casbon, et al, “Reflex: intramolecular barcoding of long-range PCR products for sequencing multiple pooled DNAs”, Nucleic Acids Res., pp. 1-6, 2013. |
| Cejas, P. et al. “Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles” Nature Med (2016) 22(6):685-691. |
| Chang et al. Droplet-based microfluidic platform for heterogeneous enzymatic assays, 2013, Lab Chip, 13, 1817-1822 (Year: 2013). |
| Chaudhary “A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins” Proc. Natl. Acad. Sci USA 87: 1066-1070 (Feb. 1990). |
| Chechetkin et al., Sequencing by hybridization with the generic 6-mer oligonucleotide microarray: an advanced scheme for data processing. J Biomol Struct Dyn. Aug. 2000;I8(1):83-101. |
| Chen, et al. Chemical transfection of cells in picoliter aqueous droplets in fluorocarbon oil. Anal Chem. Nov. 15, 2011;83(22):8816-20. doi: 10.1021/ac2022794. Epub Oct. 17, 2011. |
| Choi, et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res. Jul. 1, 2008;68(13):4971-6. doi: 10.1158/0008-5472.CAN-07-6158. |
| Chokkalingam, et al. Probing cellular heterogeneity in cytokine-secreting immune cells using droplet-based microfluidics. Lab Chip. Dec. 21, 2013;13(24):4740-4. doi: 10.1039/c3lc50945a. |
| Chou, et al. Disposable Microdevices for DNA Analysis and Cell Sorting. Proc. Solid-State Sensor and Actuator Workshop, Hilton Head, SC. Jun. 8-11, 1998; 11-14. |
| Christian, et al. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics.186 (2010): 757-761. |
| Christiansen et al. “The Covalent Eukaryotic Topoisomerase I-DNA Intermediate Catalyzes pH-dependent Hydrolysis and Alcoholysis” J Biol Chem (Apr. 14, 1994) 269(15):11367-11373. |
| Chu, et al. Controllable monodisperse multiple emulsions. Angew Chem Int Ed Engl. 2007;46(47):8970-4. |
| Chung, et al. Structural and molecular interrogation of intact biological systems. Nature. May 16, 2013;497(7449):332-7. doi: 10.1038/nature12107. Epub Apr. 10, 2013. |
| Clark, et al. Single-cell epigenomics: powerful new methods for understanding gene regulation and cell identity. Genome Biol. Apr. 18, 2016;17:72. doi: 10.1186/s13059-016-0944-x. |
| Clausell-Tormos et al., “Droplet-based microfluidic platforms for the encapsulation and screening of mammalian cells and multicellular organisms”, Chem. Biol. 15:427-437 (2008). |
| Cong, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 339.6121 (Feb. 15, 2013): 819-23. doi: 10.1126/science.1231143. Epub Jan. 3, 2013. |
| Cook, et al. Copy-number variations associated with neuropsychiatric conditions. Nature. Oct. 16, 2008;455(7215):919-23. doi: 10.1038/nature07458. |
| Co-pending U.S. Appl. No. 15/440,772, filed Feb. 23, 2017. |
| Co-pending U.S. Appl. No. 15/449,741, filed Mar. 3, 2017. |
| Co-pending U.S. Appl. No. 16/033,065, filed Jul. 11, 2018. |
| Co-pending U.S. Appl. No. 16/044,374, filed Jul. 24, 2018. |
| Co-pending U.S. Appl. No. 16/107,685, filed Aug. 21, 2018. |
| Co-pending U.S. Appl. No. 16/170,980, filed Oct. 25, 2018. |
| Co-pending U.S. Appl. No. 16/206,168, filed Nov. 30, 2018. |
| Co-pending U.S. Appl. No. 16/228,261, filed Dec. 20, 2018. |
| Co-pending U.S. Appl. No. 16/228,362, filed Dec. 20, 2018. |
| Co-pending U.S. Appl. No. 16/230,936, filed Dec. 21, 2018. |
| Co-pending U.S. Appl. No. 16/231,185, filed Dec. 21, 2018. |
| Co-pending U.S. Appl. No. 16/242,962, filed Jan. 8, 2019. |
| Co-pending U.S. Appl. No. 16/246,322, filed Jan. 11, 2019. |
| Co-pending U.S. Appl. No. 16/294,769, filed Mar. 6, 2019. |
| Co-pending U.S. Appl. No. 16/395,090, filed Apr. 25, 2019. |
| Co-pending U.S. Appl. No. 16/419,428, filed May 22, 2019. |
| Co-pending U.S. Appl. No. 16/419,461, filed May 22, 2019. |
| Co-pending U.S. Appl. No. 16/419,555, filed May 22, 2019. |
| Co-pending U.S. Appl. No. 16/419,820, filed May 22, 2019. |
| Coufal, et al. L1 retrotransposition in human neural progenitor cells. Nature. Aug. 27, 2009;460(7259)1127-31. doi: 10.1038/nature08248. Epub Aug. 5, 2009. |
| Curcio. Improved Techniques for High-Throughput Molecular Diagnostics. PhD Thesis. 2002. |
| Cusanovich; et al., “Multiplex single-cell profiling of chromatin accessibility by combinatorial cellular indexing. Sciencexpress, May 7, 2014, p. 1-9.” |
| Cusanovich, et al. Supplementary materials for Multiplex single-cell profiling of chromatin accessibility by combinatorial cellular indexing. Science. May 22, 2015;348(6237):910-4. doi: 10.1126/science.aab1601. Epub May 7, 2015. |
| Damean, et al. Simultaneous measurement of reactions in microdroplets filled by concentration gradients. Lab Chip. Jun. 21, 2009;9(12):1707-13. doi: 10.1039/b821021g. Epub Mar. 19, 2009. |
| De Bruin et al., UBS Investment Research. Q-Series®: DNA Sequencing. UBS Securities LLC. Jul. 12, 2007. 15 pages. |
| Definition of “corresponding”, Merriam-Webster Online, downloaded from http://www.merriam-webster.com/dictionary/corresponding (Year: 2019). |
| Dekker, et al. Capturing chromosome conformation. Science. Feb. 15, 2002;295(5558):1306-11. |
| Delehanty, et al. Peptides for specific intracellular delivery and targeting of nanoparticles: implications for developing nanoparticle-mediated drug delivery. Ther Deliv. Sep. 2010;1(3):411-33. |
| Demirci, et al. Single cell epitaxy by acoustic picolitre droplets. Lab Chip. Sep. 2007;7(9):1139-45. Epub Jul. 10, 2007. |
| Depristo et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nature Genet 43:491-498 (2011). |
| Dey, et al. Integrated genome and transcriptome sequencing of the same cell. Dey, Siddharth S. et al. “Integrated Genome and Transcriptome Sequencing from the Same Cell.” Nature biotechnology 33.3 (2015): 285-289. PMC. Web. Dec. 18, 2017. |
| Dixit, et al. Perturb-Seq: Dissecting Molecular Circuits with Scalable Single-Cell RNA Profiling of Pooled Genetic Screens. Cell. Dec. 15, 2016;167(7):1853-1866.e17. doi: 10.1016/j.cell.2016.11.038. |
| Doerr, “The smallest bioreactor”, Nature Methods, 2:5 326 (2005). |
| Doshi, et al. Red blood cell-mimicking synthetic biomaterial particles. Proceedings of the National Academy of Sciences 106.51 (2009): 21495-21499. |
| Dowding, et al. Oil core/polymer shell microcapsules by internal phase separation from emulsion droplets. II: controlling the release profile of active molecules. Langmuir. Jun. 7, 2005;21(12):5278-84. |
| Draper, et al. Compartmentalization of electrophoretically separated analytes in a multiphase microfluidic platform. Anal Chem. Jul. 3, 2012;84(13):5801-8. doi: 10.1021/ac301141x. Epub Jun. 13, 2012. |
| Dressler, et al. Droplet-based microfluidics enabling impact on drug discovery. J Biomol Screen. Apr. 2014;19(4):483-96. doi: 10.1177/1087057113510401. Epub Nov. 15, 2013. |
| Dressman et al. Supplementary Information pp. 1-2 of article published 2003, PNAS 100(15:8817-22). |
| Dressman et al. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc. Natl. Acad. Sci. 2003. 100(15):8817-8822. |
| Drmanac et al., Sequencing by hybridization (SBH): advantages, achievements, and opportunities. Adv Biochem Eng Biotechnol. 2002;77 :75-101. |
| Droplet Based Sequencing (slides) dated (Mar. 12, 2008). |
| Eastburn, et al. Ultrahigh-throughput mammalian single-cell reverse-transcriptase polymerase chain reaction in microfluidic droplets. Anal Chem. Aug. 20, 2013;85(16):8016-21. doi: 10.1021/ac402057q. Epub Aug. 8, 2013. |
| Epicenter, EZ-Tn5 Transposase, Epicenter, 2012, 1-5. (Year: 2012). |
| Epicentre., “EZ-Tn5TM Custom Transposome Construction Kits”, http://www.epicentre.com, pp. 1-17, 2012. |
| Esser-Kahn, et al. Triggered release from polymer capsules. Macromolecules. 2011; 44:5539-5553. |
| Fabi, et al. Correlation of efficacy between EGFR gene copy number and lapatinib/capecitabine therapy in HER2-positive metastatic breast cancer. J. Clin. Oncol. 2010; 28:15S. 2010 ASCO Meeting abstract Jun. 14, 2010:1059. |
| Fan, et al. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc Natl Acad Sci U S A. Oct. 21, 2008;105(42):16266-71. Epub Oct. 6, 2008. |
| Fan, et al. Whole-genome molecular haplotyping of single cells. Nature Biotechnology, vol. 29, No. 1. Jan. 1, 2011. pp. 51-57. |
| Fang, et al. Fluoride-cleavable biotinylation phosphoramidite for 5′-end-labeling and affinity purification of synthetic oligonucleotides. Nucleic Acids Res. Jan. 15, 2003;31(2):708-15. |
| Fanielli, M. et al. “Pathology tissue-chromatin immunoprecipitation, coupled with high-throughput sequencing, allows the epigenetic profiling of patient samples” PNAS (2010) 107(50):21535-21540. |
| Fisher, et al. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol. 2011;12(1):R1. doi: 10.1186/gb-2011-12-1-r1. Epub Jan. 4, 2011. |
| Frampton, G.M. et al. “Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing” Nature Biotechnology (2013) 31(11):1023-1031. doi:10.1038/nbr.2696. |
| Fredrickson, et al. Macro-to-micro interfaces for microfluidic devices. Lab Chip. Dec. 2004;4(6):526-33. Epub Nov. 10, 2004. |
| Freiberg, et al. Polymer microspheres for controlled drug release. Int J Pharm. Sep. 10, 2004;282(1-2):1-18. |
| Fu, et al. A Microfabricated Fluorescence-Activated Cell Sorter. Nature Biotechnology.1999; 17:1109-1111. |
| Fulton, et al. Advanced multiplexed analysis with the FlowMetrix system. Clin Chem. Sep. 1997;43(9):1749-56. |
| Gangadharan et al., DNA transposon Hermes insert into DNA in nucleosome-free regions in vivo, Proc nat Ad Sci, Dec. 21, 2010, vol. 107, No. 51, pp. 1966-1972. |
| Gao et al., Toehold of dsDNA Exchange Affects the Hydrogel Swelling Kinetic of a Polymer-dsDNA Hybrid Hydrogel, Royal Soc. Chem. 7:1741-1746 (Dec. 20, 2010). |
| Garstecki, et al. Formation of monodisperse bubbles in a microfluidic flow-focusing device. Applied Physics Letters. 2004; 85(13):2649-2651. DOI: 10.1063/1.1796526. |
| Gartner, et al. The Microfluidic Toolbox—examples for fluidic interfaces and standardization concepts. Proc. SPIE 4982, Microfluidics, BioMEMS, and Medical Microsystems, (Jan. 17, 2003); doi: 10.1117/12.479566. |
| Gericke, et al. Functional cellulose beads: preparation, characterization, and applications. Chemical reviews 113.7 (2013): 4812-4836. |
| GHADESSy, et al. Directed evolution of polymerase function by compartmentalized self-replication. Proc Natl Acad Sci USA. 2001;98:4552-4557. |
| Gonzalez, et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science. Mar. 4, 2005;307(5714):1434-40. Epub Jan. 6, 2005. |
| Granieri, Lucia. Droplet-based microfluidics and engineering of tissue plasminogen activator for biomedical applications. Ph.D. Thesis, Nov. 13, 2009 (131 pages). |
| Grasland-Mongrain, et al. Droplet coalescence in microfluidic devices. Jan.-Jul. 2003. 31 pages. http://www.eleves.ens.fr/home/grasland/rapports/stage4.pdf. |
| Green et al. Insertion site preference of Mu, Tn5, and Tn7 transposons. Mobile DNA 3.1 (2012): 3. |
| Greenleaf, et al. Assaying the epigenome in limited numbers of cells. Methods. Jan. 15, 2015;72:51-6. doi: 10.1016/j.ymeth.2014.10.010. Epub Oct. 22, 2014. |
| Guo, et al. Droplet microfluidics for high-throughput biological assays. Lab Chip. Jun. 21, 2012;12(12):2146-55. doi: 10.1039/c2lc21147e. Epub Feb. 9, 2012. |
| Gyarmati, et al. Reversible disulphide formation in polymer networks: a versatile functional group from synthesis to applications. European Polymer Journal. 2013; 49:1268-1286. |
| Hamilton, A.J. “microRNA in erythrocytes” Biochem. Soc. Trans. (2010) 38, 229-231. |
| Han, SW et al. “Targeted Sequencing of Cancer-Related Genes in Colorectal Cancer Using Next-Generation Sequencing” PLOS One (2013) 8(5):e64271. |
| Han, X. et al. “CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation” Science Advances (2015) 1(7): E1500454 (8 pages). |
| Haring, et al. Chromatin immunoprecipitation: optimization, quantitative analysis and data normalization. Plant Methods. 2007; 3: 11. |
| Hashimshony, et al. CEL-Seq: Single-Cell RNA-Seq by Multiplexed Linear Amplification. Cell Rep. Sep. 27, 2012;2(3):666-73. doi: 10.1016/j.celrep.2012.08.003. Epub Aug. 30, 2012. |
| He, “Selective Encapsulation of Single Cells and Subcellular Organelles into Picoliter- and Femtoliter-Volume Droplets” Anal. Chem 77: 1539-1544 (2005). |
| He, J. et al. “Genotyping-by-sequencing (GBS), an ultimate marker-assisted selections (MAS) tool to accelerate plant breeding” Frontiers in Plant Sci (Sep. 30, 2014) 5:1-8. |
| Hebenstreit. Methods, Challenges and Potentials of Single Cell RNA-seq. Biology (Basel). Nov. 16, 2012;1(3):658-67. doi: 10.3390/biology1030658. |
| Hiatt, et al. Parallel, tag-directed assembly of locally derived short sequence reads. Nat Methods. Feb. 2010;7(2):119-22. Epub Jan. 17, 2010. |
| Hirsch et al. (2002) “Easily reversible desthiobiotin binding to streptavidin, avidin, and other biotin-binding proteins: uses for protein labeling, detection, and isolation.” Analytical of Biochemistry 308(2):343-357. |
| Hjerten, et al. General methods to render macroporous stationary phases nonporous and deformable, exemplified with agarose and silica beads and their use in high-performance ion-exchange and hydrophobic-interaction chromatography of proteins. Chromatographia 31.1-2 (1991): 85-94. |
| Holtze, et al. Biocompatible surfactants for water-in-fluorocarbon emulsions. Lab Chip. Oct. 2008;8(10):1632-9. doi: 10.1039/b806706f. Epub Sep. 2, 2008. |
| Hosokawa, et al. Massively parallel whole genome amplification for single-cell sequencing using droplet microfluidics. Scientific Reports 7, Article No. 5199 (2017). |
| Hosono S, et al. Unbiased whole-genome amplification directly from clinical samples. Genome Res. May 2003; 13(5):954-64. Epub Apr. 14, 2003. |
| “How many species of bacteria are there” (wisegeek.com; accessed Jan. 21, 2014). |
| Hu et al., Shape Controllable Microgel Particles Prepared by Microfluidic Combining External Crosslinking, Biomicrofluidics 6:26502 (May 18, 2012). |
| Huebner, “Quantitative detection of protein expression in single cells using droplet microfluidics”, Chem. Commun. 1218-1220 (2007). |
| Hug, et al. Measurement of the number of molecules of a single mRNA species in a complex mRNA preparation. J Theor Biol. Apr. 21, 2003;221(4):615-24. |
| Illumina Nextera Enrichment Sample Preparation Guide. Feb. 2013. |
| Illumina TruSeq Custom Enrichment Kit Data Sheet. (c) 2014. |
| Imburgio, et al, “Studies of promoter recognition and start site selection by T7 RNA polymerase using a comprehensive collection of promoter variants”, Biochemistry., 39:10419-30, 2000. |
| Ioannidis, N. Manufacturing of agarose-based chromatographic adsorbents with controlled pore and particle sizes. A thesis submitted to The University of Birmingham for the degree of Doctor of Philosophy. 2009. |
| Jena, et al. Cyclic olefin copolymer based microfluidic devices for biochip applications: Ultraviolet surface grafting using 2-methacryloyloxyethyl phosphorylcholine. Biomicrofluidics. Mar. 2012;6(1):12822-1282212. doi: 10.1063/1.3682098. Epub Mar. 15, 2012. |
| Jin, et al. Genome-wide detection of DNase I hypersensitive sites in single cells and FFPE tissue samples. Nature. Dec. 3, 2015;528(7580):142-6. doi: 10.1038/nature15740. |
| Joneja, et al. Linear nicking endonuclease-mediated strand-displacement DNA amplification. Anal Biochem. Jul. 1, 2011;414(1):58-69. doi: 10.1016/j.ab.2011.02.025. Epub Feb. 20, 2011. |
| JPK “Determining the elastic modulus of biological samples using atomic force microscopy” (https://www.jpk.com/ app-technotes-img/AFM/pdf/jpk-app-elastic-modulus.14-1.pdf) 2009, pp. 1-9 (Year: 2009). |
| Jung, et al. Micro machining of injection mold inserts for fluidic channel of polymeric biochips. Sensors. 2007; 7(8):1643-1654. |
| Kamperman, et al. Centering Single Cells in Microgels via Delayed Crosslinking Supports Long-Term 3D Culture by Preventing Cell Escape. Small. Jun. 2017;13(22). doi: 10.1002/smll.201603711. Epub Apr. 28, 2017. |
| Kaper, et al. Supporting Information for “Whole-genome haplotyping by dilution, amplification, and sequencing.” Proc Natl Acad Sci U S A. Apr. 2, 2013;110(14):5552-7. doi: 10.1073/pnas.1218696110. Epub Mar. 18, 2013. |
| Kaper, et al. Whole-genome haplotyping by dilution, amplification, and sequencing. Proc Natl Acad Sci U S A. Apr. 2, 2013;110(14):5552-7. doi: 10.1073/pnas.1218696110. Epub Mar. 18, 2013. |
| Karmakar, et al. Organocatalytic removal of formaldehyde adducts from RNA and DNA bases. Nat Chem. Sep. 2015;7(9):752-8. doi: 10.1038/nchem.2307. Epub Aug. 3, 2015. |
| Katsura, et al. Indirect micromanipulation of single molecules in water-in-oil emulsion. Electrophoresis. Jan. 2001;22(2):289-93. |
| Kebschull, et al. High-Throughput Mapping of Single-Neuron Projections by Sequencing of Barcoded RNA. Neuron. Sep. 7, 2016;91(5):975-87. doi: 10.1016/j.neuron.2016.07.036. Epub Aug. 18, 2016. |
| Kenis, et al. Microfabrication Inside Capillaries Using Multiphase Laminar Flow Patterning. Science. 1999; 285:83-85. |
| Khomiakova et al., Analysis of perfect and mismatched DNA duplexes by a generic hexanucleotide microchip. Mol Biol(Mosk). Jul.-Aug. 2003;37(4):726-41. Russian. Abstract only. |
| Kim et al., Albumin loaded microsphere of amphiphilic poly( ethylene glycol)/poly(a-ester) multiblock copolymer. Eu. J. Pharm. Sci. 2004;23:245-51. Available online Sep. 27, 2004. |
| Kim, et al. Fabrication of monodisperse gel shells and functional microgels in microfluidic devices. Angew Chem Int Ed Engl. 2007;46(11):1819-22. |
| Kim, et al. Rapid prototyping of microfluidic systems using a PDMS/polymer tape composite. Lab Chip. May 7, 2009;9(9):1290-3. doi: 10.1039/b818389a. Epub Feb. 10, 2009. |
| Kirkness et al. “Sequencing of isolated sperm cells for direct haplotyping of a human genome,” Genome Res (2013) 23:826-832. |
| Kitzman et al. “Haplotype-resolved genome sequencing of a Gujarati Indian individual.” Nat Biotechnol (2011) 29:59-63. |
| Kitzman, et al. Noninvasive whole-genome sequencing of a human fetus. Sci Transl Med. Jun. 6, 2012;4(137):137ra76. doi: 10.1126/scitranslmed.3004323. |
| Kivioja, et al. Counting absolute numbers of molecules using unique molecular identifiers. Nat Methods. Nov. 20, 2011;9(1):72-4. |
| Klein, et al. Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells. Cell. May 21, 2015;161(5):1187-201. doi: 10.1016/j.cell.2015.04.044. |
| Knapp, et al. Generating barcoded libraries for multiplex high-throughput sequencing. Methods Mol Biol. 2012;840:155-70. doi: 10.1007/978-1-61779-516-9_19. |
| Knight, et al. Subtle chromosomal rearrangements in children with unexplained mental retardation. Lancet. Nov. 13, 1999;354(9191):1676-81. |
| Kolodeziejczyk et al., “The technology and biology of single-cell RNA sequencing”, Molecular Cell, vol. 58 (May 21, 2015). |
| Korlach et al., Methods in Enzymology, Real-Time DNA Sequencing from Single Polymerase Molecules, (2010) 472:431-455. |
| Koster et al., “Drop-based microfluidic devices for encapsulation of single cells”, Lab on a Chip The Royal Soc. of Chern. 8: 1110-1115 (2008). |
| Kozarewa, et al, “96-plex molecular barcoding for the Illumina Genome Analyzer”, Methods Mol Biol., 733:279-98, 2011. |
| Kozarewa, et al. “Amplification-free Illumina sequencing-library preparation facilitates improved mapping and assembly of GC-biased genomes”, Nat Methods., 6: 291-5, 2009. |
| Kutyavin, et al. Oligonucleotides containing 2-aminoadenine and 2-thiothymine act as selectively binding complementary agents. Biochemistry. Aug. 27, 1996;35(34):11170-6. |
| Kwok, et al, “Single-molecule analysis for molecular haplotyping”, Hum Mutat., 23:442-6, 2004. |
| Lagally, et al. Single-Molecular DNA Amplification and Analysis in an Integrated Microfluidic Device. Anal Chem. Feb. 1, 2001;73(3):565-70. |
| Lagus, et al. A review of the theory, methods and recent applications of high-throughput single-cell droplet microfluidics. J. Phys. D: Appl. Phys. (2013) 46:114005. (21 pages). |
| Lai; et al., ““Characterization and Use of Laser-Based Lysis for Cell Analysis On-Chip”, Journal of the Royal Society, Interface, vol. 5, Supplement 2, pp. S113-S121, Oct. 2008, (Year:2008)”, Journal of the Royal Society, Interface, Oct. 2008, vol. 5, Supplement 2, S113-S121. |
| Laird et al, Hairpin-bisulfite PCR: Assessing epigenetic methylation patterns on complementary strands of individual DNA molecules, 2004, PNAS, 101, 204-209. |
| Lake, et al. “Integrative Single-Cell Analysis by Transcriptional and Epigenetic States in Human Adult Brain”. Apr. 19, 2017. doi: https://doi.org/10.1101/128520. |
| Lan, et al. “Single-cell genome sequencing at ultra-high-throughput with microfluidic droplet barcoding” with Supplementary Material. Nat Biotechnol. May 29, 2017. doi: 10.1038/nbt.3880. [Epub ahead of print]. |
| Lander, et al. Initial sequencing and analysis of the human genome. Nature, 409 (Feb. 15, 2001): 860-921. |
| Lasken, et al. (1996) Archaebacterial DNA Polymerases Tightly Bind Uracil-containing DNA. The Journal of Biological Chemistry, 271(30):17692-17696 (Year: 1996). |
| Lebedev, A. et al. “Hot Start PCR with heat-activatable primers: a novel approach for improved PCR performance” NAR (2008) 36(20):E131-1. |
| Lee, et al. ACT-PRESTO: Rapid and consistent tissue clearing and labeling method for 3-dimensional (3D) imaging. Sci Rep. Jan. 11, 2016;6:18631. doi: 10.1038/srep18631. |
| Lee et al. Alginate: Properties and biomedical applications. Prog Polym Sci 37(1):106-126 (2012). |
| Lee, et al., “Highly multiplexed subcellular RNA sequencing in situ. Science. Mar. 21, 2014;343(6177):1360-3. doi: 10.1126/science.1250212. Epub Feb. 27, 2014.” |
| Lee, J-H. et al. “Fluorescent in situ sequencing (FISSEQ) of RNA for gene expression profiling in intact cells and tissues” Nature Protocols (Feb. 12, 2015) 10(3):442-458. |
| “Lennon et al. A scalable, fully automated process for construction of sequence-ready barcoded libraries for 454. Genome Biology 11:R15 (2010).” |
| Li, et al. A single-cell-based platform for copy number variation profiling through digital counting of amplified genomic DNA fragments. ACS Appl Mater Interfaces. Mar. 24, 2017. doi: 10.1021/acsami.7b03146. [Epub ahead of print]. |
| Li, Y., et al., “PEGylated PLGA Nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats,” Journal of Controlled Release, vol. 71, pp. 203-211 (2001). |
| Lienemann, et al. Single cell-laden protease-sensitive microniches for long-term culture in 3D. Lab Chip. Feb. 14, 2017;17(4):727-737. doi: 10.1039/c6lc01444e. |
| Linch, et al. Bone marrow processing and cryopreservation. Journal of Clinical Pathology; Feb. 1982, vol. 35, No. 2; pp. 186-190. |
| “List of sequenced bacterial genomes” (Wikipedia.com; accessed Jan. 24, 2014). |
| Liu, et al. Preparation of uniform-sized PLA microcapsules by combining Shirasu porous glass membrane emulsification technique and multiple emulsion-solvent evaporation method. J Control Release. Mar. 2, 2005;103(1):31-43. Epub Dec. 21, 2004. |
| Liu, et al. Smart thermo-triggered squirting capsules for Nanoparticle delivery. Soft Matter. 2010; 6(16):3759-3763. |
| Lo, et al. On the design of clone-based haplotyping. Genome Biol. 2013;14(9):R100. |
| Loscertales, I.G., et al., “Micro/Nano Encapsulation via Electrified Coaxial Liquid Jets,” Science, vol. 295, pp. 1695-1698 (2002). |
| Love, “A microengraving method for rapid selection of single cells producing antigen-specific antibodies”, Nature Biotech, 24:6 703 (Jun. 2006). |
| Lowe, Adam J. Norbornenes and [n]polynorbornanes as molecular scaffolds for anion recognition. Ph.D. Thesis (May 2010). (361 pages). |
| Lundin, et al, “Hierarchical molecular tagging to resolve long continuous sequences by massively parallel sequencing”, Sci Rep., 3:1186, 2003. |
| Lupski. Genomic rearrangements and sporadic disease. Nat Genet. Jul. 2007;39(7 Suppl):S43-7. |
| Macaulay; et al., “G&T-seq: parallel sequencing of single-cell genomes and transcriptomes. Nature Methods, 2015, p. 1-7.” |
| Macaulay, et al. Single-Cell Multiomics: Multiple Measurements from Single Cells. Trends in Genetics 33.2 (2017): 155-168. PMC. Web. Dec. 18, 2017. |
| Macosko, et al. Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets. Cell. May 21, 2015;161(5):1202-14. doi: 10.1016/j.cell.2015.05.002. |
| Maeda, et al. Development of a DNA barcode tagging method for monitoring dynamic changes in gene expression by using an ultra high-throughput sequencer. Biotechniques. Jul. 2008;45(1):95-7. doi: 10.2144/000112814. |
| Mair, et al. Injection molded microfluidic chips featuring integrated interconnects. Lab Chip. Oct. 2006;6(10):1346-54. Epub Jul. 31, 2006. |
| Makino, et al. Preparation of hydrogel microcapsules: Effects of preparation conditions upon membrane properties. Colloids and Surfaces B: Biointerfaces. Nov. 1998; 12(2), 97-104. |
| Mali, et al. Barcoding cells using cell-surface programmable DNA-binding domains. Nat Methods. May 2013;10(5):403-6. doi: 10.1038/nmeth.2407. Epub Mar. 17, 2013. |
| Man. Monolithic Structures for Integrated Microfluidic Analysis. PhD Thesis. 2001. |
| Marcus. Gene method offers diagnostic hope. The Wall Street Journal. Jul. 11, 2012. |
| Margulies 2005 Supplementary methods (Year: 2005). |
| Margulies et al. “Genome sequencing in microfabricated high-density picoliter reactors”, Nature (2005) 437:376-380. |
| Maricic T, et al. Optimization of 454 sequencing library preparation from small amounts of DNA permits sequence determination of both DNA strands. Biotechniques. Jan. 2009; 46(1):51-2, 54-7. |
| Matochko, et al. Uniform amplification of phage display libraries in monodisperse emulsions. Methods. Sep. 2012;58(1):18-27. doi: 10.1016/j.ymeth.2012.07.012. Epub Jul. 20, 2012. |
| Mazutis, et al. Selective droplet coalescence using microfluidic systems. Lab Chip. Apr. 24, 2012;12(10):1800-6. doi: 10.1039/c2lc40121e. Epub Mar. 27, 2012. |
| McGinnis, et al. MULTI-seq: Scalable sample multiplexing for single-cell RNA sequencing using lipid-tagged indices. bioRxiv 387241; doi: https://doi.org/10.1101/387241. |
| Merriman, et al. Progress in ion torrent semiconductor chip based sequencing. Electrophoresis. Dec. 2012;33(23):3397-417. doi: 10.1002/elps.201200424. |
| “Meyer, et al., From micrograms to picograms: quantitative PCR reduces the material demands of high-throughput sequencing, Nucleic Acids Research, 2008, vol. 36, No. 1, 6 pages”. |
| Meyer, et al. Targeted high-throughput sequencing of tagged nucleic acid samples. Nucleic Acids Res. 2007;35(15):e97. |
| Microfluidic ChipShop. Microfluidic product catalogue. Mar. 2005. |
| Microfluidic ChipShop. Microfluidic product catalogue. Oct. 2009. |
| Mignardi, M. et al. “Oligonucleotide gap-fill ligation for mutation detection and sequencing in situ” Nucl Acids Res (2015) 43(22):e151. |
| Miller JC, et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat. Biotechnol. 2007;25:778-785. |
| Miller-Stephenson Chemicals 157 FS Series catalog, www.miller-stephenon.com. |
| MiRNA (http://www.exiqon.com/what-are-microRNAs) accessed Oct. 19, 2017. |
| Mirzabekov, “DNA Sequencing by Hybridization—a Megasequencing Method and a Diagnostic Tool?” Trends in Biotechnology 12(1): 27-32 (1994). |
| Moore, et al. Behavior of capillary valves in centrifugal microfluidic devices prepared by three-dimensional printing. Microfluidics and Nanofluidics. 2011; 10(4):877-888. |
| Morgan, et al. Chapter 12: Human microbiome analysis. PLoS Comput Biol. 2012;8(12):e1002808. doi: 10.1371/journal.pcbi.1002808. Epub Dec. 27, 2012. |
| Morimoto, et al. Monodisperse semi-permeable microcapsules for continuous observation of cells. 2009. Lab Chip 9(15):2217-2223. |
| Mouritzen et al., Single nucleotide polymorphism genotyping using locked nucleic acid (LNa). Expert Rev Mol Diagn. Jan. 2003;3(1):27-38. |
| Mozhanova, A.A. et al. “Local elastic properties of biological materials studied by SFM” (2003) XP055314108, Retrieved from the Internet: URL:http://www.ntmdt.com/data/media/files/publications/2003/08.08_a.a.mozhanova_n.i.n_english.pdf. |
| Muotri, et al. L1 retrotransposition in neurons is modulated by MeCP2. Nature. Nov. 18, 2010;468(7322):443-6. doi: 10.1038/nature09544. |
| Myllykangas et al., Targeted Sequencing Library Preparation by Genomic DNA Circularization, BMC Biotechnology, 2011, 11(122), 1-12. |
| Nagano, et al. Single-cell Hi-C reveals cell-to-cell variability in chromosome structure. Nature. Oct. 3, 2013;502(7469):59-64. doi: 10.1038/nature12593. Epub Sep. 25, 2013. |
| Nagashima, et al. Preparation of monodisperse poly (acrylamide-co-acrylic acid) hydrogel microspheres by a membrane emulsification technique and their size-dependent surface properties. Colloids and Surfaces B: Biointerfaces. Jun. 15, 1998; 11(1-2), 47-56. |
| Narayanan, J. et al. “Determination of agarose gel pore size: Absorbance measurements vis a vis other techniques” Journal of Physics: Conference Series 28 (2006) 83-86 (Year: 2006). |
| Navin. The first five years of single-cell cancer genomics and beyond. Genome Res. Oct. 2015;25(10):1499-507. doi: 10.1101/gr.191098.115. |
| Nguyen, et al. In situ hybridization to chromosomes stabilized in gel microdrops. Cytometry. 1995; 21:111-119. |
| Nisisako, et al. Droplet formation in a microchannel network. Lab Chip. Feb. 2002;2(1):24-6. Epub Jan. 18, 2002. |
| Nisisako, T. et al. “Droplet Formation in a Microchannel on PMMA Plate” Abstract. 2001 Kluwer Academic Publishers. p. 137-138. |
| Novak, et al. Single cell multiplex gene detection and sequencing using microfluidicallygenerated agarose emulsions. Angew Chem Int Ed Engl. Jan. 10, 2011;50(2):390-5. doi: 10.1002/anie.201006089. |
| Oberholzer, et al. Polymerase chain reaction in liposomes. Chem Biol. Oct. 1995;2(10):677-82. |
| Ogawa, et al. Production and characterization of O/W emulsions containing cationic droplets stabilized by lecithin-chitosan membranes. J Agric Food Chem. Apr. 23, 2003;51(9):2806-12. |
| Okushima, S., et al,. “Controlled Production ofMonodisperse Double Emulsions by Two-Step Droplet Breakup in Microfluidic Devices,” Langmuir, vol. 20, pp. 9905-9908 (2004). |
| Oligotex Handbook. For purification of poly A+ RNA from total RNA and directly from cultured cells or tissues as well as purification of polyadenylated in vitro transcripts. Jun. 2012. |
| Orakdogen, N. “Novel responsive poly(N,N-dimethylaminoethyl methacrylate) gel beads: preparation, mechanical properties and pH-dependent swelling behavior” J Polym Res (2012) 19:9914. |
| Oyola, et al, “Optimizing Illumina next-generation sequencing library preparation for extremely AT-biased genomes”, BMC Genomics.,13:1, 2012. |
| Pantel, et al. Detection methods of circulating tumor cells. J Thorac Dis. Oct. 2012;4(5):446-7. doi: 10.3978/j.issn.2072-1439.2012.08.15. |
| Park. ChIP-seq: advantages and challenges of a maturing technology. Nature Reviews Genetics vol. 10, pp. 669-680 (2009). |
| Patel, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. Jun. 20, 2014;344(6190):1396-401. doi: 10.1126/science.1254257. Epub Jun. 12, 2014. |
| Perez, C., et al., “Poly(lactic acid)-poly(ethylene glycol) Nanoparticles as new carriers for the delivery of plasmid DNA,” Journal of Controlled Release, vol. 75, pp. 211-224 (2001). |
| Perrott, Jimmy. Optimization and Improvement of Emulsion PCR for the Ion Torrent Next-Generation Sequencing Platform. (2011) Thesis. |
| Peters, B.A. et al. Accurate whole-genome sequencing and haplotyping from 10 to 20 human cells. Nature, 487(7406):190-195 (Jul. 11, 2012). |
| Pfeifer, et al. Bivalent cholesterol-based coupling of oligonucleotides to lipid membrane assemblies. J Am Chem Soc. Aug. 25, 2004;126(33):10224-5. |
| Picot, J. et al. “A biomimetic microfluidic chip to study the circulation and mechanical retention of red blood cells in the spleen” Am J Hematology (Jan. 12, 2015) 90(4):339-345. |
| Pinto, et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature. Jul. 15, 2010;466(7304):368-72. doi: 10.1038/nature09146. Epub Jun. 9, 2010. |
| Plunkett, et al. Chymotrypsin responsive hydrogel: application of a disulfide exchange protocol for the preparation of methacrylamide containing peptides. Biomacromolecules. Mar.-Apr. 2005;6(2):632-7. |
| “Portable Water Filters” (http://www.portablewaterfilters.org/water-filter-guide/particle-contaminant-size-chart-microns/) 2015, accessed Oct. 19, 2017. |
| Porteus MH, Baltimore D. Chimeric nucleases stimulate gene targeting in human cells. Science. 2003;300:763. |
| Pott, et al. Single-cell ATAC-seq: strength in numbers. Genome Biol. Aug. 21, 2015;16:172. doi: 10.1186/s13059-015-0737-7. |
| Preissl, et al. Single nucleus analysis of the chromatin landscape in mouse forebrain development. Posted Jul. 4, 2017. bioRxiv 159137; doi: https://doi.org/10.1101/159137. |
| “U.S. Appl. No. 61/982,001, filed Apr. 21, 2014 (Year:2014)”. |
| Rakszewska, A. et al. “One drop at a time: toward droplet microfluidics as a versatile tool for single-cell analysis” NPG Asia Materials (2014) 6(10):e133 (12 pages). |
| Ram, et al. Strategy for microbiome analysis using 16S rRNA gene sequence analysis on the Illumina sequencing platform. Syst Biol Reprod Med. Jun. 2011;57(3):162-70. doi: 10.3109/19396368.2011 .555598. Epub Mar. 1, 2011. |
| Ramsey, J.M. “The burgeoning power of the shrinking laboratory” Nature Biotech (1999) 17:1061-1062. |
| Ramskold et al. (2012) “Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells” Nature Biotechnology 30(8):777-782. |
| Ran et al. Genome engineering using the CRISPR-Cas9 system. Nature Protocols 8:2281-2308 (2013). |
| Reis, A. et al. “CRISPR/Cas9 and Targeted Genome Editing: A New Era in Molecular Biology” (2014) XP002766825: URL:https://ww.neb.com/tools-and-resources/feabture-articles/crispr-cas9-and-targeted-genome-editing-a-new-era-in-molecular-biology. |
| Reisner, et al, “Single-molecule denaturation mapping of DNA in nanofluidic channels”, Proc Natl Acad Sci U.S.A., 107: 13294-9, 2010. |
| Repp et al. “Genotyping by Multiplex Polymerase Chain Reaction for Detection of Endemic Hepatitis B Virus Transmission” J Clinical Microbiology (1993) 31:1095-1102. |
| Richardson, et al. Novel inhibition of archaeal family-D DNA polymerase by uracil. Nucleic acids research 41.7 (2013): 4207-4218. |
| Roche. Using Multiplex Identifier (MID) Adaptors for the GS FLX Titanium Chemistry Basic MID Set Genome Sequencer FLX System, Technical Bulletin 004-2009, (Apr. 1, 2009) pp. 1-7. URL:http://454.com/downloads/my454/documentation/technical-bulletins/TCB-09004 Using MultiplexIdentifierAdaptorsForTheGSFLXTitaniumSeriesChemistry-BasicMIDSet.pdf. |
| Roche. Using Multiplex Identifier (MID) Adaptors for the GS FLX Titanium Chemistry Extended MID Set Genome Sequencer FLX System, Technical Bulletin 005-2009, (Apr. 1, 2009) pp. 1-7. URL:http://454.com/downloads/my454/documentation/technical-bulletins/TCB-09005UsingMultiplexIdentifierAdaptorsForTheGSFLXTitaniumChemistry-ExtendedMIDSet.pdf. |
| Rodrigue, S. et al. “Whole genome amplification and de novo assembly of single bacterial cells” PLoS One. Sep. 2, 2009;4(9):e6864. doi: 10.1371/journal.pone.0006864. |
| Rogozin, et al. A highly conserved family of inactivated archaeal B family DNA polymerases. Biol Direct. Aug. 6, 2008;3:32. doi: 10.1186/1745-6150-3-32. |
| Ropers. New perspectives for the elucidation of genetic disorders. Am J Hum Genet. Aug. 2007;81(2):199-207. Epub Jun. 29, 2007. |
| Rotem, et al. High-Throughput Single-Cell Labeling (Hi-SCL) for RNA-Seq Using Drop-Based Microfluidics. PLoS One. May 22, 2015;10(5):e0116328. doi: 10.1371/journal.pone.0116328. eCollection 2015. |
| Rotem, et al. Single Cell Chip-Seq Using Drop-Based Microfluidics. Abstract #50. Frontiers of Single Cell Analysis, Stanford University Sep. 5-7, 2013. |
| Rotem, et al. Single-cell ChIP-seq reveals cell subpopulations defined by chromatin state. Nat Biotechnol. Nov. 2015;33(11):1165-72. doi: 10.1038/nbt.3383. Epub Oct. 12, 2015. |
| Ryan, “Rapid assay for mycobacterial growth and antibiotic susceptibility using gel microdrop and encapsulation”, J. Clinical Microbial., 33:7 1720-1726 (1995). |
| Sakaguchi, et al. (1996) Cautionary Note on the Use of dUMP-Containing PCR Primers with Pfu and VentR. Biotechniques, 21(3): 369-370 (Year: 1996). |
| Sander JD, et al. Selection-free zinc-finger-nuclease engineering by context-dependent assembly (CoDA). Nat. Methods. 2011;8:67-69. |
| Savva, et al. The structural basis of specific base-excision repair by uracil-DNA glycosylase. Nature. Feb. 9, 1995;373(6514):487-93. |
| Schirinzi et al., Combinatorial sequencing-by-hybridization: Analysis of the NF1 gene. Genet Test. 2006 Spring;10(1):8-17. |
| Schmeider, et al. Fast identification and removal of sequence contamination from genomic and metagenomic datasets. PLoS One. Mar. 9, 2011;6(3):e17288. doi: 10.1371/journal.pone.0017288. |
| Schmitt, “Bead-based multiplex genotyping of human papillomaviruses”, J. Clinical Microbial., 44:2 504-512 (2006). |
| Schubert, et al. Microemulsifying fluorinated oils with mixtures of fluorinated and hydrogenated surfactants. Colloids and Surfaces A; Physicochemical and Engineering Aspects, 84(1994) 97-106. |
| Schwartz, et al., “Capturing native long-range contiguity by in situ library construction and optical sequencing”, PNAS (Nov. 2012), 109(46)18749-18754. |
| Sebat, et al. Strong association of de novo copy number mutations with autism. Science. Apr. 20, 2007;316(5823):445-9. Epub Mar. 15, 2007. |
| Seiffert, et al. Smart microgel capsules from macromolecular precursors. J Am Chem Soc. May 12, 2010;132(18):6606-9. doi: 10.1021/ja102156h. |
| Shah, “Fabrication of mono disperse thermosensitive microgels and gel capsules in micro fluidic devices”, Soft Matter, 4:2303-2309 (2008). |
| Shahi, et al. Abseq: Ultrahigh-throughput single cell protein profiling with droplet microfluidic barcoding. Sci Rep. 2017; 7: 44447. Published online Mar. 14, 2017. doi: 10.1038/srep44447. |
| Shaikh, et al. A modular microfluidic architecture for integrated biochemical analysis. Proc Natl Acad Sci U S A. Jul. 12, 2005;102(28):9745-50. Epub Jun. 28, 2005. |
| Shimkus, et al. A chemically cleavable biotinylated nucleotide: usefulness in the recovery of protein-DNA complexes from avidin affinity columns. Proc Natl Acad Sci U S A. May 1985;82(9):2593-7. |
| Shlien, et al. Copy number variations and cancer. Genome Med. Jun. 16, 2009;1(6):62. doi: 10.1186/gm62. |
| Shlien, et al. Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc Natl Acad Sci U S A. Aug. 12, 2008;105(32):11264-9. doi: 10.1073/pnas.0802970105. Epub Aug. 6, 2008. |
| Shuttleworth, et al. Recognition of the pro-mutagenic base uracil by family B DNA polymerases from archaea. J Mol Biol. Mar. 26, 2004;337(3):621-34. |
| Sigma. Streptavidin-agarose (S1638) product information sheet. www.sigma-aldrich.com. |
| Simeonov et al., Single nucleotide polymorphism genotyping using short, fluorescently labeled locked nucleic acid (LNA) probes and fluorescence polarization detection. Nucleic Acids Res. Sep. 1, 2002;30(17):e91. |
| Simon, et al., “Using formaldehyde-assisted isolation of regulatory elements (FAIRE) to isolate active regulatory DNA”, Nature Protocols, 2012, 7(2): 256-267. |
| Skerra. Phosphorothioate primers improve the amplification of DNA sequences by DNA polymerases with proofreading activity. Nucleic Acids Res. Jul. 25, 1992; 20(14):3551-4. |
| Smith, et al. Highly-multiplexed barcode sequencing: an efficient method for parallel analysis of pooled samples. Nucleic Acids Research, 38(13): e142 (2010). |
| Song, et al., “DNase-seq: A High-Resolution Technique for Mapping Active Gene Regulatory Elements across the Senome from Mammalian Cells”, Cold Spring Harbor Laboratory Press, 2010, 2010(2), doi:10.1101/pdb.prot5384. |
| Song, et al. Reactions in droplets in microfluidic channels. Angew Chem Int Ed Engl. Nov. 13, 2006;45(44):7336-56. |
| Sorokin et al., Discrimination between perfect and mismatched duplexes with oligonucleotide gel microchips: role of thermodynamic and kinetic effects during hybridization. J Biomol Struct Dyn. Jun. 2005;22(6):725-34. |
| Holmberg, et al. The biotin-streptavidin interaction can be reversibly broken using water at elevated temperatures. Feb. 2, 2005. Electrophoresis, 26:501-510. |
| Invitrogen Dynal. Dynabeads M-280 Streptavidin 2006 product sheet. |
| Morton. Parameters of the human genome. Apr. 23, 1991. Proceedings of the National Academy of Sciences of the United States of America, 88: 7474-7476. |
| National Human Genome Research Institute (NHGRI). The Human Genome Project Completion: Frequently Asked Questions. Last Updated: Oct. 30, 2010. |
| Qiagen. Omniscript Reverse Transcription Handbook. Oct. 2010. |
| Seiffert, et al. Microfluidic fabrication of smart microgels from macromolecular precursors. 2010. Polymer. |
| Mamedov, I.Z., et al. (2013), Preparing unbiased T-cell receptor and antibody cDNA libraries for the deep next generation sequencing profiling, Front Immunol 4: 456. |
| Spormann Laboratory, Polymerase Chain Reaction (PCR), Alfred Spormann Laboratory, 2009, 1-3. (Year: 2009). |
| Stoeckius, et al. Large-scale simultaneous measurement of epitopes and transcriptomes in single cells. bioRxiv 113068; doi: https://doi.org/10.1101/113068. |
| Stoeckius, et al. Simultaneous epitope and transcriptome measurement in single cells. Nature methods. Jul. 31, 2017. Supplemental Materials. |
| Su, et al., Microfluidics-Based Biochips: Technology Issues, Implementation Platforms, and Design-Automation Challenges. IEEE Transactions on Computer-Aided Design of Integrated Circuits and Systems. 2006;25(2):211-23. (Feb. 2006). |
| Sun et al., Progress in research and application of liquid-phase chip technology. Chinese Journal Experimental Surgery. May 2005;22(5):639-40. |
| Susaki, et al. Whole-brain imaging with single-cell resolution using chemical cocktails and computational analysis. Cell. Apr. 24, 2014;157(3):726-39. doi: 10.1016/j.cell.2014.03.042. Epub Apr. 17, 2014. |
| Syed, et al. Next-generation sequencing library preparation: simultaneous fragmentation and tagging using in vitro transposition. Nature Methods 2 pgs (Nov. 2009). |
| Tawfik, D.S., et al., “Man-made cell-like compartments for molecular evolution,” Nature Biotechnology, vol. 16, pp. 652-656 (1998). |
| Tayyab, S. et al. “Size exclusion chromatography and size exclusion HPLC of proteins” Biochem Ed, Pergamon, (1991) 19(3):149-152. |
| Tewhey, et al. Microdroplet-based PCR amplification for large-scale targeted sequencing. Nat Biotechnol. Nov. 2009;27(11):1025-31. doi: 10.1038/nbt.1583. Epub Nov. 1, 2009. |
| Tewhey et al., Supplementary Materials, Nature Biotechnology, 2009, 27(11), 1-22. |
| Thaxton, C.S. et al. “A Bio-Bar-Code Assay Based Upon Dithiothreitol Oligonucleotide Release” Anal Chem (2005) 77:8174-8178. |
| Theberge, et al. Microdroplets in microfluidics: an evolving platform for discoveries in chemistry and biology. Angew Chem Int Ed Engl. Aug. 9, 2010;49(34):5846-68. doi: 10.1002/anie.200906653. |
| ThermoFisher, Protocols, M-270 Streptavidin, ThermoFisherScientific, 2007, 1-5. (Year: 2007). |
| Thorsen, et al. Dynamic pattern formation in a vesicle-generating microfluidic device. Physical Review Letters. American Physical Society. 2001; 86(18):4163-4166. |
| Tomer, et al. Advanced Clarity for rapid and high-resolution imaging of intact tissues. Nat Protoc. Jul. 2014;9(7):1682-97. doi: 10.1038/nprot.2014.123. Epub Jun. 19, 2014. |
| Tonelli, et al. Perfluoropolyether functional oligomers: unusual reactivity in organic chemistry. Journal of fluorine chemistry. 2002; 118(1)107-121. |
| Tubeleviciute, et al. Compartmentalized self-replication (CSR) selection of Thermococcus litoralis Sh1B DNa polymerase for diminished uracil binding. Protein Eng Des Sel. Aug. 2010;23(8):589-97. doi: 10.1093/protein/gzq032. Epub May 31, 2010. |
| Turner, et al. Assaying chromosomal inversions by single-molecule haplotyping. Nat Methods. Jun. 2006;3(6):439-45. |
| Turner, et al, “High-throughput haplotype determination over long distances by haplotype fusion PCR and ligation haplotyping”, Nat Protoc., 4:1771-83, 2009. |
| Turner, et al. Methods for genomic partitioning. Annu Rev Genomics Hum Genet. 2009;10:263-84. doi: 10.1146/annurev-genom-082908-150112. Review. |
| Ullal et al. Cancer Cell Profiling by Barcoding Allows Multiplexed Protein Analysis in Fine-Needle Aspirates. Sci Transl Med. Jan. 15, 2014; 6(219): 219ra9. |
| Ushijima et al, Detection and interpretation of altered methylation patterns in cancer cells, 2005, Nature reviews, 5, 223-231. |
| Van Nieuwerburgh, et al, “Illumina mate-paired DNA sequencing-library preparation using Cre-Lox recombination”, Nucleic Acids Res., 40:1-8, 2012. |
| Wagner, et al. Biocompatible fluorinated polyglycerols for droplet microfluidics as an alternative to PEG-based copolymer surfactants. Lab Chip. Jan. 7, 2016;16(1):65-9. doi: 10.1039/c5lc00823a. Epub Dec. 2, 2015. |
| Wang, et al. A novel thermo-induced self-bursting microcapsule with magnetic-targeting property. Chemphyschem. Oct. 5, 2009;10(14):2405-9. |
| Wang, et al. Digital karyotyping. Proc Natl Acad Sci U S A. Dec. 10, 2002;99(25):16156-61. Epub Dec. 2, 2002. |
| Wang et al., “Self-Formed Adaptor PCR: a Simple and Efficient Method for Chromosome Walking”, Applied and Environmental Microbiology (Aug. 2007), 73(15):5048-5051. |
| Wang et al., Single nucleotide polymorphism discrimination assisted by improved base stacking hybridization using oligonucleotide microarrays. Biotechniques. 2003;35:300-08. |
| Ward, et al. Microfluidic flow focusing: Drop size and scaling in pressure versus flow-rate-driven pumping. Electrophoresis. Oct. 2005;26(19):3716-24. |
| Weaver, “Rapid clonal growth measurements at the single-cell level: gel microdroplets and flow cytometry”, Biotechnology, 9:873-877 (1991). |
| Weigl, et al. Microfluidic Diffusion-Based Separation and Detection. Science. 1999; pp. 346-347. |
| Wesolowska, et al. Cost-effective multiplexing before capture allows screening of 25 000 clinically relevant SNPs in childhood acute lymphoblastic leukemia. Leukemia. Jun. 2011;25(6):1001-6. doi: 10.1038/leu.2011.32. Epub Mar. 18, 2011. |
| Whitesides, “Soft lithography in biology and biochemistry”, Annual Review of Biomedical Engineering, 3:335-373 (2001). |
| Williams, et al. Amplification of complex gene libraries by emulsion PCR. Nature Methods. 2006;3(7):545-50. |
| Wiseman, R.W. et al. “Major histocompatibility complex genotyping with massively parallel pyrosequencing” Nature Medicine (Oct. 11, 2009) 15(11):1322-1326. |
| Wong, et al. Multiplexed Barcoded CRISPR-Cas9 Screening Enabled by CombiGEM. PNAS. Mar. 1, 2016, vol. 113, pp. 2544-2549. |
| Woo, et al. G/C-modified oligodeoxynucleotides with selective complementarity: synthesis and hybridization properties. Nucleic Acids Res. Jul. 1, 1996;24(13):2470-5. |
| Wood AJ, et al. Targeted genome editing across species using ZFNs and TALENs. Science. 2011;333:307. |
| Xi, et al. New library construction method for single-cell genomes. PLoS One. Jul. 19, 2017;12(7):e0181163. doi: 10.1371/journal.pone.0181163. eCollection 2017. |
| Xia and Whitesides, Soft Lithography, Angew. Chem. Int. Ed. 37:550-575 (1998). |
| Xia and Whitesides, Soft Lithography, Ann. Rev. Mat. Sci. 28:153-184 (1998). |
| Xiao, et al, “Determination of haplotypes from single DNA molecules: a method for single-molecule barcoding”, Hum Mutat., 28:913-21, 2007. |
| Yamamoto, et al. Chemical modification of Ce(IV)/EDTA-base artificial restriction DNA cutter for versatile manipulation of double-stranded DNA. Nucleic Acids Research. 2007; 35(7):e53. |
| Yan, Pu et al. “Rapid one-step construction of hairpin RNA” Biochem and Biophys Res Comm (Jun. 12, 2009) 383(4):464-468. |
| Zeng, et al. High-performance single cell genetic analysis using microfluidic emulsion generator arrays. Anal Chem. Apr. 15, 2010;82(8):3183-90. doi: 10.1021/ac902683t. |
| Zentner, et al. Surveying the epigenomic landscape, one base at a time. Genome Biol. Oct. 22, 2012;13(10):250. doi: 10.1186/gb4051. |
| Zhang, “Combinatorial marking of cells and organelles with reconstituted fluorescent proteins”, Cell, 119:137-144 (Oct. 1, 2004). |
| Zhang, et al. Degradable disulfide core-cross-linked micelles as a drug delivery system prepared from vinyl functionalized nucleosides via the RAFT process. Biomacromolecules. Nov. 2008;9(11):3321-31. doi: 10.1021/bm800867n. Epub Oct. 9, 2008. |
| Zhang, et al. One-step fabrication of supramolecular microcapsules from microfluidic droplets. Science. Feb. 10, 2012;335(6069):690-4. doi: 10.1126/science.1215416. |
| Zhang, et al. Reconstruction of DNA sequencing by hybridization. Bioinformatics. Jan. 2003;19(1):14-21. |
| Zhang F, et al. Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat. Biotechnol. 2011;29:149-153. |
| Zhang. Genomics of inherited bone marrow failure and myelodysplasia. Dissertation [online]. University of Washington. 2015 [Retrieved on May 3, 2017]. |
| Zhao, J., et al., “Preparation of hemoglobin-loaded Nano-sized particles with porous structure as oxygen carriers,” Biomaterials, vol. 28, pp. 1414-1422 (2007). |
| Zheng, et al. Massively parallel digital transcriptional profiling of single cells. Nat Commun. Jan. 16, 2017;8:14049. doi: 10.1038/ncomms14049. |
| Zheng, X.Y. et al. “Haplotyping germline and cancer genomes with high-throughput linked-read sequencing” Nature Biotech (Feb. 1, 2016) 34(3):303-311. |
| Zhou, Y. et al. “Development of an enzyme activity screening system for p-glucosidase-displaying yeasts using calcium alginate micro-beads and flow sorting” Appl Microbiol Biotechnol (2009) 84:375-382 (Year: 2009). |
| Zhu et al. Hydrogel Droplet Microfluidics for High-Throughput Single Molecule/Cell Analysis. Accounts of Chemical Research Article ASAP. DOI: 10.1021/acs.accounts.6b00370. |
| Zhu, et al. Reverse transcriptase template switching: a Smart approach for full-length cDNA library construction. Biotechniques. Apr. 2001;30(4):892-7. |
| Zhu, et al. Synthesis and self-assembly of highly incompatible polybutadienepoly(hexafluoropropoylene oxide) diblock copolymers. Journal of Polymer Science Part B: Polymer Physics. 2005; 43(24):3685-3694. |
| Zimmermann et at., Microscale production of hybridomas by hypo-osmolar electrofusion. Hum▪ Antibodies Hybridomas. Jan. 1992;3(1 ): 14-8. |
| Zong et al. Genome-Wide Detection of Single Nucleotide and Copy Number Variations of a Single Human Cell. Science 338(6114):1622-1626 (2012). |
| Number | Date | Country | |
|---|---|---|---|
| 20200248176 A1 | Aug 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62650223 | Mar 2018 | US | |
| 62527529 | Jun 2017 | US | |
| 62511905 | May 2017 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16419555 | May 2019 | US |
| Child | 16841411 | US | |
| Parent | 15842687 | Dec 2017 | US |
| Child | 16206168 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16206168 | Nov 2018 | US |
| Child | 16419555 | US | |
| Parent | PCT/US2018/034774 | May 2018 | US |
| Child | 16419555 | US |
